

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14420 A2

(51) International Patent Classification⁷: **C07K 14/00**

(21) International Application Number: **PCT/US00/23365**

(22) International Filing Date: **25 August 2000 (25.08.2000)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
60/150,576 25 August 1999 (25.08.1999) US

(71) Applicants (*for all designated States except US*): **UNIVERSITY OF TORINO [IT/IT]**; Department of Biomedical Sciences and Human Oncology, IRCC, SP 142, I-10060 Candiolo (IT). **REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]**; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ARTIGIANI, Stefania [IT/IT]**; Corso Brunelleschi, 121/B, I-10100 Torino (IT). **COMOGLIO, Paolo, M. [IT/IT]**; Strada Valsalice, 183/8, I-10100 Torino (IT). **GOODMAN, Corey, S. [US/US]**; Regents of the University of California, 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). **TESIER-LAVIGNE, Marc [US/US]**; Regents of

the University of California, 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US). **TAMAGNONE, Luca [IT/IT]**; Corso Einaudi, 43, I-10129 Torino (IT).

(74) Agent: **COX, Niki, D.**; Biogen, Inc., 14 Cambridge Center, Cambridge, MA 02142 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *Without international search report and to be republished upon receipt of that report.*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **NOVEL PLEXINS AND USES THEREOF**

(57) Abstract: The invention provides methods and compositions related to novel plexins. The polypeptides may be produced recombinantly from transformed host cells and from the disclosed plexin encoding nucleic acids or purified from human cells. The invention provides isolated plexin hybridization probes and primers capable of specifically hybridizing with the disclosed plexin genes, plexin-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in biopharmaceutical industry. The invention also provides novel plexin neuropilin multimeric receptor complexes for semaphorins and methods of use thereof, including but not limited to, the treatment and diagnosis of neurological disease and neuroregeneration, immune modulation, and viral and oncological diseases.



WO 01/14420 A2

NOVEL PLEXINS AND USES THEREOF

BACKGROUND OF THE INVENTION

Field of the Invention

5 The invention relates to the identification and characterization of four novel proteins that are members of the plexin family.

Summary of the Related Art

Plexin family members encode large transmembrane proteins, whose cysteine-rich extracellular domains share regions of homology with the Scatter Factor receptors (encoded by the Met gene family). The extracellular domains of plexins also contain
10 ~500 amino acid Semaphorin domains (see below). The highly conserved cytoplasmic moieties of plexins (approx. 600 amino acids), however, have no homology with the Met tyrosine kinase domain, nor with any other known protein. Met-like receptors and their ligands, the Scatter Factors, mediate a complex biological program including
15 dissociation of cell-cell contacts, motility and invasion (for a review see Tamagnone, L. and Comoglio, P.M. (1997) "Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors." *Cytokine Growth Factor Rev* 8, 129-142). During embryogenesis Scatter Factor-1 and Met promote the dissociation of cell layers in the
somites and drive the migration of myogenic cells to their appropriate location (Bladt,
20 F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier, C. (1995) "Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud." *Nature* 376, 768-771; Maina, F., Casagrande, F., Audero, E., Simeone, A., Comoglio, P.M., Klein, R.a., and Ponzetto, C. (1996) "Uncoupling of grb2 from the met receptor in vivo reveals complex roles in muscle development." *Cell* 87, 531-542).
25 Met and Scatter Factor-1 are also involved in controlling neurite outgrowth and axonal guidance (Ebens, A., Brose, K., Leonardo, E.D., Hanson, M.G.J., Bladt, F., Birchmeier, C., Barres, B.A., and Tessier-Lavigne, M. (1996) "Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons." *Neuron* 17, 1157-1172; Maina, F., Hilton, M.C., Ponzetto, C., Davies, A.M., and
30 Klein, R. (1997) "Met receptor signaling is required for sensory nerve development and HGF promotes axonal growth and survival of sensory neurons." *Genes Dev* 11, 3341-3350; Maina, F., Hilton, M.C., Andres, R., Wyatt, S., Klein, R., and Davies, A.M.

(1998) "Multiple roles for hepatocyte growth factor in sympathetic neuron development." *Neuron* 20, 835-846).

The first clue regarding a possible function for plexins came from the finding that a novel plexin, Vespri, interacts with the viral semaphorin A39R (Comeau, M.R., Johnson, R., DuBose, R.F., Petersen, M., Gearing, P., VandenBos, T., Park, L., Farrah, T., Buller, R.M., Cohen, J.I., Strockbine, L.D., Rauch, C., and Spriggs, M.K. (1998) "A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR." *Immunity*. 8, 473-482). Semaphorins are a large family of secreted and membrane-bound molecules that are characterized by an extracellular domain containing a ~500 amino acid Semaphorin domain (Kolodkin et al. (1993) "The semaphorin genes encode a family of transmembrane and secreted growth cone guidance molecules." *Cell* 75, 1389-1399). As noted above, plexins contain a more divergent but nevertheless conserved Semaphorin domain.

Semaphorins were originally characterized in the nervous system, where they have been implicated in repulsive axon guidance (Kolodkin et al. (1993) *supra*; Luo, Y., Raible, D., and Raper, J.A. (1993) "Collapsin: a protein in brain that induces the collapse and paralysis of neuronal growth cones." *Cell* 75, 217-227; Tessier-Lavigne, M. and Goodman, C.S. (1996) "The molecular biology of axon guidance." *Science* 274, 1123-1133). More recently, semaphorins have been furthermore implicated in cardiac and skeletal development (Behar, O., Golden, J.A., Mashimo, H., Schoen, F.J., and Fishman, M.C. (1996) "Semaphorin III is needed for normal patterning and growth of nerves, bones and heart." *Nature* 383, 525-528), in the immune response (Hall, K.T., Boumsell, L., Schultze, J.L., Boussiotis, V.A., Dorfman, D.M., Cardoso, A.A., Bensussan, A., Nadler, L.M., and Freeman, G.J. (1996) "Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation." *Proc.Natl.Acad.Sci.U.S.A.* 93, 11780-11785), in the regulation of angiogenesis (Miao, H.Q., Soker, S., Feiner, L., Alonso, J.L., Raper, J.A., and Klagsbrun, M. (1999) "Neuropilin-1 mediates collapsin-1/Semaphorin III inhibition of endothelial cell motility. Functional competition of collapsin-1 and vascular endothelial growth factor-165" [In Process Citation]. *J Cell Biol* 146, 233-242), and in tumor growth and metastasis (Christensen, C.R., Klingelhofer, J., Tarabykina, S., Hulgaard, E.F., Kramerov, D., and Lukanidin, E. (1998) "Transcription of a novel mouse semaphorin

gene, M-semaH, correlates with the metastatic ability of mouse tumor cell lines." Cancer Res. 58, 1238-1244).

Previously identified plexins have been shown to be expressed in the developing nervous system, (i.e. Plexin-A is a receptor for class 1 semaphorins (Sema-1a and Sema-1b). Moreover, Plexin-A has been shown via genetic analysis to control motor and CNS axon guidance induced by semaphorins (Winberg, M.L., Noordermeer, J.N., Tamagnone, L., Comoglio, P.M., Spriggs, M.K., Tessier-Lavigne, M., and Goodman, C.S. (1998). Plexin A is a neuronal semaphorin receptor that controls axon guidance. Cell 95, 903-916).

Thus a need exists for discovery of other members of the plexin family of proteins.

SUMMARY OF THE INVENTION

The present invention provides four novel plexin family members.

In one aspect, the invention provides an isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in (SEQ ID NO: 2), (SEQ ID NO: 4), (SEQ ID NO: 6) and (SEQ ID NO: 8).

In other aspects, the invention provides isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown in (SEQ ID NO: 1), (SEQ ID NO: 3), (SEQ ID NO: 5) and (SEQ ID NO: 7).

In another aspect, the invention provides a vector comprising the nucleic acid of the above-aspects.

The invention also provides an isolated polypeptide the amino acid sequence of which comprises residues 1-18, 19-518, 451-530, 601-680, 751-830, 800-1010, or 1196-1215 of SEQ ID NO: 2; 1-23, 24-507 or 1100-1119 of SEQ ID NO: 4; or 1-42, 43-600, 541-620, 691-770, 831-910, 900-1110 or 1270-1293 of SEQ ID NO: 6; or 8-49, 154-199 or 1-199 of SEQ ID NO: 8.

In another aspect, the invention provides an isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in (SEQ ID NO: 2), (SEQ ID NO: 4), (SEQ ID NO: 6) and (SEQ ID NO: 8)

The invention also provides a chimeric molecule comprising a polypeptide of the above aspects fused to a heterologous amino acid sequence. In one embodiment the heterologous amino acid sequence is a Fc region of an immunoglobulin.

In other aspects, the invention provides an antibody that specifically
5 binds to the polypeptides of the above aspects.

The invention also provides a method of treating, suppressing or altering a disorder involving aberrant immune regulation involving a signaling pathway between a plexin and a neuropilin in a mammal comprising the step of administering an effective amount of an agent to said mammal capable of interfering with the association between
10 the plexin and neuropilin. Contemplated agents include a chimeric molecule or an antibody of the above aspects.

DESCRIPTION OF THE DRAWINGS

Figure 1.

(A) Phylogenetic tree of human plexins. Known family members cluster in two
15 major groups: plexin A and plexin-B subfamilies. (B) Structural features of plexins, Met-like receptors and semaphorins. In the extracellular moieties, yellow boxes indicate the "sema" domains and blue boxes mark the cysteine-rich MRS motifs, some of which are stippled to indicate their atypical sequence; atypical MRS are also found in the *sema*
domain of semaphorins. Sequence identity among *sema* domains ranges from 15-50%,
20 as previously described (see Winberg et al., 1998 *supra*). Potential furin-like proteolytic sites are marked by red ribbons. plexin-B1 "truncated" is the product of a splicing variant (see text). plexin-D1 and plexin-C1 (VESPR) are more distant family members, since they include atypical features in their extracellular domains. The intracellular domain of plexins (SP domain) is highly conserved through all family
25 members, and it includes two separate regions of high homology (Maestrini, E., Tamagnone, T., Longati, P., Cremona, O., Gulisano, M., Bione, S., Tamanini, F., Neel, B.G., Toniolo, D., and Comoglio, P.M. (1996) "A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor." Proc. Natl. Acad. Sci. USA 93, 674-678) (green oval and box). Met-like receptors are disulfide-bound
30 heterodimers and include a cytoplasmic tyrosine kinase domain (red box). Mammalian semaphorins can be either secreted or cell surface proteins. Molecular weights of representative proteins are Plexin-A1 220 kDa, Plexin-B1 250 kDa, Plexin-C1 200

kDa, HGF-R/Met 145+45 kDa (heterodimer), Sema 4D 150 kDa (transmembrane), Sema7A approx. 100 kDa (membrane GPI-linked).

Figure 2.

(a) Cell surface semaphorins specifically bind human plexins. Micrographs of the binding assays done testing i) the extracellular domain of semaphorin CD100 fused to alkaline phosphatase (CD100-AP) on COS cells transfected with *plexin-B1 cDNA*; ii) control AP on plexin-B1; iii) CD100-AP on plexin-B2; iv) CD100-AP on the entire extracellular domain of plexin-B1; v) CD100-AP on isolated "plexin-B1 truncated" (including *sema* domain, 1° and 2° MRS); vi) CD100-AP on a "plexin-B1-Δsema" (including 2° and 3° MRS; vii) extracellular domain of semaphorin A39R fused to AP, on plexin-C1 (Vespr); viii) SemaK1-AP on plexin-C1. The final detection of the binding was done either using alkaline phosphatase substrates (i-vi) or by immunofluorescence (vii and viii). (B) Scatchard analysis and binding curve of CD100-AP to plexin-B1 ($K_D = 0.9 \text{ nM} \pm 0.15$).

Figure 3.

Plexins associate with neuropilins *via* specific extracellular domains. Western blots of immunoprecipitated samples from cells co-expressing neuropilins and plexins. Specific MoAbs were used, directed against the VSV-tag included in plexins or the myc-tag included in neuropilin-2 (Np2, 130 kDa). Np2 co-immunoprecipitates with plexins, such as plexin-A3 (220 kDa), the extracellular domain of plexinA1 (approx. 160 kDa), and plexin-B1 (250 kDa) but not with the unrelated cell surface receptor DCC (170 kDa). Np2 can also associate a truncated form of the extracellular moiety of plexin-B1 ("plex-B1 trunc.", approx. 110 kDa), containing the *sema domain*.

Figure 4.

Expression of mRNAs for plexins A1 (panel A, B), -A2 (panel C, D) and A3 (panel E, F) in the spinal cord (sc), dorsal root ganglia (d) and sympathetic ganglia (sg) of E13.5 mouse embryos. Expression of the mRNAs was detected by RNA in situ hybridization. Scale bar: 1 μm .

Figure 5.

Effect of a truncated plexin-A1 construct (lacking the cytoplasmic domain) on repulsive and attractive responses of *Xenopus* spinal neurons to Sema3A and netrin-1. (A-F) A control spinal neuron exposed to a gradient of Sema3A emanating from a pipette (A) is repelled away over a period of 1 hr (B). In contrast, a GFP-expressing

spinal neuron from an embryo injected with mRNA for the truncated plexin-A1 construct (C) is not affected by Sema3A (D). A similar neuron (E) shows a normal attractive response to netrin-1 (F).

- (G) Cumulative distribution plot of turning angles for all the neurons studied. Curves show the percent of neurons with turning angles less than the angle indicated on the abscissa, under different conditions (open circles, control neurons; black and blue circles, control neurons responding to Sema3A or netrin-1, respectively; red and green circles, responses of neurons expressing the truncated plexin-A1 construct to Sema3A and netrin-1, respectively. (H) Mean turning angle under all the conditions just mentioned.

Figure 6.

- Tyrosine phosphorylation of plexin-A3 and plexin-B1. (a) Anti-phosphotyrosine western blotting of immunoprecipitated p220^{plex-A3} and p250^{plex-B1} proteins. plexin-B1 is larger since it contains an extra sequence between the second and the third MRS motif, in the extracellular domain (see Fig. 1). (b) The same immunoprecipitated samples underwent *in vitro* kinase assay in the presence of [γ ³²P]ATP, Mg⁺⁺ and Mn⁺⁺ ions. The SDS-PAGE was treated with alkali in conditions known to eliminate the phosphate labeling of Ser/Thr residues and specifically preserving phosphotyrosines.

Figure 7

- Plexin-A3 overexpression mediates cell repelling cues. (a) Epithelial kidney MDCK cells transfected to overexpress plexin-A3 (or mock transfected) were cocultured with mesenchymal KJ-29 or NIH-3T3 cells. After 16-30 hours, mixed cultures of control cells (upper panels) reached confluency and stopped growing: typically the epithelial cells formed islets (circled) surrounded by a fibroblasts lawn. In contrast, MDCKs overexpressing plexin-A3 (lower panels) overwhelmed the adjacent mesenchymal cells. The latter withdrew and selectively detached from the culture dish (dying cell clusters are indicated by arrowheads), and eventually epithelial cells only survived. To allow an easier detection of the mesenchymal cells, these were labeled with DiI before being plated in mixed cultures. (b) Plexin-A3 expressing cells do not induce apoptotic signal on repelled fibroblasts. Mixed cultures of NIH 3T3 and control or plexin-A3 overexpressing MDCKs were tested for the presence of TUNEL-AP positive cells. Apoptotic cells were not present in clusters of repelled cells (indicated by

arrows). The right panel shows a positive control where apoptosis was induced on the same cells by UV treatment. (c) Plexin-A3 over-expressing cells form very transient contacts with fibroblasts. Time-lapse video-microscopy of control and plexin-A3 overexpressing MDCK cells grown in presence of fibroblasts. On top, snap-shot images from the movie, taken every 50 minutes (real time). In the upper row is shown the persistent contact of a fibroblast (marked by an arrow) with an islet of control MDCK cells (marked by a star). In the lower row another fibroblast, instead, forms a transient contact with an islet of plexin-A3 transfected cells, which also, in turn, reshapes. At the bottom, the diagrams show the relative frequency of persistent, transient or very transient contacts between fibroblasts and MDCK cells.

DETAILED DESCRIPTION OF THE INVENTION

The reference works, patents, patent applications, and scientific literature, including accession numbers to GenBank database sequences, that are referred to herein establish the knowledge of those with skill in the art and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. Any conflict between any reference cited herein and the specific teachings of this specification shall be resolved in favor of the later. Likewise, any conflict between an art-understood definition of a word or phrase and a definition of the word or phrase as specifically taught in this specification shall be resolved in favor of the latter.

Four novel human plexins have been identified: plexin-B2, plexin-B3, plexin-D1 and Plexin A-4. Plexin-A4 is located on human chromosome 7 and is a family member of the plexin-A subfamily which also includes plexin-A1 (alternatively named plexin-1/NOV), plexin-A2 (alternatively named plexin-2/OCT) and plexin-A3 (alternatively named plexin-2/SEX). Plexin-B2 and plexin-B3 are located on human chromosome 22 and chromosome X, respectively, and are family members of the plexin-B subfamily which also includes plexin-B1 (alternatively named SEP). Plexin-B3 maps very close to the plexin-A3 genomic locus on Xq28. Plexin-D1 is the first identified member of the plexin-D subfamily and is atypical of any of the other subfamilies. A fourth subfamily of plexins, the plexin-C subfamily, is defined by VESPR (now plexin-C1).

The four novel plexins as described herein have in their extracellular domains regions of homology with two other protein families: (a) Scatter Factors Receptors, encoded by the *MET* oncogene family (Tamagnone and Comoglio, 1997 *supra*), and (b)

Semaphorins (Kolodkin et al. (1993) *supra* (Figure 1b). In particular, plexins and Met-like receptors contain short cysteine-rich motifs, termed "Met Related Sequences" (MRS), whose minimal consensus is: C-X(5-6)-C-X(2)-C-X(6-8)-C-X(2)-C-X(3-5)-C (Maestrini et al., 1996 *supra*); Tamagnone and Comoglio, 1997 *supra*); blue boxes in Fig. 1B). The proteins of the Met family contain a single MRS (in their receptor β chains), whereas in plexin family members there are two/three repeated MRS motifs. Furthermore, all plexin family members contain in their extracellular moiety a 500 amino acid region similar to the sema domain of semaphorins (Kolodkin et al. (1993) *supra*; Winberg et al., 1998 *supra*); yellow boxes in Fig. 1B. The MRS motif is proposed to function as protein-protein interaction domain.

The cytoplasmic domain of plexins contains a ~600 amino acid domain which we term the SP domain ("Sex and Plexins", marked in green in Fig. 1B) that is highly conserved within the family (57-97% similarity) and in evolution (over 50% similarity between invertebrates and humans). The SP domain does not share homology with any known protein. It includes a number of potential tyrosine phosphorylation sites, but lacks the typical motifs of catalytic tyrosine kinases. Interestingly, the predicted secondary structure of the SP domain includes long conserved alpha helices, typically found in protein-protein interaction modules. Furthermore, there are several dihydrophobic amino acid motifs (such as LL or LI), known to mediate the internalization and downregulation of transmembrane receptors (Sandoval, I.V. and Bakke O. (1994). Targeting of membrane proteins to endosomes and lysosomes. Trends in Cell Biology 4, 292-297).

The present invention also demonstrates that plexins can form complexes with neuropilins, which in turn demonstrates that a receptor for semaphorins can be hetero-oligomers of plexins and neuropilins. As demonstrated by in situ mRNA expression analysis, plexins and neuropilins are in fact simultaneously expressed in several neuronal populations during embryonic development. The plexin-neuropilin complex predates ligand binding, since the association is not influenced by the presence of class 3 semaphorins. That the observed plexin-neuropilin complexes are formed in *cis* is furthermore supported by the experimental conditions used (cotransfection of isolated cells with the two constructs). An interaction in *trans* might also be envisioned (considering that plexins and semaphorins share similar *sema* domains), however by

analyzing mixed cultures of cells separately transfected with plexins and neuropilins we did not isolate associated complexes (data not shown).

We observed that the main semaphorin binding domain of neuropilins (CUB domain (Giger, R.J., Urquhart, E.R., Gillespie, S.K., Levengood, D.V., Ginty, D.D., and Kolodkin, A.L. (1998) "Neuropilin-2 is a receptor for semaphorin IV: insight into the structural basis of receptor function and specificity." *Neuron* 21, 1079-1092; Nakamura, F., Tanaka, M., Takahashi, T., Kalb, R.G., and Strittmatter, S.M. (1998) "Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse" [In Process Citation]. *Neuron* 21, 1093-1100; Chen et al. 1998 *supra*) is not required for the interaction with plexins, as indicated by the association of the relevant Neuropilin-2 deletion construct with plexin-B1 (not shown). A ternary complex, where neuropilins use two distinct protein modules to form a bridge between the sema domain of semaphorins and the sema domain of plexins is thus contemplated. It is further contemplated that plexins are the functional partners of neuropilins, required for transducing signals mediated by semaphorins, preferably class 3 semaphorins. For example, in flies, which lack both neuropilins and class 3 semaphorins, D Plex A appears sufficient as a functional receptor for *Sema 1a*, a transmembrane class 1 semaphorin (Winberg et al., 1998 *supra*). Further support that plexins are functional co-receptors for secreted semaphorins is demonstrated in an experiment that shows that a truncated plexin-A1 construct expressed in *Xenopus* spinal neurons abolishes repulsive responses to *Sema3A* without markedly affecting attractive responses to *netrin-1*. These results are consistent with the involvement of plexins.

The intracellular signals transduced by plexins are still largely obscure. The cytoplasmic domain of plexins is large and highly conserved within and across species and contains stretches of alpha helices, which are putative protein-protein interaction domains, and could thus mediate the association with cytosolic partners. We demonstrate herein that the cytoplasmic domain of plexins can be tyrosine phosphorylated, suggesting that, like other receptors devoid of intrinsic catalytic activity, plexins may signal by associating a tyrosine kinase (Stahl, N. and Yancopoulos, G.D. (1993). The alphas, betas, and kinases of cytokine receptor complexes. *Cell* 74, 587-590; Glass, D.J., Bowen, D.C., Stitt, T.N., Radziejewski, C., Bruno, J., Ryan, T.E., Gies, D.R., Shah, S., Mattsson, K., Burden, S.J., DiStefano, P.S.,

Valenzuela, D.M., DeChiara, T.M., and Yancopoulos, G.D. (1996). Agrin acts via a MuSK receptor complex. *Cell* 85, 513-523).

In addition, we show herein that expression of plexins, particularly plexin-A3, mediates cell-repelling cues. By time-lapse video-microscopy we observed a true
5 repelling effect on fibroblasts. Intriguingly, we observed that -upon interaction with fibroblasts- also the islets of plexin-A3 MDCKs at times reshaped. This may be explained by the existence of intra-epithelial repelling cues, balanced by the attractive forces exerted by epithelial cell junctions.

Moreover we have demonstrated that in the nervous system (i.e. *Drosophila*), that
10 defasciculating motor axons co-express both Plexin A and one of its interacting partners, the transmembrane semaphorin Sema-1a (Winberg et al., 1998 *supra*). This demonstrates that plexins act *in vivo* either as receptors or ligands for cell surface semaphorins, which in turn can transduce intracellular signals, as reported for ephrins (Holland et al., 1996 *supra*). Semaphorins, therefore, besides being pivotal in axon
15 guidance, have a general role in morphogenesis and tissue remodeling by mediating cell-repelling cues via their interactions with plexins.

Accordingly, in a first aspect, the invention provides an isolated nucleic acid molecule encoding a novel human plexin polypeptide. By "plexin polypeptide" is meant
a member of the plexin family comprising an amino acid sequence that shares at least
20 60% amino acid sequence homology with SEQ ID NOS: 2 (plexin B-2), 4 (plexin B-3), 6 (plexin D-1) or 8 (plexin A-4), preferably, at least 65% sequence homology, more preferably, at least 70% sequence homology, more preferably, at least at least 75% sequence homology, more preferably, at least 80% sequence homology, still more preferably at least 85% sequence homology, even more preferably, at least 90% sequence
25 homology, and most preferably at least 95% sequence homology with SEQ ID NOS: 2, 4, 6 or 8. Plexin polypeptides of the invention are useful for modulating cell growth (i.e. nerve) and immune regulation.

As used herein, by "modulating" is meant increasing or decreasing cell growth. By "cell growth" is meant any change in cell number or size, including, without
30 limitation, increase or decrease in cell number, increase or decrease in rate of cell division, increase or decrease in rate of cell death, and/or increase or decrease in cell size.

Standard methods for measuring cell growth include standard apoptosis assays (e.g., TUNEL assays, DNA fragmentation, trypan blue exclusion) and cell proliferation assays

(*e.g.*, ^3H -thymidine incorporation). It will be appreciated that the degree of modulation of cell growth provided by a plexin polypeptide in a given assay will vary, but one of skill in the art can readily determine the statistically significant change in cell growth of a cell exposed to a plexin polypeptide.

5 By "immune regulation" is meant increasing or decreasing the biological functions of immune cells (*i.e.*, cells involved in an immune response). Immune cells include, without limitation, lymphocytes (T and B), NK cells, dendritic cells, myeloid cells (*e.g.*, macrophages and neutrophils), and other hematopoietic cells involved in an immune response.

10 By "nucleic acid molecule" or "nucleic acid" as used herein, is meant any deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), including, without limitation, complementary DNA (cDNA), genomic DNA, RNA, heteronuclear RNA (hnRNA), messenger RNA (mRNA), DNA/RNA hybrids, or synthetic nucleic acids (*e.g.*, an oligonucleotide) comprising ribonucleic and/or deoxyribonucleic acids or synthetic
15 variants thereof. The nucleic acid of the invention includes, without limitation, an oligonucleotide or a polynucleotide. The nucleic acid can be single stranded, or partially or completely double stranded (duplex). Duplex nucleic acids can be homoduplex or heteroduplex.

By "polypeptide" is meant any molecule comprising two or more amino acids
20 joined together with a peptide bond, regardless of length or post-translational modifications (*e.g.*, without limitation, glycosylation, lipidation, acetylation, or phosphorylation). Useful plexin polypeptides of the invention include, without limitation, the full length plexin polypeptides having the amino acid sequence of SEQ ID NOS: 2, 4, 6, 8 or 10; an extracellular domain of the polypeptide having the amino
25 acid sequence 1 to 1199 of SEQ ID NO: 2; 1 to 1099 of SEQ ID NO: 4; 1 to 1270 of SEQ ID NO: 6 or 1 to 199 of SEQ ID NO: 8, with its associated signal peptide; or an extracellular domain of the polypeptide having the amino acid sequence 19 to 1199 of SEQ ID NO: 2; 24 to 1099 of SEQ ID NO: 4; or 43 to 1270 of SEQ ID NO: 6, lacking its associated signal peptide; an intracellular domain of the polypeptide having the
30 amino acid sequence of SEQ ID NOS: 2, 4, 6 or 8; and polypeptides, the amino acid sequence of which comprises about residues 1-18 (putative signal sequence), 19-518 (sema domain), 451-530 (1° MRS), 601-680 (2° MRS), 751-830 (3° MRS), 800-1010 (G-P repeats) or 1196-1215 (putative transmembrane domain) of SEQ ID

NO: 2; about residues 1-23 (putative signal sequence), 24-507 518 (sema domain) or 1100-1119 (putative transmembrane domain) of SEQ ID NO: 4; or about residues 1-42 (putative signal sequence), 43-600 (sema domain), 541-620 (1° MRS), 691-770 (2° MRS), 831-910 (3° MRS), 900-1110 (G-P repeats) or 1270-
5 1293 (putative transmembrane domain) of SEQ ID NO: 6; or about residue 8-49 (1° MRS) or 154-199 (2° MRS) of SEQ ID NO: 8.

By "isolated" is meant a compound (*e.g.*, a nucleic acid molecule or a protein) that has been separated from components (*e.g.*, nucleic acid molecules, proteins, lipids, and/or carbohydrates) which naturally accompany it. Water, buffers, and other small
10 molecules (*e.g.*, molecules having a molecular weight of less than about 1000 daltons) may accompany an isolated compound of the invention. Preferably, an isolated compound is at least 70%, by weight, free from components which naturally accompany it. More preferably, an isolated is at least 75%, by weight, free from components which naturally accompany it; still more preferably, at least 80%, by
15 weight, free; even more preferably, at least 85%, by weight, free; and even more preferably, at least 90%, by weight, free from components which naturally accompany it. Most preferably, a substantially purified compound is at least 95%, by weight, free from components which naturally accompany it.

Where the isolated compound is a nucleic acid molecule, the isolated nucleic acid
20 molecule is separated from other nucleic acids (*e.g.*, genes or transcripts) or proteins which, in the naturally-occurring genome of the organism from which the nucleic acid molecule was derived, flanked the nucleic acid molecule. Isolated nucleic acid molecules therefore include, without limitation, a recombinant nucleic acid molecule incorporated into a plasmid or other vector (*e.g.*, a replication-defective virus); a
25 recombinant nucleic acid molecule incorporated into the genome of a prokaryotic or eukaryotic organism; or a nucleic acid molecule which exists as a separate molecule independent of other nucleic acids (*e.g.*, a PCR product, a chemically synthesized nucleic acid molecule, or a nucleic acid molecule produced by restriction endonuclease digestion). Purification of a nucleic acid molecule can be accomplished and measured by
30 any standard method including, without limitation, sequence analysis, chemical synthesis, PCR, CsCl gradient, phenol:chloroform extraction, ethanol precipitation, Southern or Northern blotting analysis followed by band extraction and purification, and

high performance liquid chromatography (HPLC; see, *e.g.*, Fisher (1980) Laboratory Techniques in Biochemistry and Molecular Biology, Work and Burdon (eds.), Elsevier).

Thus, in one non-limiting example, to obtain an isolated nucleic acid molecule encoding a plexin polypeptide, a nucleic acid molecule is chemically synthesized on a standard oligonucleotide synthesis machine. The resulting single stranded molecule is then subjected to second strand synthesis to form a duplex DNA molecule, which is then ligated into a plasmid capable of replication in a prokaryotic or eukaryotic cell. The nucleic acid molecule is then replicated in the cell, purified (*e.g.*, by CsCl gradient), and subjected to sequence analysis.

In certain embodiments of the first aspect of the invention, the nucleic acid molecule has a nucleic acid sequence comprising SEQ ID NOS: 1, 3, 5, 7 or 9. Preferably, the nucleic acid molecule of the invention has not more than 500 nucleotides flanking each of the 5' and 3' ends of SEQ ID NOS: 1, 3, 5, 7 or 9. In certain embodiments, the plexin polypeptide has an amino acid sequence that comprises SEQ ID NOS: 2, 4, 6, 8 or 10. Preferably, the plexin polypeptide of the invention has not more than 50 amino acid residues flanking each of the N-terminal and C-terminal ends of SEQ ID NOS: 2, 4, 6, 8 or 10.

In certain embodiments of the first aspect of the invention, the nucleic acid molecule hybridizes under stringent conditions (as defined herein) to SEQ ID NOS: 1, 3, 5, 7 or 9.

The invention also includes nucleic acid molecules that hybridize under stringent hybridization conditions (as defined herein) to all or a portion of the nucleotide sequence represented by SEQ ID NOS: 1, 3, 5, 7 or 9 or its complement. The hybridizing portion of the hybridizing nucleic acid is at least 80%, *e.g.*, at least 95%, or at least 98%, homologous to the sequence of a portion or all of a nucleic acid encoding a polypeptide having the amino acid sequence of SEQ ID NOS: 2, 4, 6, 8 or 10, or its complement. Hybridizing nucleic acids of the type described herein can be used, for example, as a cloning probe, a primer (*e.g.*, a PCR primer) or a diagnostic probe.

Hybridization of the oligonucleotide probe to a nucleic acid sample typically is performed under stringent conditions. Nucleic acid duplex or hybrid stability is expressed as the melting temperature or T_m , which is the temperature at which a probe dissociates from a target DNA. This melting temperature is used to define the required stringency conditions. If sequences are to be identified that are related and substantially

identical, rather than identical, then it is useful to first establish the lowest temperature at which only homologous hybridization occurs with a particular concentration of salt (*e.g.*, SSC or SSPE). Then, assuming that 1% mismatch results in a 1°C decrease in the T_m , the temperature of the final wash in the hybridization reaction is reduced accordingly (for example, if the sequences have > 95% identity with the probe are sought, the final wash temperature is decreased 5°C). In practice, the change in the T_m can be between 0.5 C and 1.5 C per 1% mismatch. "Stringent conditions" involve hybridization at 68°C in 5x SSC/5x Denhardt's solution/1.0% SDS, and washing in 0.2xSSC/0.1% SDS at room temperature. "Moderately stringent conditions" include washing in 3xSSC at 42°C. The parameters of salt concentration and temperature can be varied to achieve the optimal level of identity between the probe and the target nucleic acid. Additional guidance regarding such conditions is readily available in the art, for example, by Sambrook *et al.*, *supra*; and Ausubel *et al.*, *supra*.

Nucleic acid sequence homology (as well as amino acid sequence homology) can be measured according to standard methods. Unless otherwise specified, as used herein used herein, "percent homology" of two amino acid sequences or of two nucleic acids is determined using the algorithm of Karlin and Altshul (*Proc. Natl. Acad. Sci. USA* **87**: 2264-2268, 1990), modified as in Karlin and Altschul (*Proc. Natl. Acad. Sci. USA* **90**: 5873-5877, 1993). Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al. (*J. Mol. Biol.* **215**: 403-410, 1990). BLAST nucleotide searches are performed with the NBLAST program, e (score) = 100, word length = 12, to obtain nucleotide sequences homologous to a nucleic acid molecule of the invention. BLAST protein searches are performed with the XBLAST program, e (score) = 50, word length = 3, to obtain amino acid sequences homologous to a reference polypeptide (*e.g.*, SEQ ID NO: 2). To obtain gapped alignments for comparison purposes, Gapped BLAST is utilized as described in Altschul et al. (*Nucleic Acids Res.* **25**: 3389-3402, 1997). When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) are used, namely $e=10$; $w=11$ for nucleic acid; $w=3$ for amino acid (the Blosum 62 scoring matrix); low complexity sequence filtering. The default settings of BLAST emphasize regions of local alignment to detect relationships among sequences which share only isolated regions of similarity (Altschul et al., *J. Mol. Biol.* **215**: 403-410 (1990). See <http://www.ncbi.nlm.nih.gov>.

Thus, in a non-limiting example to obtain an isolated nucleic acid molecule encoding a plexin polypeptide, a nucleic acid molecule having the sequence of SEQ ID NOS: 1, 3, 5 or 7 is used to probe a cDNA library under stringent conditions according to standard techniques (see., *e.g.*, Ausubel *et al.*, *supra*). Upon identification of a positive
5 clone (*i.e.*, a clone that hybridizes to SEQ ID NOS: 1, 3, 5 or 7 under stringent conditions), that clone is expanded and subjected to sequence analysis. A nucleic acid molecule having a nucleic acid sequence that is at least 70% identical, preferably at least 75% identical, more preferably, at least 80% identical, still more preferably at least 85% identical, even more preferably, at least 90% identical, and most preferably at least 95%
10 identical (as measured by the basic BLAST program of NCBI on default settings) to SEQ ID NOS: 1, 3, 5 or 7 is a nucleic acid molecule of the invention.

In a second aspect, the invention provides four novel isolated plexin polypeptides.

"Isolated" is as defined for the first aspect of the invention. Where the isolated compound is a polypeptide, the isolated polypeptide is separated from organic molecules,
15 such as nucleic acid molecules, polypeptides, and/or carbohydrates, which, in the naturally-occurring organism from which the polypeptide was derived, accompany the polypeptide. Isolated polypeptides therefore also include a recombinant polypeptide (*e.g.*, a human polypeptide expressed in an insect cell), or a chemically synthesized
polypeptide. Purification of a polypeptide can be accomplished and measured by any
20 standard method including, without limitation, chemical synthesis, recombinant polypeptide expression in prokaryotic or eukaryotic cells, affinity chromatography, Western blotting analysis, SDS-PAGE analysis, and/or HPLC.

In accordance with this aspect, the invention provides all derivatives, mutants, truncations, and/or splice variants of the four novel plexin polypeptides, so long as these
25 derivatives, mutants, truncations, and/or splice variants share at least 60% amino acid sequence homology with SEQ ID NOS: 2, 4, 6 or 8, preferably, at least 65% sequence homology, more preferably, at least 70% sequence homology, more preferably, at least at least 75% sequence homology, more preferably, at least 80% sequence homology, still more preferably at least 85% sequence homology, even more preferably, at least 90%
30 sequence homology, and most preferably at least 95% sequence homology with SEQ ID NOS: 2, 4, 6 or 8 as determined using the basic BLAST program of the National Center for Biotechnology (NCBI; National Library of Medicine, Bethesda, MD), using the

default settings defined therein using the sequence of the four novel plexin derivative, mutant, truncation and/or splice variance as the probe.

Preferred plexin polypeptide derivatives include polypeptides whose sequences differ from the sequence given in SEQ ID NOS: 2 ,4 ,6 or 8, by one or more
5 conservative amino acid substitutions, or by one or more non-conservative amino acid substitutions, deletions or insertions which do not abolish the biological activity of the plexins. Conservative amino acid substitutions typically include the substitution of one amino acid for another with similar biochemical characteristics, such as polarity, size, and/or charge. Non-limiting examples of conservative substitutions are substitutions
10 within the following groups: valine, glycine, glycine, alanine, valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine, phenylalanine, and tyrosine.

Useful methods for mutagenesis to generate plexin mutants are known in the art (see, *e.g.*, Sambrook *et al.*, *supra*; Ausubel *et al.*, *supra*). Preferred methods for
15 mutagenesis are described in PCT Publication WO99/12965 and include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences.

In certain embodiments of the second aspect of the invention, the plexin
20 polypeptide has a sequence comprising the sequence of SEQ ID NOS: 2 ,4 ,6 or 8. In one non-limiting example, in accordance with the invention, an isolated plexin polypeptide comprising the sequence of SEQ ID NOS: 2 ,4 ,6 or 8 can chemically synthesized according to standard techniques (*e.g.*, at a commercial peptide generating facility).

25 For example, a putative plexin polypeptide is purified and subjected to N-terminal sequencing to determine its amino acid sequence. The amino acid sequence of the polypeptide is then compared to SEQ ID NOS: 2 ,4 ,6, 8 or 10 (as measured by the basic BLAST program of NCBI on default settings). A polypeptide that shares at least 60% homology with SEQ ID NOS: 2 ,4 ,6, 8 or 10 is a plexin polypeptide of the
30 invention.

In another example, purification of a plexin polypeptide is facilitated by the addition of a tag to the polypeptide that enables purification of the tagged polypeptide. Non-limiting examples of a tag include a hemagglutinin (HA) tag, a his tag, a GST tag, a

FLAG-tag, and a myc tag. Thus, a nucleic acid molecule of the first aspect is engineered using standard molecular biology techniques to incorporate the nucleic acid sequence encoding the tag. The engineered nucleic acid molecule is then introduced and positioned for expression in an appropriate cell to produce the recombinant tagged polypeptide, which can then be readily purified by binding of the tag to its substrate. For example, the his tag binds to Ni-NTA agarose. Likewise, a GST (glutathione S-transferase) tag binds to glutathione agarose beads. Both his tag and GST tag expression and purification kits are commercially available from PharMingen (San Diego, CA). Likewise, myc-tagged plexin polypeptide are produced by cells introduced with a nucleic acid molecule encoding the tagged protein and positioned for expression in the cell.

It will be appreciated that particularly useful polypeptides of this aspect of the invention are secreted by the cell in which they are produced, thus facilitating purification of the polypeptide from the culture media in which the cells have been maintained, without requiring lysis of the cell.

In a third aspect, the invention provides a cell engineered to comprise a nucleic acid molecule encoding one of the four plexin polypeptides. By "engineered" is meant that the cell of the invention has been modified by standard molecular biology techniques. Where the cell is "engineered to comprise a nucleic acid molecule," standard molecular biology techniques have been employed to introduce the indicated nucleic acid molecule into the cell, either by transformation or transfection of the cell with a plasmid, or by infection or transduction of the cell with a recombinant virus.

The nucleic acid molecule of the first aspect of the invention is preferably subcloned into a plasmid or vector (for example, but not limited to, a vector used to generate a recombinant virus), wherein the nucleic acid molecule is positioned for expression in the plasmid or vector. The plasmid or vector is then introduced into a cell by standard techniques to produce an engineered cell in accordance with the third aspect of the invention.

In certain embodiments of the third aspect, the cell is a prokaryotic cell (e.g., a bacterium). For example, *E. coli* cells (e.g., DH5 α) are transformed (using, e.g., electroporation) with a bacterial plasmid (i.e., a plasmid containing an *E. coli* origin of replication) containing a nucleic acid molecule of the first aspect of the invention. The transformed bacteria are selected using, for example, an antibiotic-resistance encoding nucleic acid molecule (e.g., ampicillin resistance) on the plasmid such that the antibiotic

resistance protein is expressed by the transformed bacteria. The transformed bacteria are then propagated, and can be cryopreserved and stored frozen in glycerol.

Those of skill in the art will appreciate that in accordance with the third aspect of the invention, a nucleic acid molecule encoding one of the four plexin polypeptides may be introduced into a large variety of cells. For example, a nucleic acid molecule encoding one of the four plexin polypeptides can be introduced into prokaryotic cells (*e.g.*, bacteria), and any eukaryotic cell into which an exogenous nucleic acid molecule may be introduced. Thus, in certain embodiments of the third aspect of the invention, the cell is a eukaryotic cell. Eukaryotic cells according to this aspect of the invention that comprise a nucleic acid molecule encoding one of the four plexin polypeptides include, without limitation, yeast cells, plant cells, insect cells, and mammalian cells. Within the category of mammalian cells are cells from any mammalian species (including, without limitation, mouse, hamster, monkey, human), of any lineage (including, without limitation, lymphocyte, fibroblast, stem cell), and may be an immortalized cell, or a non-immortalized cell. Cells, as well as plasmids and/or vectors (*e.g.*, vectors that can be packaged to form infectious virus particles), are commercially available, for example, from the American Type Culture Collection ("ATCC"; Manassas, VA).

In certain embodiments of the third aspect of the invention, the nucleic acid molecule is positioned for expression in the cell. By "positioned for expression" is meant that the nucleic acid molecule is operably linked to at least one regulatory sequence which directs the transcription and translation of the nucleic acid molecule in a cell, such that the cell engineered to comprise the nucleic acid molecule produces (*i.e.*, expresses) the protein encoded by the nucleic acid molecule. By "operably linked" is meant that the nucleic acid molecule and the regulatory sequence are connected in a such a way as to permit expression of the nucleic acid molecule when the nucleic acid molecule is present in a cell. Regulatory sequences include, without limitation, promoters, enhancers, IRES sequences, and polyadenylation signals. Since plexin polypeptides are involved in immune regulation and the modulation of cell growth, it may be desirable to operably link a nucleic acid molecule encoding one of the four plexin polypeptides to an inducible promoter.

The four plexin polypeptides that are encoded by the nucleic acid molecules do not necessarily include the transmembrane domain of the four plexin polypeptides, and so may be produced by the cell as an intracellular polypeptide or a soluble secreted

polypeptide. For example, if the polypeptide fragment is secreted by the cell, it can be purified from the conditioned growth media of the transfected cells, without having to lyse the cells. Likewise, although a soluble intracellular polypeptide fragment is purified from only lysed cells, the fragment, being soluble, does not have to be extracted from the cell membrane; thus, different lysis conditions may be used to obtain purified soluble intracellular polypeptide fragment as compared to the lysis conditions required to obtain purified full length plexin polypeptides (which has a transmembrane domain).

Protein expression systems have been established for a variety of cells and are known to those of skill in the art. Cells are also commercially available from the ATCC, and a variety of protein expression system kits are commercially available from, for example, Invitrogen Corp. (Carlsbad, CA), Clontech Laboratories (Palo Alto, CA), PharMingen (San Diego, CA), Promega Corp. (Madison, WI), and Stratagene (La Jolla, CA).

For example, a nucleic acid molecule encoding one of the four plexin polypeptides is operably linked to bacterial regulatory sequences (*e.g.*, T7 late promoter or bacteriophage regulatory sequences), and the resulting nucleic acid molecule is used to transform bacterial cells, where the transformed bacterial cells produce one of the four plexin polypeptides. In another example, a nucleic acid molecule encoding one of the four plexin polypeptides is operably linked to baculovirus regulatory sequences in a baculovirus vector. Recombinant baculovirus are then generated and used to transduce insect cells (using, for example, the expression kit commercially available from Clontech Laboratories. The transduced insect cells comprise a nucleic acid molecule encoding one of the four plexin polypeptides positioned for expression in the insect cell, and thus produce one of the four plexin polypeptides.

Mammalian cells are widely used as protein expression systems. For example, a mammalian cell may be transduced with a recombinant retrovirus or adenovirus comprising a nucleic acid molecule encoding one of the four plexin polypeptides operably linked to regulatory sequences that are either endogenous to the particular virus or exogenous to the virus (*e.g.*, a CMV promoter in a retroviral vector). The transduced mammalian cell is then propagated *in vitro* in tissue culture, *in vivo* (*e.g.*, in an immunocompromised animal), and/or cryopreserved and stored frozen in DMSO.

In another example, mammalian cells are transfected with an expression plasmid comprising a nucleic acid molecule encoding one of the four plexin polypeptides

operably linked to one or more regulatory sequences on the plasmid. By "expression plasmid" is meant a plasmid in which an inserted nucleic acid molecule of interest (*e.g.*, encoding one of the four plexin polypeptides, a plexin chimeric molecule, or tagged plexin polypeptide) is operably linked to at least one regulatory sequence such that when
5 the expression plasmid containing the inserted nucleic acid molecule of interest is introduced (*e.g.*, by transfection) into a cell, the inserted nucleic acid molecule is positioned for expression in that cell. The nucleic acid molecule in the expression plasmid, upon being introduced into the cell, is thus positioned for expression in that cell, and enables the cell to produce one of the four plexin polypeptides encoded by the
10 nucleic acid molecule.

In one non-limiting example, a nucleic acid molecule according to the first aspect of the invention is inserted into a standard mammalian expression plasmid (*e.g.*, pCDNA3.1 commercially available from Invitrogen Corp., Carlsbad, California), such that the inserted nucleic acid molecule encoding one of the four plexin polypeptides is
15 operably linked to the regulatory sequences in the mammalian expression plasmid. Mammalian cells are then transfected with this expression plasmid (using, *e.g.*, CaPO_4 or DEAE-dextran). Where the expression plasmid contains an antibiotic-resistance encoding nucleic acid molecule (*e.g.*, neomycin resistance on the pCDNA3.1 plasmid)
such that the antibiotic resistance protein is expressed by the transfected cells, transfected
20 cells may be selected for the ability to grow in the presence of the antibiotic. The transfected cells may then be propagated and cryopreserved and stored in frozen in DMSO.

In a fourth aspect, the invention provides an isolated nucleic acid molecule encoding a chimeric molecule comprising at least two segments, wherein one of the
25 segments comprises one of the four plexin polypeptides. By "chimeric molecule" is meant a protein that comprises at least two segments of polypeptide joined together by any means, including, without limitation, a covalent bond (*e.g.*, peptide bond), a non-covalent bond (*e.g.*, ionic bond or hydrogen bond) or by a chemical crosslinker. It should be noted that one of the four plexin polypeptides that has been tagged is within the
30 definition of a chimeric molecule.

In certain embodiments of the fourth aspect of the invention, the nucleic acid molecule encoding the segment of a chimeric molecule comprising one of the four plexin

polypeptides hybridizes under stringent conditions to SEQ ID NO: 1, 3, 5 or 7.

“Stringent conditions” are as described above for the first aspect of the invention.

Standard molecular biology techniques may be employed to generate nucleic acid molecules encoding chimeric molecules according to the fourth aspect of the invention.

5 For example, a nucleic acid molecule encoding the extracellular domain of one of the four plexin polypeptides may be joined, in frame, to a nucleic acid molecule encoding the constant region of an immunoglobulin molecule (see, *e.g.*, Chamow S.M., Antibody Fusion Proteins, John Wiley & Sons, New York, 1999). By “in frame” is meant that a first nucleic acid molecule is ligated to a second nucleic acid molecule such that the each
10 of the amino acid sequences of the polypeptides encoded by each of the first and the second nucleic acid molecules is not frame-shifted.

In one non-limiting example, a chimeric molecule comprising the extracellular domain of one of the four plexin polypeptides including the amino acid sequence of SEQ ID NOS: 2, 4, 6 or 8 is generated. In this example, a nucleic acid molecule encodes
15 amino acid residue number 1(19) through about amino acid residue number 1199 of SEQ ID NO: 2; amino acid residue number 1(24) through about amino acid residue number 1099 of SEQ ID NO: 4; amino acid residue number 1(43) through about amino acid residue number 1270 of SEQ ID NO: 6 and amino acid residue number 1 through about
amino acid residue number 199 of SEQ ID NO: 8 with its associated signal peptide
20 (parenthesis depicts about the beginning of the amino acid sequence of the extracellular domain lacking its signal peptide). This nucleic acid molecule is fused in frame with a nucleic acid molecule encoding the constant region of an immunoglobulin, such that the chimeric molecule encoded by the resulting nucleic acid molecule generally has the following structure:

25

N-terminus	extracellular domain of SEQ ID NO: 2 with or lacking its signal peptide	amino acids from the constant region of an Ig molecule	C-terminus
N-terminus	extracellular domain of SEQ ID NO: 4 with or lacking its signal peptide	amino acids from the constant region of an Ig molecule	C-terminus
N-terminus	extracellular domain of SEQ ID NO: 6 with or lacking its signal peptide	amino acids from the constant region of an Ig molecule	C-terminus
N-terminus	extracellular domain of SEQ ID NO: 8 with or lacking its signal	amino acids from the constant region of an Ig molecule	C-terminus

	peptide		
--	---------	--	--

The heavy chain class (*e.g.*, IgG, IgA, IgM, IgD, or IgE) can be varied in this chimeric molecule depending upon which constant region is used. Nucleic acid molecules encoding the constant region of various immunoglobulin (Ig) heavy chains are known (see, *e.g.*, Zettlmeissl et al., *DNA Cell Biol.* 9(5):347-53, 1990) Indeed, expression plasmids are available, into which the nucleic acid molecule of interest (*i.e.*, a nucleic acid molecule encoding an extracellular domain of the polypeptide of SEQ ID NO: 2; SEQ ID NO: 4; SEQ ID NO: 6; or SEQ ID NO: 8) can be inserted, and the resulting plasmid introduced into a cell to produce one of the four extracellular plexin-Ig chimeric molecule s (see, *e.g.*, Zettlmeissl et al., *supra*; Miller et al., *J. Exp. Med.* 178 (1): 211-222, 1993).

Any variety of chimeric molecule carrying the extracellular domains of one of the four plexin polypeptide may be generated. For example, the extracellular domain of one of the four plexin polypeptides can be myc-tagged, his-tagged, or FLAG tagged according to standard molecular biology techniques.

Such extracellular proteins are particularly useful for identifying ligands to which the extracellular domain of one of the four plexin polypeptides bind. For example, extracellular plexin-D1-Ig chimera can be immobilized on a protein A-sepharose column. Molecules suspected of binding the extracellular domain of plexin-D1 are added to the column, to which the molecule that binds to the extracellular domain of plexin-D1 adhere, and the non-binding molecules flow through the column. The extracellular plexin-D1-binding molecules are readily eluted, for example, by changing the pH or ion concentration of the elution buffer.

Extracellular plexin proteins are also used to identify cells expressing the ligand of plexin extracellular domain on their cell surface (and thereby also identify the ligand itself). For example, cells are incubated with a FLAG-tagged plexin extracellular domain chimeric molecule. A FLAG-tagged plexin extracellular domain chimeric molecule is generated. An anti-FLAG antibody that is detectably labeled is then added to the cells. By "detectably labeled" is meant any means for marking and identifying the presence of a molecule. Detectable labels include, without limitation, radioactive labels (*e.g.*, ³²P or ³⁵S) and fluorophore labels (*e.g.*, FITC, phycoerythrin, or rhodamine). For example, FITC-labeled anti-FLAG antibodies are commercially available from Babco, Richmond,

CA. The "stained" cells (*i.e.*, cells incubated first with the FLAG-tagged plexin extracellular domain chimeric molecule and then with the FITC-labeled anti-FLAG antibody), are then subjected to flow cytometry analysis to select those cells that are labeled with FITC, and so express a molecule that binds to the extracellular domain of one of the four plexin polypeptides. The FITC labeled cells are then further manipulated (*e.g.*, characterized to determine which cells express the plexin polypeptide ligand).

The ligand of the plexin extracellular domain is itself identified, for example, by lysing the cells, adding the lysate to one of the four plexin extracellular domain-Ig chimeric molecule columns described above, and purifying the ligand. The ligand is then sequenced by N-terminal sequencing.

In another non-limiting example, the intracellular domain of one of the four plexin polypeptides is used as "bait" in a yeast two-hybrid system to identify ligands that interact with the intracellular domain of one of the four plexins described herein. For general description of the two-hybrid system, see U.S. Patent Nos. 5,283,173; 5,468,614; and 5,695,941. In this example, a nucleic acid molecule encoding from about amino acid residue number 143 through at least amino acid residue number 214 of SEQ ID NO: 2 is inserted into a standard DNA binding domain expression plasmid (*e.g.*, the GAL4 DNA binding domain plasmid in the Interactor kit commercially available from PharMingen (San Diego, CA). (It will be understood that the nucleic molecule may encode amino acid residue number 138-148 through at least amino acid residue number 214 of SEQ ID NO: 2.) A variety of cDNA libraries in transcriptional activation domain vectors are available (*e.g.*, from Clontech, Palo Alto CA). The cDNA libraries are screened employing standard methods (see, *e.g.*, the methods employed in U.S. Patent No. 5,780,262) to identify cDNA clones encoding a ligand that binds to the intracellular domain of one of the four plexin polypeptides. One preferable cDNA library screened in this example is a cDNA library generated from an immune cell (*e.g.*, a lymphocyte or NK cell).

In a fifth aspect, the invention provides a purified chimeric molecule comprising one of the four plexin polypeptides. Methods for purifying proteins are as described for the second aspect of the invention.

In a sixth aspect, the invention provides a cell engineered to comprise a nucleic acid molecule encoding a chimeric molecule comprising at least two segments, wherein one of the segments comprises one of the four plexin polypeptides. As described for the

third aspect of the invention, a nucleic acid encoding a chimeric molecule comprising one of the four plexin polypeptides may be introduced into any variety of cells. In certain embodiments, the cell is a prokaryotic cell or a eukaryotic cell. In certain embodiments, the eukaryotic cell is a yeast cell or a mammalian cell (*e.g.*, a human cell).

5 In a seventh aspect, the invention provides an isolated binding agent that specifically binds one of the four plexin polypeptides, or specifically binds a chimeric molecule comprising a segment comprising one of the four plexin polypeptides. In certain embodiments, the plexin protein has an amino acid sequence comprising SEQ ID NOS:2, 4, 6 or 8.

10 By "specifically binds" is meant a binding agent (*e.g.*, an antibody) that binds to its specific target (*e.g.*, one of the four plexin polypeptides) with greater affinity than it binds to other molecules. Preferably, where the binding agent is an antibody, the antibody preferably specifically binds to its specific target with a dissociation constant (K_D) of at least 10^{-5} M, more preferably, 10^{-6} M, even more preferably 10^{-7} M, and most
15 preferably, the binding agent specifically binds to its specific target with a K_D of at least 10^{-8} M.

Preferably, the binding agent of this aspect of the invention is an antibody, such as a monoclonal antibody or a polyclonal antibody, or a fragment of an antibody that specifically binds one of the four plexin polypeptides. Standard methods may be
20 employed to generate both monoclonal and polyclonal antibodies that specifically bind to one of the four plexin polypeptides of the invention. See, *e.g.*, Ausubel et al., *supra*; Coligan, J.E. et al., Current Protocols in Immunology, John Wiley & Sons, New York (1991); and Delves, P.J., Antibody Production: Essential Techniques, John Wiley & Sons, New York (1997). Briefly, the plexin polypeptides of the present invention,
25 purified according to the methods described for the second aspect of the invention, are used to immunize rabbits (*e.g.*, for polyclonal antibodies) or mice (*e.g.*, for monoclonal antibodies) to generate antibody-mediated immunity to the four plexin polypeptides used to immunize the animal. For monoclonal antibodies, antibodies can be screened by, *e.g.*, ELISA, to identify those antibodies that show the highest affinity for the immunizing
30 plexin protein or polypeptide fragment. The cloned cell producing the high affinity monoclonal antibody can then be propagated *in vitro* (where the antibody is purified from the culture supernatant) or *in vivo* (where the antibody is purified from ascites fluid), and

can also be cryopreserved and stored frozen at, *e.g.*, -70°C in DMSO, to provide a potentially limitless supply of monoclonal antibody.

In addition to intact monoclonal and polyclonal antibodies, the invention also provides various antibody fragments, such as Fab, F(ab')₂, Fv, and sFv fragments.

5 Recombinant, chimeric, and humanized antibodies are also provided.

Recombinant "humanized antibodies" which specifically bind to one of the four plexin polypeptides can be synthesized according to methods known in the art (see, *e.g.*, Green L.L. *et al.*, *Nature Genetics* 7: 13-21, 1994 for fully humanized antibodies expressed in transgenic animals; see also U.S. Patent Nos: 5,693,761; 5,777,085; and 10 5,585,089). Humanized antibodies are chimeras comprising mostly human IgG sequences into which at least portions of the regions responsible for specific antigen-binding (*e.g.*, CDR's) have been inserted. Animals are immunized with the desired antigen, the corresponding antibodies are isolated, and the portion of the variable region sequences responsible for specific antigen binding are removed. The animal-derived 15 antigen binding regions are then cloned into the appropriate position of human antibody genes in which the antigen binding regions have been deleted. Humanized antibodies minimize the use of heterologous (*i.e.*, inter-species) sequences in human antibodies, and thus are less likely to elicit immune responses in the treated subject (see also, *e.g.*, U.S. Patent No. 5,807,715).

20 Construction of different classes of recombinant antibodies can also be accomplished by making chimeric or humanized antibodies comprising nonhuman variable domains and human constant domains (CH1, CH2, CH3) isolated from different classes of immunoglobulins. For example, antibodies with increased antigen binding site valencies can be recombinantly produced by cloning the antigen binding 25 site into vectors carrying the human chain constant regions (see, *e.g.*, Arulanandam *et al.*, *J. Exp. Med.* 177: 1439-1450, 1993).

In addition, standard recombinant DNA techniques can be used to alter the binding affinities of recombinant antibodies with their antigens by altering amino acid residues in the vicinity of the antigen binding sites. The antigen binding affinity of a 30 humanized antibody can be increased by mutagenesis based on molecular modeling (see, *e.g.*, Queen *et al.*, *Proc. Natl. Acad. Sci.* 86: 10029-10033, 1989).

Also provided in the invention are plexin polypeptide-specific single polypeptide chain antibodies (see general methods in U.S. Patent Nos. 4,946,788 and

4,704,692); single domain antibodies (Ward, E.S. et al., *Nature* **341**: 544-546, 1989); and chimeric antibodies (U.S. Patent No. 4,816,567).

Binding agents that specifically bind the plexin polypeptides of the present invention are useful, for example, in determining expression levels of the plexin polypeptides in various tissues of the body, Western blotting analysis, and immunochromatography. Particularly, binding agents that specifically bind the plexin polypeptides are useful for binding the plexin polypeptide on a cell expressing the plexin polypeptide, thereby activating the cell.

A binding agent that specifically binds one of the four plexin polypeptides, for example, is effective as an immune modulator. Additional applications include, without limitation, an injectable formulation comprising a binding agent that specifically binds one of the four plexin polypeptides that is useful to antagonize activity in a disease involving aberrant immune regulation or a disease involving aberrant cell growth.

In an eighth aspect, the invention provides an isolated antisense oligonucleotide complementary to a portion of a nucleic acid molecule encoding one of the four plexin polypeptides. In certain embodiments, hybridization of the antisense oligonucleotide to the nucleic acid molecule inhibits transcription or translation of the nucleic acid molecule.

By two nucleic acid molecules being "complementary" to one another is meant that the first nucleic acid molecule (*e.g.*, an oligonucleotide) is able to form Watson-Crick base pair hydrogen bonds (*i.e.*, hybridize) with the second nucleic acid molecule to form a duplex. The first nucleic acid molecule is thus a "complement" of the second nucleic acid molecule.

The antisense oligonucleotides according to the invention are complementary to a region of a nucleic acid molecule (or a region at the intron/exon boundary of DNA or RNA) that encodes one of the four plexin polypeptides. Preparation of antisense oligonucleotides is well known (see, *e.g.*, Agrawal *et al.*, *Trends Biotechnol.* **10**:152-158, 1992; U.S. Patent No. 5,149,798; Agrawal *et al.*, *Proc. Natl. Acad. Sci. USA* **85**:7079-7083, 1988; Froehler, *Tetrahedron Lett.* **27**:5575-5578, 1986; and Bergot *et al.*, *J. Chromatog.* **559**:35-42, 1992).

In a ninth aspect, the invention provides a method for identifying a nucleic acid molecule encoding one of the four plexin polypeptides, comprising contacting a pool of candidate nucleic acid molecules with a nucleic acid molecule encoding one of the four

plexin polypeptides, wherein hybridization of the nucleic acid molecule encoding one of the four plexin polypeptides under stringent conditions to a candidate nucleic acid molecule identifies the candidate nucleic acid molecule as a nucleic acid molecule that encodes one of the four plexin polypeptides. According to this aspect of the invention,
5 “hybridization” and “stringent conditions” are as defined above for the first aspect of the invention. In certain embodiments, the nucleic acid molecule encoding one of the four plexin polypeptides has a nucleic acid sequence comprising SEQ ID NOS: 1, 3, 5 or 7.

It will be understood that the isolated plexin polypeptides according to the second aspect of the invention, the plexin chimeric molecules according to the fifth aspect of the invention, and binding agents that specifically bind the plexin polypeptides according to
10 the seventh aspect of the invention, are useful as therapeutics to treat an individual suffering from, or suspected of having, a disease or disorder involving aberrant immune regulation or an individual suffering from, or suspected of having, a disease or disorder involving aberrant cell growth, particularly nerve cell growth.

15 By “disease or disorder involving aberrant immune regulation” is meant any disease or disorder in which an abnormal immune response is generated in response to either self or foreign antigens. Thus, this definition includes, without limitation, autoimmune diseases (*e.g.*, lupus, inflammatory bowel disease, or Diabetes Type 1) and immunosuppressive diseases (*e.g.*, multiple sclerosis or rheumatoid arthritis).

20 By “disease or disorder involving aberrant cell growth” is meant any disease or disorder in which an abnormal amount of cell growth is observed. “Cell growth” is defined above. Thus, diseases and disorders involving aberrant cell growth include hyperplasia, neoplasia, and cancer, as well as degenerative diseases, such as neurodegenerative diseases.

25 Preferable therapeutically useful plexin polypeptides are soluble polypeptides (*e.g.*, lacking the hydrophobic transmembrane domain of the plexin polypeptides), particularly soluble polypeptide fragments that are secreted by the cell in which the fragment was produced. In a preferred embodiment the soluble plexin polypeptides are selected from the group consisting of plexin-A-1 (Maestrini et al. 1996 *supra*), plexin-A-
30 2 (Maestrini et al. 1996 *supra*), plexin-A-3 (Maestrini et al. 1996 *supra*), plexin-A-4, plexin-B-1 (Maestrini et al. 1996, *supra*), plexin-B-2, plexin-B-3, plexin-C1 (Comeau et al. 1998 *supra*), plexin-D-1.

In a tenth aspect, the invention provides a method for diagnosing a disease involving aberrant immune regulation or a disease involving aberrant cell growth, comprising comparing the amino acid sequence of one of the four plexin polypeptides from an individual suspected of having the disease with the amino acid sequence of one of the four plexin polypeptides from an unaffected individual, wherein the presence of a difference between the two amino acid sequences identifies the individual suspected of having the disease as having the disease. "Disease or disorder involving aberrant immune regulation" and "disease or disorder involving aberrant cell growth" are as defined above.

10 By "difference" in the amino acid sequence of one of the four plexin polypeptides from an individual suspected of having the disease or disorder as compared with the amino acid sequence of one of the four plexin polypeptides from an unaffected individual, is meant any mutation that changes the amino acid sequence including substitution, deletion, or addition of one or more amino acid residues.

15 Thus, in one nonlimiting example, one of the four plexin polypeptides is extracted from cells of an individual suspected of having a disease involving aberrant immune regulation (*e.g.*, using an antibody according to the seventh aspect of the invention). The amino acid sequence of the plexin polypeptide is determined by N-terminal sequencing and compared to the amino acid sequence of one of the four plexin polypeptides from an unaffected individual (*i.e.*, a normal individual of the same species that does not have a disease involving aberrant immune regulation or a disease involving aberrant cell growth). If there is a difference in the two amino acid sequences, the individual suspected of having a disease involving aberrant immune regulation is identified as having a disease involving aberrant immune regulation, and may be treated accordingly.

25 In certain embodiments of the tenth aspect, the amino acid sequence of the plexin polypeptide from the unaffected individual comprises the sequence of SEQ ID NO: 2, 4, 6, 8 or 10.

30 The following examples are intended to further illustrate certain preferred embodiments of the invention and are not limiting in nature. Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and procedures described herein. Such

equivalents are considered to be within the scope of this invention, and are covered by the following claims.

Practice of the present invention will employ, unless indicated otherwise, conventional techniques of cell biology, cell culture, molecular biology, microbiology, recombinant DNA, protein chemistry, and immunology, which are within the skill of the art. Such techniques are described in the literature. See, for example, **Molecular Cloning: A Laboratory Manual**, 2nd edition. (Sambrook, Fritsch and Maniatis, eds.), Cold Spring Harbor Laboratory Press, 1989; **DNA Cloning**, Volumes I and II (D.N. Glover, ed), 1985; **Oligonucleotide Synthesis**, (M.J. Gait, ed.), 1984; U.S. Patent No. 4,683,195 (Mullis et al.); **Nucleic Acid Hybridization** (B.D. Hames and S.J. Higgins, eds.), 1984; **Transcription and Translation** (B.D. Hames and S.J. Higgins, eds.), 1984; **Culture of Animal Cells** (R.I. Freshney, ed). Alan R. Liss, Inc., 1987; **Immobilized Cells and Enzymes**, IRL Press, 1986; **A Practical Guide to Molecular Cloning** (B. Perbal), 1984; **Methods in Enzymology**, Volumes 154 and 155 (Wu et al., eds), Academic Press, New York; **Gene Transfer Vectors for Mammalian Cells** (J.H. Miller and M.P. Calos, eds.), 1987, Cold Spring Harbor Laboratory; **Immunochemical Methods in Cell and Molecular Biology** (Mayer and Walker, eds.), Academic Press, London, 1987; **Handbook of Experiment Immunology**, Volumes I-IV (D.M. Weir and C.C. Blackwell, eds.), 1986; **Manipulating the Mouse Embryo**, Cold Spring Harbor Laboratory Press, 1986.

The following Examples are provided to illustrate the present invention, and should not be construed as limiting thereof.

EXAMPLES

Example 1

Identification and cDNA cloning of *plexins* and sequence analysis

Since the coding sequences of human *plexin-B1(SEP)*, *plexin-A2(OCT)* and
5 *plexin-A1(NOV)* were incomplete, we obtained the missing cDNA by RT-PCR; primers
were designed by homology to orthologous murine sequences and corresponding ESTs.
Updated database entries are X87904, X87831 and X87832, respectively. Partial cDNA
of *plexin-A4* was obtained by assembling five overlapping human ESTs (HGI THC
Report: THC203425), deriving from chromosome 7 specific cDNA pools. Another EST
10 from chr. 7 (clone 7B19F10) encodes the cytoplasmic domain of a plexin and
presumably derives from the same gene as *plexin-A4*. *Plexin-B2* cDNA was amplified
by RT-PCR starting from the partial cDNA sequences of clones *MM1* (Shinoura, N.,
Shamraj, O.I., Hugenholtz, H., Zhu, J.G., McBlack, P., Warnick, R., Tew, J.J., Wani,
M.A., and Menon, A.G. (1995). Identification and partial sequence of a cDNA that is
15 differentially expressed in human brain tumors. *Cancer Lett* 89, 215-221) and
KIAA0315 (Genbank database); the genomic locus of *SEP-B* was identified due to its
100% sequence identity with clone C22_311 from human chromosome 22. *Plexin-B3*
coding sequence was identified in the genomic sequence of ALD locus on human
chromosome Xq28, using the algorithms HEXON and GENIE. *Plexin-D1* was similarly
20 found in the genomic sequence of chromosome 3 (pac pDJ70i11). The genomic
sequence of *plexin-B1(SEP)*, in the region of the alternative splicing of the extracellular
domain, was obtained using the following primers: sense
5'GCAGCACCTGTGCACCCACAAGGC3' and antisense:
5'TGCAGGCTGGACGGGAGGATGAGG3'. The common donor site is
25 CCATCAG/gtgattgt (position 2028 from ATG); the alternative splice acceptor sites are:
(i) ccccttcag/AGCCC, leading to the canonical plexin-B1 sequence, and (ii)
ctccttcag/GTGAT, leading to "plexin-B1 truncated" variant. All these new sequences
were analyzed using the algorithms BLAST2, NETPHOS (phosphorylation prediction
sites, by Nicolaj Blom), PH-PREDICT and Consensus Protein Secondary Structure
30 prediction at IBCP. The phylogenetic tree was generated using AllAll algorithm of the
Darwin sequence analysis system (at CBRG).

Example 2

Plexin cDNA expression constructs and protein analysis

Cell transfections were carried out by Calcium phosphate and DEAE-dextran methods, using 5-10 µg of each cDNA (1-2 µg each in case of cotransfections). For transient transfections in COS and BOSC-23 cells the cDNA was cloned in pCDNA3 or derived expression plasmids (Invitrogen). MDCK stable transfectants for *plexin-A3* were obtained using pCEP4 expression plasmid (Invitrogen); the selection was done in the presence of Hygromycin-B (100-200 µg/ml). Plexin-A3 positive clones of MDCK cells were isolated from two independent transfections, and showed identical biological properties. Plexin and neuropilin expression constructs included a VSV- and myc-tag at the N' and C' protein termini, respectively, detected by monoclonal antibodies anti-VSV-G (cat. V-5507, Sigma) and anti-cMyc-tag (cat. OP10-100UG, Calbiochem). "Plexin-B1 truncated" splice variant was expressed from a cDNA fragment isolated by RT-PCR and VSV-tagged at the N' terminus: the encoded amino acid sequence spans up to aa 676 (including the *sema* domain and two MRS motifs). "Plexin-B1-sema" derives from a further deletion of the plexin-B1 extracellular domain, and exclusively includes the *sema* domain. "Plexin-B1-Δsema" protein mutant includes only the C' terminal half of plexin-B1 extracellular domain, starting from amino acid 606, i.e. excluding sema domain and first MRS but including second and third MRS, transmembrane and intracellular domains.

For immunoprecipitations, cells were lysed with EB buffer (20 mM Tris-HCl pH 7.4, 5 mM EDTA, 150 mM NaCl, 10% glycerol, 1% Triton X-100), in the presence of a cocktail of protease inhibitors and 1mM Na-ortovanadate. Immunoprecipitations were performed at 4°C for 4h with the appropriate antibodies; high stringency washes were performed, in the presence of 1 M LiCl.

For *in vitro* kinase assays, immunopurified proteins were incubated with kinase buffer (50 mM Hepes, 100 µM DTT, 5 mM MnCl₂, 5 mM MgCl₂) in the presence of redivue 5 µCi [γ-³²P] ATP (Amersham) for 10 minutes at 4°C in agitation. Samples were then submitted to SDS-PAGE and autoradiography, or analysed using a Phosphor-Imager system (Molecular Dynamics). Alkali treatment of the polyacrilamide gels was performed with 1M KOH for two hours at 55°C.

Western blots were performed according to standard methods. Specific detection of phospho-tyrosines was done with PY20 MoAb (Trasduction laboratories). Final detection was done with ECL system (Amersham).

Example 3

Semaphorin-SEAP binding assays

Soluble forms of Semaphorin extracellular domains were expressed as chimeric molecules with placental Secreted Alkaline Phosphatase (SEAP) and harvested from the conditioned media of transiently transfected COS or BOSC-23 cells. Serum-free media were concentrated over 100 times using Centricon Plus-20 filters (Millipore) with a molecular weight cutoff of 100 kDa. The AP activity of these media was assessed as described (Flanagan, J.G. and Leder, P. (1990). The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. *Cell* 63, 185-194); the specific activity of chimeric molecules was approx. 1000 U/mg. Concentrated Semaphorin-SEAP were diluted as appropriate in a Hepes buffered saline, additioned with 0.2% BSA, 0.1% NaN₃, 5 mM CaCl₂ and 1 mM MgCl₂ (HBSBA). For binding assays, COS cells transiently transfected with plexins were seeded on 48 well plates to reach confluence, and then incubated with Semaphorin-SEAP preparations (approx 1-5 nM) for 90 minutes at room temperature. The binding was detected as described (Flanagan and Leder, 1990). Binding experiments with plexin-C1/VESPR were as described (Comeau, M.R., Johnson, R., DuBose, R.F., Petersen, M., Gearing, P., VandenBos, T., Park, L., Farrah, T., Buller, R.M., Cohen, J.I., Strockbine, L.D., Rauch, C., and Spriggs, M.K. (1998). A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR. *Immunity*. 8, 473-482; He, Z. and Tessier-Lavigne, M. (1997). Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. *Cell* 90, 739-751).

For *in vitro* binding assays, plexin-B1 was purified from cell extracts by immunoprecipitation with anti-VSV antibody. Extracts of mock-transfected cells were used as control samples. After washing, the immunocomplexes were incubated with serial dilutions of CD100-SEAP (prepared as above) for 2 hours at 4°C, in continuous agitation. Samples were then washed 3 times with HBSBA and the bound alkaline phosphatase activity was measured by colorimetric assay using p-nitro-phenyl-phosphate, as described (Flanagan and Leder, 1990). Scatchard analysis was done using Equilibrate (by GertJan C. Veenstra).

Example 4

In situ hybridization analysis

RNA *in situ* hybridization was performed essentially as described (He, Z. and Tessier-Lavigne, M. (1997). Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. *Cell* 90, 739-751). Briefly cDNA fragments of plexin-A1, -A2, and -A3 were used to generate ³⁵S-labeled antisense and sense RNA probes, which were
5 used for in situ hybridization histochemistry of cryostat sections of rat embryos.

Example 5

Xenopus turning assay

The methods for injecting mRNA encoding various constructs, and for studying the turning responses of the neurons, are exactly as described previously (Hong, K.,
10 Hinck, L., Nishiyama, M., Poo, M.M., Tessier-Lavigne, M., and Stein, E. (1999). A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion. *Cell* 97, 927-941); Song, H., Ming, G., He, Z., Lehmann, M., Tessier-Lavigne, M., and Poo, M. (1998). Conversion of neuronal growth cone responses from repulsion to attraction by
15 cyclic nucleotides [see comments]. *Science* 281, 1515-1518).

Example 6

Mixed-culture assays and time-lapse videomicroscopy

Mock-transfected and plexin-A3 overexpressing MDCK cells were seeded with mesenchymal cells (NIH 3T3, KJ29, D17, among others), in multiwell culture plates by
20 1:4 or 1:1 ratio. NIH and KJ-29 cells were sometimes labeled by addition of DiI (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate, Fluka) in the culture medium, 4 hours before harvesting for the assay; clusters of cells marked with this dye are marked in blue (in light microscopy) and emit red epifluorescence (TRITC filter). The repelling effect was observed 16-30 hours after confluency, by contrast phase
25 microscopy using Leica DM IL. The progress of the assays was also monitored by time-lapse video-microscopy (320 minutes recording were converted into 1 minute play). To determine the time-length of cell contacts, for each assay, randomly chosen fibroblasts were followed during several hours and the duration of each contact between their lamellipodia and MDCK cells was measured. The doubling time of cells and their
30 viability during the assay could also be analyzed, and no differences were observed in presence of control or plexin-A3 expressing cells. Substrate adhesion of plexin-A3 overexpressing MDCKs was analyzed by counting attached cells after 30 minutes from

seeding on micro-wells coated with fibronectin, collagen or polylysine, in the absence of calf serum: no differences versus control cells were observed.

Example 7

Apoptosis detection

5 TUNEL reaction (Boehringer detection kit) was performed on mixed cultures of MDCK and NIH3T3 cells, 24 hours after seeding in a 24-well culture plate. The labeling was converted into a colorimetric signal for analysis by light microscopy using the TUNEL-AP detection kit (Boehringer). As a positive control for the induction of apoptosis, the same cells were treated with UV-C (50 $\mu\text{J}/\text{cm}^2$) or 1 μM staurosporin.

10 Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent to those skilled in the art that certain changes and modifications will be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.

Example 8

Plexins are specific receptors for cell surface semaphorins in vertebrates

Plexin-C1 (VESPR) has been shown to bind the soluble viral semaphorins Sema VA and VB (Comeau et al., 1998 *supra*), and we recently found that Drosophila Plexin A (D Plex A) interacts with transmembrane Sema 1a (Winberg et al., 1998 *supra*). We
20 therefore examined in vertebrates whether the extracellular domain of several different cellular semaphorins -fused to alkaline phosphatase- could bind members of the human plexin-A, -B and -C subfamilies. Multiple secreted semaphorins of class 3 (Sema3A, Sema 3C or Sema3F; see below) did not interact with plexins-A1, -A2, -A3, -B1, B2, or -C1 (data not shown). In contrast, plexin-C1(Vespr) specifically bound Sema7A(Sema-
25 K1) (Fig. 2a), a GPI-membrane linked semaphorin (class 7). This result is not entirely unexpected, since Sema7A may represent the cellular counterpart of viral semaphorin SemaVB, previously shown to interact with this plexin (Comeau et al., 1998 *supra*). More interestingly, the class 4 transmembrane semaphorin Sema4D (CD100) did interact strongly and specifically with plexin-B1 (Fig. 2a). Thus the prototypes of two
30 distinct plexin families are the receptors for members of two distinct semaphorin sub-classes. We also found that Sema7A and Sema4D do not bind to neuropilin-1 or -2 alone, nor did co-transfection of either neuropilin with plexin-B1 significantly modify

its binding efficiency (not shown). Neuropilins thus seem so far to function as receptors only for vertebrate semaphorins of class 3.

The affinity constant of Sema4D for plexin-B1 was estimated by Scatchard plot to be in the subnanomolar range ($K_D = 0.9$ nM, Fig. 2b; the estimated K_D of Sema7A for plexin-C1 is 2.1 nM, not shown). These values are consistent with those observed for semaphorins-neuropilins, and fly semaphorin1-Plexin A interactions (He and Tessier-Lavigne, 1997 *supra* Winberg et al., 1998).

We used two deletion constructs of plexin-B1 to explore the semaphorin binding sites of plexins. Neither the N-terminal half of plexin-B1 extracellular domain ("plexin-B1 truncated", see previous paragraph), nor its C-terminal half ("plexin-B1- Δ sema", see Experimental Procedures) was sufficient alone to bind CD100 (see Fig. 2a), suggesting that the binding of Sema4D depends on multiple structural determinants of the extracellular domain of plexin-B1.

Example 9

15 Plexins associate with class 3 Semaphorin receptors. Neuropilins

As outlined above, secreted semaphorins of subclass 3 are known to bind neuropilins (He and Tessier-Lavigne, 1997 *supra*; Kolodkin et al., 1997 *supra*; Chen, H., Chedotal, A., He, Z., Goodman, C.S., and Tessier-Lavigne, M. (1997) "Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III." *Neuron* 19, 547-559). However, the short cytoplasmic tail of neuropilins seems to be dispensable for their biological activity (Nakamura, et al (1998) *supra*), indicating the requirement of an associated co-receptor for signal transduction. Interestingly, in *Drosophila* (where neuropilins have not been identified to date) Plexin A is sufficient to mediate the biological response to semaphorin-1 in axon guidance (Winberg et al., 1998*supra*).

In an initial set of experiments, we could not observe binding of the class 3 semaphorins Sema3A(Sema III), Sema3C(Sema E) or Sema3F(Sema IV) to plexins-A1, A2, A3, B1, B2 or C1 (not shown). To test whether plexins might be coreceptors with neuropilins for class 3 semaphorins, we set up co-precipitation experiments in COS cells to test whether neuropilins may interact with plexins. Three tested plexins (plexin-A1, -A3 and -B1) associated both with neuropilin-2 (Np2, shown in Fig. 3) and neuropilin-1 (not shown). The binding was specific, inasmuch as neither neuropilin nor any plexins coimmunoprecipitated with the netrin receptor DCC, under conditions

where DCC coimmunoprecipitated with the other netrin receptor UNC5H2 (Fig. 3 and data not shown). We observed finally that the plexin-neuropilin association is mediated by the *sema domain* of plexins, as demonstrated using either the “plexin-B1 truncated” splice variant (Figure 3) or an even shorter form of the extracellular domain (“plexin-B1-sema”, see Experimental procedures, not shown).

To further support the idea of a plexin-neuropilin multimeric receptor complex for semaphorins, we show here that plexin-A3 (e.g.) is expressed in a large number of neuronal classes, including sensory, sympathetic, motor, and olfactory bulb neurons (Figure 4 and data not shown), which are known to respond to class 3 semaphorins, and which express either neuropilin-1 or neuropilin-2 or both (Chen et al., 1997 *supra*; Feiner, L., Koppel, A.M., Kobayashi, H., and Raper, J.A. (1997). Secreted chick semaphorins bind recombinant neuropilin with similar affinities but bind different subsets of neurons in situ. *Neuron* 19, 539-545; He and Tessier-Lavigne, 1997 *supra*; Kolodkin et al., 1997 *supra*). Thus, plexin-A3 is a candidate for a physiological coreceptor involved in mediating class 3 semaphorin effects on these axons. Other plexins may also have a role as neuropilin coreceptors in specific cell populations, such as plexin-A2, which is expressed in a subset of sensory neurons and in dorsal horn cells, and plexin-A1, which is expressed at low levels and broadly in the spinal cord (Figure 4).

To directly test the possible involvement of plexins in class 3 semaphorin signal transduction, we studied the repulsive responses of *Xenopus* spinal neurons to Sema3A, which is mediated by a receptor mechanism involving neuropilin-1 (Song et al., 1998 *supra*). We asked whether these responses could be altered by expression of a presumed dominant-negative plexin-A1 construct lacking the cytoplasmic domain of the protein. Transmembrane proteins can be reliably expressed in these neurons by injecting the encoding mRNA at the developmental two cell stage, allowing the embryos to grow to tadpole stage, and then removing the spinal cord and culturing the neurons (Hong et al., 1999 *supra*). We therefore injected the mRNA encoding the truncated plexin-A1 construct, together with mRNA encoding GFP (as a reporter) and then studied the responses of spinal neurons expressing GFP that were derived from these embryos. Whereas control spinal neurons are repelled by Sema3A (Figure 5A, B and Song et al. 1998 *supra*), neurons from embryos injected with mRNA for truncated plexin-A1 did not respond with either repulsion or attraction to Sema3A (Figure 5C,

D). This blocking effect appeared to be specific, since expression of a different heterologous receptor, UNC5H2, did not impair repulsion by Sema3A (Hong et al., 1997 *supra*), and since expression of the truncated plexin construct did not block attractive responses to netrin-1 (Figure 5E, F). Figure 5G, H quantifies these effects.

5 As can be seen, the effect of Sema3A is completely abolished by the truncated plexin; although there is a slight apparent decrease in the attractive effect of netrin-1 the effect is not statistically significant.

Although we have used a truncated plexin-A1 construct, this construct may be expected to interfere with the function of various plexins, since all the plexins tested
10 (A1, A3 and B1) associated with neuropilin-1. These results support a role for one or more plexins in mediating the repulsive Sema3A signal in the *Xenopus* spinal neurons.

Example 10

Plexins signal via a novel type of tyrosine phosphorylated cytoplasmic domain

The sequences of plexin cytoplasmic domains are highly conserved among
15 plexins but do not match any known sequences. We found that the plexin-A3 and plexin-B1 proteins are phosphorylated on tyrosine residues when overexpressed in human kidney cells (BOSC-23), as demonstrated using anti-phosphotyrosine antibodies (Fig. 6a). Furthermore, after immunoprecipitation and in vitro kinase assays, plexin-A3
and plexin-B1 became phosphorylated (Fig. 6b). Resistance to an alkali treatment (see
20 Experimental procedures) confirmed the specific phosphorylation of tyrosine residues.

The cytoplasmic domains of several receptors, including Met proteins, become tyrosine phosphorylated owing to an intrinsic kinase activity (Ullrich, A. and Schlessinger, J. (1990) "Signal transduction by receptors with tyrosine kinase activity." *Cell* 61, 203-212). Since the cytoplasmic domain of plexins is not similar to any bona
25 fide or atypical tyrosine kinase, this suggests that a distinct tyrosine kinase co-immunoprecipitates in association with plexins, and is responsible for their tyrosine phosphorylation. Although some additional phosphorylated proteins can be found specifically with plexin-A3 and -B1, we have not as yet identified this associated kinase. A number of endogenously expressed tyrosine kinases, namely Met, Ron, Abl
30 and Src, were not found associated with plexin-A3 by immunoprecipitation and Western blotting (not shown). Since tyrosine phosphorylated residues often function as docking sites for intracellular signal transducers (Cantley, L.C., Auger, K.R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., and Soltoff, S. (1991) "Oncogenes and

signal transduction." Cell 64, 281-302), the fact that the cytoplasmic domains of plexins are tyrosine phosphorylated further suggests that they are part of signaling complexes.

Example 11

5 Plexin-A3 expressing cells induce repulsion of co-cultured cells

Stable transfectants expressing recombinant human plexin-A3 were successfully obtained in four different cell lines: IMR32 and AF8 (human neuroblasts), and BOSC-23 and MDCK (human and canine kidney cells, respectively). We observed modest phenotypic changes in the transfected cells, which generally become flatter and larger in
10 size. The growth rate of plexin-A3 overexpressing cells was comparable to parental lines and we did not observe differences in the ability to adhere on different substrates (data not shown).

In keeping with previous report on the related Plexin of *Xenopus laevis* (Ohta, K., Mizutani, A., Kawakami, A., Murakami, Y., Kasuya, Y., Takagi, S., Tanaka, H.,
15 and Fujisawa, H. (1995). "Plexin: a novel neuronal cell surface molecule that mediates cell adhesion via a homophilic binding mechanism in the presence of calcium ions." Neuron 14, 1189-1199), we observed a modest increase in calcium-dependent homotypic cell aggregation of plexin-A3 transfectants (not shown). Surprisingly, we
found that epithelial MDCK cells overexpressing plexin-A3 mediate strong repelling
20 cues for adjacent cells. This was observed by co-culturing mock-transfected and plexin-A3 overexpressing MDCK cells together with several non-epithelial cell lines (such as NIH3T3, KJ29, and D17; Fig. 7A). Mock MDCKs grew alongside mesenchymal cells until confluency, when both cell types stopped proliferating. In contrast, when plexin-A3-overexpressing epithelial cells were grown in the same conditions, the adjacent
25 mesenchymal cells withdrew from them, and ultimately detached from the plate.

To analyze the dynamics of this repulsion process, we monitored for 36 hours, by time-lapse video-microscopy, mixed cultures of transfected MDCK cells and fibroblasts, in a number of independent experiments. At low cell density, fibroblasts showed intrinsic motility, exploring the surface of the plate with long lamellipodia and
30 filopodia, and thus coming in contacts with a high number of stationary MDCK islets. The time-length of the contacts between fibroblasts and control MDCK cells varied from 30 minutes to several hours, lasting mostly over 100 minutes. However, when fibroblasts were cultured with MDCK cells overexpressing plexin-A3, transient

contacts were observed, often lasting less than 30 minutes (see Fig. 7C). At higher cell density, fibroblasts stopped and clustered alongside the islands of control MDCKs, whereas they kept moving in a hectic fashion between the islands of plexin-A3 transfected cells (data not shown).

5 This cell-repelling effect is not due to the release of soluble factors, since exchanging conditioned media between mixed cultures was without effect (not shown). Moreover, the two different cell populations grew normally until they came into contact, indicating that the repelling effect requires cell-cell interaction. To rule out the possibility that plexin-A3 expressing cells generate an apoptotic signal for fibroblasts,
10 we monitored cell viability and apoptosis by TUNEL staining. As shown in Figure 7B, the clusters of repelled fibroblasts did not include apoptotic cells; furthermore, the detaching cells still excluded Trypan blue stain and were able to spread again on a new culture plate (not shown).

 Taken together, these results demonstrate that in our experimental system, plexin-
15 A3 mediates cell repelling cues, presumably by interacting with surface bound ligands on opposing cells. We could not identify –so far– the specific ligand for plexin-A3, however we propose that this may be a transmembrane semaphorin. It should be noted that the intracellular domains of transmembrane semaphorins, such as Sema4D, also
20 include tyrosine residues, which may themselves become phosphorylated and associate with cytoplasmic signal transducer molecules, a property shown for ligands of the ephrin family (Holland, S.J., Gale, N.W., Mbamalu, G., Yancopoulos, G.D., Henkemeyer, M., and Pawson, T. (1996) "Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands." *Nature* 383, 722-725).

What is claimed is:

- 5 1. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence that encodes an amino acid sequence selected from the group consisting of the amino acid sequence shown in (SEQ ID NO: 2 (plexin B-2)), (SEQ ID NO: 4 (plexin B-3)), (SEQ ID NO: 6 (plexin D-1)) and (SEQ ID NO: 8 (plexin A-4))
- 10 2. Isolated nucleic acid having at least 80% nucleic acid sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequence shown (SEQ ID NO: 1 (plexin B-2)), (SEQ ID NO: 3 (plexin B-3)), (SEQ ID NO: 5 (plexin D-1)) and (SEQ ID NO: 7 (plexin A-4)).
3. A vector comprising the nucleic acid of any one of claims 1 or 2.
- 15 4. An isolated polypeptide having at least 80% amino acid sequence identity to an amino acid sequence selected from the group consisting of the amino acid sequence shown in (SEQ ID NO: 2 (plexin B-2)), (SEQ ID NO: 4 (plexin B-3)), (SEQ ID NO: 6 (plexin D-1)) and (SEQ ID NO: 8 (plexin A-4)).
5. An isolated polypeptide having at least 80% amino acid sequence identity to:
 - 20 (a) the polypeptide shown in (SEQ ID NO: 2 (plexin B-2)), (SEQ ID NO: 4 (plexin B-3)), (SEQ ID NO: 6 (plexin D-1)) and (SEQ ID NO: 8 (plexin A-4)), lacking its associated signal peptide;
 - (b) an extracellular domain of the polypeptide shown in (SEQ ID NO: 2 (plexin B-2)), (SEQ ID NO: 4 (plexin B-3)), (SEQ ID NO: 6 (plexin D-1)) and (SEQ ID NO: 8 (plexin A-4)), with its associated signal peptide; or
 - 25 (c) an extracellular domain of the polypeptide shown in (SEQ ID NO: 2 (plexin B-2)), (SEQ ID NO: 4 (plexin B-3)), (SEQ ID NO: 6 (plexin D-1)) and (SEQ ID NO: 8 (plexin A-4)), lacking its associated signal peptide.

6. A chimeric molecule comprising a polypeptide according to claim 4 or 5 fused to a heterologous amino acid sequence.
7. The chimeric molecule of claim 6, wherein the heterologous amino acid sequence is a Fc region of an immunoglobulin.
- 5 8. An antibody that specifically binds to a polypeptide according to claim 4 or 5.
9. The antibody according to claim 8, wherein the antibody is a monoclonal, a humanized antibody or a single-chain antibody.
- 10 10. A method of suppressing or altering aberrant cell growth involving a signaling pathway between a plexin and a neuropilin in a mammal comprising the step of administering an effective amount of an agent to said mammal capable of interfering with the association between the plexin and neuropilin
- 15 11. A method of treating, suppressing or altering a disorder involving aberrant immune regulation involving a signaling pathway between a plexin and a neuropilin in a mammal comprising the step of administering an effective amount of an agent to said mammal capable of interfering with the association between the plexin and neuropilin.
-
- 20 12. The method according to claim 10 or 11 wherein said agent is a chimeric molecule according to claim 6 or 7.
13. The method according to claim 10 or 11, wherein said agent is an antibody according to claim 8 or 9.
- 25 14. A method of diagnosing or screening for tumors in a subject characterized by the expression profiles of the polypeptides according to claim 4 or 5 wherein the expression profile of the polypeptides is different in a non-tumor sample as compared to the expression profile of the polypeptides in a tumor sample.








Figure 1 (Tamagnone et al.)



#16.2





FIG. 3

Plexin-A3



Plexin-A2



Plexin-A1






FIG. 4


FIG. 5



G



H









Fig. 6



c

Persistent contacts (over 100 min)
 Transient contacts (less than 100 min)
 Very transient contacts (less than 30 min)

SEQUENCE LISTING

<110> University of Torino

<120> Novel Plexins and Uses Thereof

<130> A077PCT

<140> Not assigned yet

<141> 2000-08-25

<150> 60/150576

<151> 1999-08-25

<160> 12

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 6252

<212> DNA

<213> HOMO SAPIEN

<400> 1

gcgggggggca	atggcactgc	agctctgggc	cctgaccctg	ctgggcctgc	tgggcgcagg	60
tgccagcctg	aggccccgca	agctggactt	cttccgcagc	gagaaagagc	tgaaccacct	120
ggctgtggat	gaggcctcag	gcgtggtgta	cctggggggc	gtgaatgcc	tctaccagct	180
ggatgcgaag	ctgcagctgg	agcagcaggt	ggccacgggc	ccggccctgg	acaacaagaa	240
gtgcacgccg	cccatcgagg	ccagccagtg	ccatgaggct	gagatgactg	acaatgtcaa	300
ccagctgctg	ctgctcgacc	ctcccaggaa	gcgcctgggt	gagtgcggca	gcctcttcaa	360
gggcatctgc	gctctgcgcg	ccctgagcaa	catctccctc	cgctgttct	acgaggacgg	420
cagcggggag	aagtctttcg	tggccagcaa	tgatgagggc	gtggccacag	tggggctggt	480
gagctccacg	ggtcctgggt	gtgaccgcgt	gctgtttgtg	ggcaaaggca	atggggccaca	540
cgacaacggc	atcatcggtg	gcactcgggt	ggtggaccgg	actgacagca	gggaggcctt	600
tgaagcctac	acggaccacg	ccacctacaa	ggccgggtac	ctgtccacca	acacacagca	660
gttcgtggcg	gccttcgagg	acggccccta	cgtcttcttt	gtcttcaacc	agcaggacaa	720
gcacccggcc	cggaaccgca	cgctgctggc	acgcatgtgc	agagaagacc	ccaactacta	780
ctcctacctg	gagatggacc	tgcagtggcg	ggaccccgac	atccacgccg	ctgcctttgg	840
cacctgcctg	gccgcctccg	tggctgcgcc	tggctctggc	aggggtgctat	atgctgtctt	900
cagcagagac	agccggagca	gtggggggcc	cggtgcgggc	ctctgcctgt	tcccgctgga	960
caaggtgcac	gccaagatgg	aggccaaccg	caacgcctgt	tacacaggca	cccgggaggc	1020
ccgtgacatc	ttctacaagc	ccttccacgg	cgatatccag	tgcggcgggc	acgcgccggg	1080
ctccagcaag	agcttcccat	gtggctcgga	gcacctgccc	tacctgctgg	gcagccgcga	1140
cgggctcaga	ggcacagccg	tgctgcagcg	tggaggcctg	aacctcacgg	ccgtgacggt	1200
cgccgcggag	aacaaccaca	ctgttgcttt	tctgggcacc	tctgatggcc	ggatcctcaa	1260
ggtgtacctc	acccagatg	gcacctcctc	agagtacgac	tctatccttg	tggagataaa	1320
caagagagtc	aagcgcgacc	tggtagctgc	tggagacctg	ggcagcctgt	acgccatgac	1380
ccaggacaag	gtgttccggc	tgccggtgca	ggagtgcctg	agctacccca	cctgcaccca	1440
gtgccgcgac	tcccaggacc	cctactgcgg	ctggtgcgtc	gtcgagggac	gatgcacccg	1500
gaaggccgag	tgtccgcggg	ccgaggaggc	cagccactgg	ctgtggagcc	gaagcaagtc	1560
ctgcgtggcc	gtcaccagcg	cccagccaca	gaacatgagc	cgccggggcc	agggggagggt	1620
gcagctgacc	gtcagccccc	tccctgccct	gagcgaggag	gacgagttgc	tgtgcctttt	1680
tggggagtcg	ccgccacacc	ccgcccgcgt	ggagggcgag	gccgtcatct	gcaactcccc	1740

aagcagcattc	cccgtcacac	cgccaggcca	ggaccacgtg	gccgtgacca	tccagctcct	1800
ccttagacga	ggcaacatct	tcctcacgtc	ctaccagtac	cccttctacg	actgccgcca	1860
ggccatgagc	ctggaggaga	acctgccgtg	catctcctgc	gtgagcaacc	gctggacctg	1920
ccagtgggac	ctgcgtacc	acgagtgccg	ggaggcttcg	cccaaccctg	aggacggcat	1980
cgctccgtgcc	cacatggagg	acagctgtcc	ccagttcctg	ggacccagcc	ccctgggtgat	2040
ccccatgaac	cacgagacag	atgtgaactt	ccaggggcaag	aacctggaca	ccgtgaaggg	2100
ttcctccctg	cacgtgggca	gtgacttgct	caagttcatg	gagccgggtga	ccatgcagga	2160
atctgggacc	ttcgcccttc	ggacccccaa	gctgtcccac	gatgccaacg	agacgtgcc	2220
cccgcaacctc	tacgtcaagt	cttacggcaa	gaatatcgac	agcaagctcc	atgtgacctc	2280
ctacacacgc	tccttttgcc	gcagcgactg	cagcctgtgc	cgggccgcta	accccgaacta	2340
caggtctgcg	tggtgcgggg	gccagagcag	gtgctgtgat	gaggccctgt	gcaacaccac	2400
ctccgagtgc	ccgccgcccc	tcataccag	gatccagcct	gagacgggcc	ccctgggtgg	2460
gggcatccgc	atcaccatcc	tggggtccaa	tttgggcgtc	caagcagggg	acatccagag	2520
gatctctgtg	gcccggccgga	actgtccctt	tcagccggaa	cgttactccg	tgtccacctg	2580
gatcctgtgt	gtgactcggt	ctgcggagac	gcctttcacg	gggggtgtcg	aggtggacgt	2640
cttcgggaaa	ctgggcggtt	cgccctccaa	tgtccagttc	accttccaac	agcccaagcc	2700
tcctcagtg	gagccgcagc	agggaccgca	ggcggggcgg	accacactga	ccatccacgg	2760
cacccacctg	gacacgggct	cccaggagga	cgtgcgggtg	accctcaacg	gcgtcccgtg	2820
taaagtgcag	aagtttgggg	cgcagctcca	gtgtgtcact	ggcccccagg	cgacacgggg	2880
ccagatgctt	ctggaggctt	cctacggggg	gtcccccggt	cccaaccccg	gcattcttct	2940
cacctaccgc	gaaaaccccc	tactgcgacg	cttcgagccg	ctacgaagct	ttgccagtgg	3000
tggcccgagc	atcaacgtca	cgggtcaggg	cttcagcctg	atccagaggt	ttgccatggt	3060
ggctatcgcg	gagccctgc	agtccctggc	gccgcccgcg	gaggctgaat	ccctgcagcc	3120
catgacgggtg	gtgggtacag	actacgtggt	ccacaatgac	accaaggtcg	tcttctctgt	3180
cccggctgtg	cctgaggagc	cagaggccta	caacctcacg	gtgctgatcg	agatggacgg	3240
gcaccgtgcc	ctgctcagaa	cagaggcccg	ggccttcag	tacgtgcctg	accccacctt	3300
tgagaacttc	acaggtggcg	tcaagaagca	ggccaacaag	ctcatccacg	cccggggcac	3360
caatctgaac	aaggcgatga	cgctgcagga	ggccgaggcc	ttcgtgggtg	ccgagcgctg	3420
caccatgaag	acgctgacgg	agaccgacct	gtactgtgag	cccccgagg	tgcagcccc	3480
gcccacgagg	cggcagaaac	gagacaccac	acacaacctg	cccagattca	ttgtgaagtt	3540
cggtctccgc	gagtggtgct	tgggccgcgt	ggagtacgac	acacgggtga	gcgacgtgcc	3600
gcacagcctc	atcttgccgc	tggctatcgt	gcccattggt	gtcgtcatcg	cggtgtctgt	3660
ctactgctac	tggaggaaga	gccagcaggg	cgaacgagag	tatgagaaga	tcaagtccca	3720
gctggagggc	ctggaggaga	gcgtgcggga	ccgctgcaag	aagggaattca	cagacctgat	3780
gatcgagatg	gaggaccaga	ccaacgacgt	gcacgaggcc	ggcatccccg	tgctggacta	3840
caagacctac	accgaccgcg	tcttcttctt	gccctccaag	gacggcgaca	aggacgtgat	3900
gatcacccgc	aagctggaca	tccctgagcc	gcggcgcccg	gtggtggagc	aggccctcta	3960
ccagttctcc	aacctgctga	acagcaagtc	tttctctatc	aatttctatc	acacctgga	4020
gaaccagcgg	gagttctcgg	cccgcgcca	ggtctacttc	gcgtccctgc	tgacggtggc	4080
gctgcacggg	aaactggagt	actacacgga	catcatgcac	acgtctcttc	tggagctcct	4140
ggagcagtac	gtggtggcca	agaaccccaa	gctgatgctg	cgcaggtctg	agactgtggt	4200
ggagaggtatg	ctgtccaact	ggatgtccat	ctgcctgtac	cagtaacctca	aggacagtgc	4260
cggggagccc	ctgtacaagc	tcttcaaggc	catcaaacat	caggtggaaa	agggcccggt	4320
ggatgcggta	cagaagaagg	ccaagtacac	tctcaacgac	acggggctgc	tgggggatga	4380
tgtggagtac	gcacccctga	cggtagcgt	gatcgtgcag	gacgaggag	tggacgccat	4440
cccgggtgaag	gtcctcaact	gtgacaccat	ctcccaggtc	aaggagaaga	tcattgacca	4500
gggtgacctg	gggcagccct	gctcctgctg	gcccaggcca	gacagcgtgg	tcctggagtg	4560
gcgtccgggc	tccacagcgc	agatcctgtc	ggacctggac	ctgacgtcac	agcgggaggg	4620
ccggtggaag	cgcgtcaaca	cccttatgca	ctacaatgtc	cgggatggag	ccacctcat	4680
cctgtccaag	gtgggggtct	cccagcagcc	ggaggacagc	cagcaggacc	tgcctgggga	4740
gcgccatgcc	ctcctggagg	aggagaaccg	ggtgtggcac	ctggtgcggc	cgaccgacga	4800
gggtggacgag	ggcaagtcca	agagaggcag	cgtgaaagag	aaggagcgga	cgaaggccat	4860
caccgagatc	tacctgacgc	ggctgctctc	agtcaagggc	acactgcagc	agtttgtgga	4920
caacttcttc	cagagcgtgc	tggcgccctg	gcacgcggtg	ccacctgcag	tcaagtactt	4980
cttcgacttc	ctggacgagc	aggcagagaa	gcacaacatc	caggatgaag	acaccatcca	5040

catctggaag	acgaacagct	taccgctccg	gttctgggtg	aacatcctca	agaacccccca	5100
cttcatcttt	gacgtgcatg	tccacgaggt	ggtggacgcc	tcgctgtcag	tcacgcgcga	5160
gaccttcatg	gatgcctgca	cgcgcacgga	gcataagctg	agccgcgatt	ctcccagcaa	5220
caagctgctg	tacgccaagg	agatctccac	ctacaagaag	atggtggagg	attactacaa	5280
ggggatccgg	cagatgggtc	aggtcagcga	ccaggacatg	aacacacacc	tggcagagat	5340
ttcccggggc	cacacggact	ccttgaacac	cctcgtggca	ctccaccagc	tctaccaata	5400
cacgcagaag	tactatgacg	agatcatcaa	tgccttggag	gaggatcctg	ccgcccagaa	5460
gatgcagctg	gccttccgcc	tgcagcagat	tgccgctgca	ctggagaaca	aggctactga	5520
cctctgacct	acaatctcca	gtgctgcctt	gggacatagg	tacctgaggt	acctgagagc	5580
ccctcagggg	aggaggccga	gtggctgtgg	ctgaggcccc	caccctcccc	tggaacgcgc	5640
cccaagccgg	agtgggtgca	gccggaaccc	gccagcgctc	tagactgtag	catcttcctc	5700
tgagcaatac	cgcggggcac	cgcaccagca	ccagccccag	ccccagctcc	ctccggccgc	5760
agaaccagca	tcgggtgttc	actgtcagat	ctcagatgat	ttgaaaatgt	gccttacgct	5820
gccacgctgg	gggcagctgg	cctccgcctc	cgccccacgca	ccagcagccg	cctccatgcc	5880
ctagggttggg	cccctggggg	atctgagggc	ctgtggcccc	cagggcaagt	tcccagatcc	5940
tatgtctgtc	tgtccaccac	gagatgggag	gaggagaaaa	agcggtaacga	tgccttcctg	6000
acctcacccg	cctccccaag	ggtgccggca	ctctgggtgg	actcacggct	gctgggcccc	6060
acgtcaaagg	tcaagtgaga	cgtaggtcaa	gtcctacgtc	ggggcccaga	catcctgggg	6120
tcctggtctg	tcagacaggc	tgccctagag	ccccaccag	tccgggggga	ctgggagcag	6180
ttccaagacc	acccccaccc	tttttgtaaa	tcttgttcat	tgtaaatcaa	atacagcgtc	6240
tttttcactc	cg					6252

<210> 2
 <211> 1838
 <212> PRT
 <213> HOMO SAPIEN

<400> 2

Met	Ala	Leu	Gln	Leu	Trp	Ala	Leu	Thr	Leu	Leu	Gly	Leu	Leu	Gly	Ala
1			5				10				15				
Gly	Ala	Ser	Leu	Arg	Pro	Arg	Lys	Leu	Asp	Phe	Phe	Arg	Ser	Glu	Lys
			20				25					30			
Glu	Leu	Asn	His	Leu	Ala	Val	Asp	Glu	Ala	Ser	Gly	Val	Val	Tyr	Leu
		35				40					45				
Gly	Ala	Val	Asn	Ala	Leu	Tyr	Gln	Leu	Asp	Ala	Lys	Leu	Gln	Leu	Glu
	50				55				60						
Gln	Gln	Val	Ala	Thr	Gly	Pro	Ala	Leu	Asp	Asn	Lys	Lys	Cys	Thr	Pro
65				70		75					80				
Pro	Ile	Glu	Ala	Ser	Gln	Cys	His	Glu	Ala	Glu	Met	Thr	Asp	Asn	Val
			85			90					95				
Asn	Gln	Leu	Leu	Leu	Leu	Asp	Pro	Pro	Arg	Lys	Arg	Leu	Val	Glu	Cys
		100				105						110			
Gly	Ser	Leu	Phe	Lys	Gly	Ile	Cys	Ala	Leu	Arg	Ala	Leu	Ser	Asn	Ile
	115				120						125				
Ser	Leu	Arg	Leu	Phe	Tyr	Glu	Asp	Gly	Ser	Gly	Glu	Lys	Ser	Phe	Val
	130				135						140				
Ala	Ser	Asn	Asp	Glu	Gly	Val	Ala	Thr	Val	Gly	Leu	Val	Ser	Ser	Thr
145					150					155					160
Gly	Pro	Gly	Gly	Asp	Arg	Val	Leu	Phe	Val	Gly	Lys	Gly	Asn	Gly	Pro
			165						170					175	
His	Asp	Asn	Gly	Ile	Ile	Val	Ser	Thr	Arg	Leu	Leu	Asp	Arg	Thr	Asp
		180						185					190		
Ser	Arg	Glu	Ala	Phe	Glu	Ala	Tyr	Thr	Asp	His	Ala	Thr	Tyr	Lys	Ala

Leu	Arg	Tyr	His	Glu	Cys	Arg	Glu	Ala	Ser	Pro	Asn	Pro	Glu	Asp	Gly	645	650	655
Ile	Val	Arg	Ala	His	Met	Glu	Asp	Ser	Cys	Pro	Gln	Phe	Leu	Gly	Pro	660	665	670
Ser	Pro	Leu	Val	Ile	Pro	Met	Asn	His	Glu	Thr	Asp	Val	Asn	Phe	Gln	675	680	685
Gly	Lys	Asn	Leu	Asp	Thr	Val	Lys	Gly	Ser	Ser	Leu	His	Val	Gly	Ser	690	695	700
Asp	Leu	Leu	Lys	Phe	Met	Glu	Pro	Val	Thr	Met	Gln	Glu	Ser	Gly	Thr	705	710	715
Phe	Ala	Phe	Arg	Thr	Pro	Lys	Leu	Ser	His	Asp	Ala	Asn	Glu	Thr	Leu	725	730	735
Pro	Leu	His	Leu	Tyr	Val	Lys	Ser	Tyr	Gly	Lys	Asn	Ile	Asp	Ser	Lys	740	745	750
Leu	His	Val	Thr	Leu	Tyr	Asn	Cys	Ser	Phe	Gly	Arg	Ser	Asp	Cys	Ser	755	760	765
Leu	Cys	Arg	Ala	Ala	Asn	Pro	Asp	Tyr	Arg	Cys	Ala	Trp	Cys	Gly	Gly	770	775	780
Gln	Ser	Arg	Cys	Val	Tyr	Glu	Ala	Leu	Cys	Asn	Thr	Thr	Ser	Glu	Cys	785	790	795
Pro	Pro	Pro	Val	Ile	Thr	Arg	Ile	Gln	Pro	Glu	Thr	Gly	Pro	Leu	Gly	805	810	815
Gly	Gly	Ile	Arg	Ile	Thr	Ile	Leu	Gly	Ser	Asn	Leu	Gly	Val	Gln	Ala	820	825	830
Gly	Asp	Ile	Gln	Arg	Ile	Ser	Val	Ala	Gly	Arg	Asn	Cys	Ser	Phe	Gln	835	840	845
Pro	Glu	Arg	Tyr	Ser	Val	Ser	Thr	Arg	Ile	Val	Cys	Val	Ile	Glu	Ala	850	855	860
Ala	Glu	Thr	Pro	Phe	Thr	Gly	Gly	Val	Glu	Val	Asp	Val	Phe	Gly	Lys	865	870	875
Leu	Gly	Arg	Ser	Pro	Pro	Asn	Val	Gln	Phe	Thr	Phe	Gln	Gln	Pro	Lys	885	890	895
Pro	Leu	Ser	Val	Glu	Pro	Gln	Gln	Gly	Pro	Gln	Ala	Gly	Gly	Thr	Thr	900	905	910
Leu	Thr	Ile	His	Gly	Thr	His	Leu	Asp	Thr	Gly	Ser	Gln	Glu	Asp	Val	915	920	925
Arg	Val	Thr	Leu	Asn	Gly	Val	Pro	Cys	Lys	Val	Thr	Lys	Phe	Gly	Ala	930	935	940
Gln	Leu	Gln	Cys	Val	Thr	Gly	Pro	Gln	Ala	Thr	Arg	Gly	Gln	Met	Leu	945	950	955
Leu	Glu	Val	Ser	Tyr	Gly	Gly	Ser	Pro	Val	Pro	Asn	Pro	Gly	Ile	Phe	965	970	975
Phe	Thr	Tyr	Arg	Glu	Asn	Pro	Val	Leu	Arg	Ala	Phe	Glu	Pro	Leu	Arg	980	985	990
Ser	Phe	Ala	Ser	Gly	Gly	Arg	Ser	Ile	Asn	Val	Thr	Gly	Gln	Gly	Phe	995	1000	1005
Ser	Leu	Ile	Gln	Arg	Phe	Ala	Met	Val	Val	Ile	Ala	Glu	Pro	Leu	Gln	1010	1015	1020
Ser	Trp	Gln	Pro	Pro	Arg	Glu	Ala	Glu	Ser	Leu	Gln	Pro	Met	Thr	Val	1025	1030	1035
Val	Gly	Thr	Asp	Tyr	Val	Phe	His	Asn	Asp	Thr	Lys	Val	Val	Phe	Leu	1045	1050	1055
Ser	Pro	Ala	Val	Pro	Glu	Glu	Pro	Glu	Ala	Tyr	Asn	Leu	Thr	Val	Leu	1060	1065	1070
Ile	Glu	Met	Asp	Gly	His	Arg	Ala	Leu	Leu	Arg	Thr	Glu	Ala	Gly	Ala			

1075	1080	1085
Phe Glu Tyr Val Pro Asp	Pro Thr Phe Glu Asn	Phe Thr Gly Gly Val
1090	1095	1100
Lys Lys Gln Val Asn Lys	Leu Ile His Ala Arg	Gly Thr Asn Leu Asn
1105	1110	1115
Lys Ala Met Thr Leu Gln	Glu Ala Phe Val Gly	Ala Glu Arg
1125	1130	1135
Cys Thr Met Lys Thr Leu	Thr Glu Thr Asp Leu	Tyr Cys Glu Pro Pro
1140	1145	1150
Glu Val Gln Pro Pro Lys	Arg Arg Gln Lys Arg	Asp Thr Thr His
1155	1160	1165
Asn Leu Pro Glu Phe Ile	Val Lys Phe Gly Ser	Arg Glu Trp Val Leu
1170	1175	1180
Gly Arg Val Glu Tyr Asp	Thr Arg Val Ser Asp	Val Pro Leu Ser Leu
1185	1190	1195
Ile Leu Pro Leu Val Ile	Val Pro Met Val Val	Val Ile Ala Val Ser
1205	1210	1215
Val Tyr Cys Tyr Trp Arg	Lys Ser Gln Gln Ala	Glu Arg Glu Tyr Glu
1220	1225	1230
Lys Ile Lys Ser Gln Leu	Glu Gly Leu Glu Glu	Ser Val Arg Asp Arg
1235	1240	1245
Cys Lys Lys Glu Phe Thr	Asp Leu Met Ile Glu	Met Glu Asp Gln Thr
1250	1255	1260
Asn Asp Val His Glu Ala	Gly Ile Pro Val Leu	Asp Tyr Lys Thr Tyr
1265	1270	1275
Thr Asp Arg Val Phe Phe	Leu Pro Ser Lys Asp	Gly Asp Lys Asp Val
1285	1290	1295
Met Ile Thr Gly Lys Leu	Asp Ile Pro Glu Pro	Arg Arg Pro Val Val
1300	1305	1310
Glu Gln Ala Leu Tyr Gln	Phe Ser Asn Leu Leu	Asn Ser Lys Ser Phe
1315	1320	1325
Leu Ile Asn Phe Ile His	Thr Leu Glu Asn Gln	Arg Glu Phe Ser Ala
1330	1335	1340
Arg Ala Lys Val Tyr Phe	Ala Ser Leu Leu Thr	Val Ala Leu His Gly
1345	1350	1355
Lys Leu Glu Tyr Tyr Thr	Asp Ile Met His Thr	Leu Phe Leu Glu Leu
1365	1370	1375
Leu Glu Gln Tyr Val Val	Ala Lys Asn Pro Lys	Leu Met Leu Arg Arg
1380	1385	1390
Ser Glu Thr Val Val Glu	Arg Met Leu Ser Asn	Trp Met Ser Ile Cys
1395	1400	1405
Leu Tyr Gln Tyr Leu Lys	Asp Ser Ala Gly Glu	Pro Leu Tyr Lys Leu
1410	1415	1420
Phe Lys Ala Ile Lys His	Gln Val Glu Lys Gly	Pro Val Asp Ala Val
1425	1430	1435
Gln Lys Lys Ala Lys Tyr	Thr Leu Asn Asp Thr	Gly Leu Leu Gly Asp
1445	1450	1455
Asp Val Glu Tyr Ala Pro	Leu Thr Val Ser Val	Ile Val Gln Asp Glu
1460	1465	1470
Gly Val Asp Ala Ile Pro	Val Lys Val Leu Asn	Cys Asp Thr Ile Ser
1475	1480	1485
Gln Val Lys Glu Lys Ile	Ile Asp Gln Val Tyr	Arg Gly Gln Pro Cys
1490	1495	1500
Ser Cys Trp Pro Arg Pro	Asp Ser Val Val Leu	Glu Trp Arg Pro Gly
1505	1510	1515
		1520

Ser Thr Ala Gln Ile Leu Ser Asp Leu Asp Leu Thr Ser Gln Arg Glu
 1525 1530 1535
 Gly Arg Trp Lys Arg Val Asn Thr Leu Met His Tyr Asn Val Arg Asp
 1540 1545 1550
 Gly Ala Thr Leu Ile Leu Ser Lys Val Gly Val Ser Gln Gln Pro Glu
 1555 1560 1565
 Asp Ser Gln Gln Asp Leu Pro Gly Glu Arg His Ala Leu Leu Glu Glu
 1570 1575 1580
 Glu Asn Arg Val Trp His Leu Val Arg Pro Thr Asp Glu Val Asp Glu
 1585 1590 1595 1600
 Gly Lys Ser Lys Arg Gly Ser Val Lys Glu Lys Glu Arg Thr Lys Ala
 1605 1610 1615
 Ile Thr Glu Ile Tyr Leu Thr Arg Leu Leu Ser Val Lys Gly Thr Leu
 1620 1625 1630
 Gln Gln Phe Val Asp Asn Phe Phe Gln Ser Val Leu Ala Pro Gly His
 1635 1640 1645
 Ala Val Pro Pro Ala Val Lys Tyr Phe Phe Asp Phe Leu Asp Glu Gln
 1650 1655 1660
 Ala Glu Lys His Asn Ile Gln Asp Glu Asp Thr Ile His Ile Trp Lys
 1665 1670 1675 1680
 Thr Asn Ser Leu Pro Leu Arg Phe Trp Val Asn Ile Leu Lys Asn Pro
 1685 1690 1695
 His Phe Ile Phe Asp Val His Val His Glu Val Val Asp Ala Ser Leu
 1700 1705 1710
 Ser Val Ile Ala Gln Thr Phe Met Asp Ala Cys Thr Arg Thr Glu His
 1715 1720 1725
 Lys Leu Ser Arg Asp Ser Pro Ser Asn Lys Leu Leu Tyr Ala Lys Glu
 1730 1735 1740
 Ile Ser Thr Tyr Lys Lys Met Val Glu Asp Tyr Tyr Lys Gly Ile Arg
 1745 1750 1755 1760
 Gln Met Val Gln Val Ser Asp Gln Asp Met Asn Thr His Leu Ala Glu
 1765 1770 1775
 Ile Ser Arg Ala His Thr Asp Ser Leu Asn Thr Leu Val Ala Leu His
 1780 1785 1790
 Gln Leu Tyr Gln Tyr Thr Gln Lys Tyr Tyr Asp Glu Ile Ile Asn Ala
 1795 1800 1805
 Leu Glu Glu Asp Pro Ala Ala Gln Lys Met Gln Leu Ala Phe Arg Leu
 1810 1815 1820
 Gln Gln Ile Ala Ala Ala Leu Glu Asn Lys Val Thr Asp Leu
 1825 1830 1835

<210> 3
 <211> 5367
 <212> DNA
 <213> HOMO SAPIEN

<400> 3
 atggctcgct ggccctccctt cggcctctgc ctccctcctgc tgctgctgctc cccaccgcca 60
 ctgcccttga cagggggccca tcgcttctcc gcaccttaata ccactctcaa ccacttggca 120
 ctggcacctg gccgaggcac actctatgtc ggcgagtgta accgcctctt ccagctcagc 180
 cccgagctgc agctcgaggc cgtggctgtc actggccctg taatcgacag ccctgactgc 240
 gtgcccttcc gtgacccagc cgagtgccca caggcccagc tcaactgacaa tgccaaccag 300
 ctgctgctgg tgagcagccg cgcccaggag ctggtggcct gcgggcaggt gcggcagggc 360
 gtgtgtgaga cacgggcgct tggggatgtg gccgaggtgc tgtaccaggc tgaggaccct 420
 ggtgacgggc agtttgtggc tgccaatacc ccgggagtggt caacggtggg gctggtggtg 480

cccttgcccc	gccgggacct	cctgcttggt	gccagaggcc	tggcgggcaa	gctgtcggca	540
ggggtgccac	ccctggccat	ccgccagctg	gccgggtctc	agcccttctc	cagcgagggc	600
ctgggcccgc	tgggtggtgg	cgacttctcc	gactacaaca	acagctacgt	cggggccttt	660
gccgacgccc	gctccgccta	cttcgtgttc	cgccgcccgc	gggcccgggc	ccaggctgag	720
taccgctcct	acgtggcccc	cgtctgcctg	ggggacacca	acctgtactc	ctacgtggag	780
gtccccctcg	cctgccaggc	ccagggcctc	atccaggccc	ccttccttgc	cccgggcacc	840
ttgctagggg	tgtttgccgc	gggcccgaag	ggcaccacag	cggcgctctg	tgccttcccc	900
atgggtggagc	tgggtgccag	catggagcag	gcccggagac	tctgctacac	ggcgggcggc	960
cgggggcccca	gcggcgcgaga	ggaagccacc	gtggagtacg	gcgtcacgtc	gcgctgcgtc	1020
accctgcccc	ttgattcccc	cgagtcgtac	ccctgtggcg	acgagcacac	ccccagcccc	1080
attgtgtggc	gccagcccc	ggaggtccag	cctctgttga	agctcgggca	gccggtcagc	1140
gccgtggcag	ctctccaggc	agatggggac	atgatagcct	tcctggggga	cacccagggc	1200
cagctgtaca	aggtctttct	ccacggctcc	cagggccagg	tttaccactc	ccagcaagtg	1260
gggcctccag	gctcagccat	cagcccagac	ctgctgtctg	acagcagtgg	cagtcacctc	1320
tatgtcctga	ctgcccacca	ggtggaccgg	atacctgtgg	cagcctgccc	ccagttccct	1380
gactgtgcca	gctgcctcca	ggcccaggac	ccgctgtgtg	gctgggtgtg	cctccagggc	1440
aggtgtacca	ggaaggccca	gtgcggcgcg	gcaggccagc	tgaaccagtg	gctgtggagt	1500
tatgaggagg	acagccactg	cctgcacatc	cagagcctgc	tgccgggcca	ccacccccgc	1560
caggagcagg	gccaggtcac	tttgtctgtc	ccccggctgc	ccatcctgga	tgcagatgaa	1620
tacttccatt	gtgcgttcgg	ggactatgac	agcttggctc	atgtggaagg	gccccacgtg	1680
gcctgtgtca	ccccccccca	agaccagggt	ccacttaacc	ctccaggcac	agaccacgtc	1740
actgtgcccc	tggccctgat	gttcgaggac	gtgactgtgg	ctgccaccaa	cttctccttt	1800
tatgactgca	gtgccgtcca	ggccttggag	gcggctgccc	ccgtccttcc	ccagggcctg	1860
cctgcctcct	tccactgctg	gctggagctg	cctggagaac	ttcggggact	gccggccacc	1920
ctggaggaga	cagcagggga	ttcaggcctc	atccactgcc	aggccccacca	gcggggagctc	1980
ccagtgccca	tctacgtcac	ccagggtgaa	gcccagaggc	tggacaacac	ccatgctcct	2040
tatggtgagc	ctgagggcag	ccaggcaggc	gggtgagggt	gggtggcaga	caggaggcgc	2100
tcagcacact	ccctgaccct	ccctagtgat	cctgtacgac	tgcgccatgg	gccacccgga	2160
ctgcagccac	tgccaaagcg	ccaacaggag	cctgggctgc	ctgtgaccag	ccctgccccca	2220
ggcccccaaa	ccccagcagc	tcggcctggc	tgggttggtt	ggctggccgg	gcacccagca	2280
ctgcagagtg	gagcgtgggt	gcgggggacc	ccatctgcca	tcatttgcct	gctgcaggtc	2340
gagcccttga	ccggtcccc	tgaggggagg	ttggccctca	ccatcctggg	ctccaacctg	2400
ggccgggcct	tcgccgatgt	gcagtacgcc	gacctgtcc	tgctgagcct	gagtcctcgc	2460
tggggccccc	aggcaggggg	cacccagctc	accatccgag	gtcagcacct	ccagacaggt	2520
ggcaacacca	gtgccttcgt	gggtggccaa	ccctgtccca	tgggtgggcg	actgatccgt	2580
gtcaggggca	ccggcctaga	cgtggtgcag	cggccctac	tgtctgtgtg	gctggaggct	2640
gacgcagagg	tgcaggcttc	cagggcccag	ccccaggacc	cacagccaag	gaggagctgt	2700
ggagcccttg	ctgcggaccc	ccaggcttgt	atccagctcg	gtgggggggct	gctgcagcgc	2760
acagcagagc	ccagctcact	ccacctgtgg	tcggccctga	atgccccaca	gtgctccacc	2820
gtctgtctcg	tcaactcgtc	cagcctcctc	ctgtgcccga	gccctgctgt	accagacaga	2880
gcccacccgc	agcgggtctt	cttcacctta	gacaactgtc	aagtggactt	cgccagtgcc	2940
agtggggggc	agggcttctc	gtaccagccc	aacccccgcc	tggcaccctt	cagccgcgag	3000
gggcctgccc	gcccctaccg	cctcaagcca	ggccatgtcc	tggatgtgga	gggcgagggc	3060
gtcaaccttg	gcacagcaca	ggaggagggt	cgcgtgcaca	tcggcccgcg	cgagtgcctg	3120
gtgaagacgc	tcacgcgcac	ccacctgtac	tgcgagccgc	ctgcgcacgc	cccgcagcct	3180
gccaatggct	ccggcctgcc	acagttcctg	gtgcagatgg	gcaatgtgca	gctggccctg	3240
ggccctgtgc	agtacgaggg	tgaacccccg	ctgtctgcct	ttcccgtgga	ggcccaggca	3300
ggcgtgggca	tgggtgctgc	agtgtgatt	gccgccgtgc	tcctcctcac	cctcatgtac	3360
aggcacaaga	gcaagcaggc	cctgcccggac	taccagaagg	tgctagtgca	gctggagagc	3420
ctggagaccg	gcgtgggaga	ccagtgccgc	aaggagtcca	cagacctcat	gacggagatg	3480
accgacctca	gcagcgacct	ggagggcagc	gggatcccct	tcctggacta	ccgcacctac	3540
gccgagcgcg	ccttcttccc	tggccatggc	ggttgcccgc	tgcagcccaa	gcctgagggg	3600
ccaggggagg	acggccactg	tgccactgtg	cgccagggcc	tcacgcagct	ctccaacctg	3660
ctcaacagca	agctcttctc	cctcacgggt	agggccgtgt	ggcgggagtg	cccagtgggc	3720
aaggagggtg	ggctggggaa	ctactggcct	gagacaaagg	tgggggagga	gacagagacc	3780

```

atggtggaga aactgctcac caactggctg tccatctgcc tgtacgcctt cctgagggag 3840
gtggctgggtg aaccactgta catgctcttc cgggccatcc agtaccaggt ggacaaaggg 3900
cccggtggacg ccgtgacagg caaggccaaa cggaccctga atgatagccg cttgctgcgg 3960
gaggacgtgg agttccagcc cctgacgctg atggtgctgg tggggcccgg ggctggcggg 4020
gccgcaggca gcagcgagat gcagcgctg ccagcccggg tgctcgacac ggacaccatc 4080
acccaggtca aggagaaggt gttggaccaa gtctacaagg gcaccccctt ctcccagagg 4140
cccttcctga atgcccctaga ccttgggtgag agagccagcc ctgcccaccc accccagggg 4200
cccttcctga cccctccggc acctggagcc cctcaactgt gtcttactat gaacataccc 4260
acgctggagg atggcgaggga ggggggggtg tgctctctggc acctggtgaa agccaccgag 4320
gagccagaag gggccaaggt gcggtgcagc agcctgcggg agcgcgagcc agcaagggcc 4380
aaggccattc cggaaatcta cctcaccctg ctgctgtcca tgaaggttgg tgcggcctgg 4440
gtggctgggg ctgagaggag gctcagccag ggaccccggc cgagccaggg tgtgggaggg 4500
gcagggggcag cctcagccgt ggatggcccc cacaccctgc cctccacaca gcccttatcc 4560
cctgcctcgc agggcacgct gcagaagttt gtggacgaca ccttccaggc cattctcagc 4620
gtgaaccggc ccatcccatat cgccgtcaag tacctgtttg accttctgga tgagctagca 4680
gagaagcacg gcatcgagga cccagggacc ctgcacatct ggaagaccaa cagtctgctg 4740
ctgcggttct ggggtgaatgc cttgaagaac ccacagctca tctttgatgt acgggtgtcg 4800
gacaatgtgg acgcccacatc tgctgtcatc gcccagacct tcattgactc ctgtaccacc 4860
tcggagcata aagtggggccg ggtgagagca gtgccagcag cagcagctgg caggggcttg 4920
aggaggaaag gcttatgggg gaagcctaga gggctgtgca cagagctctg ggtgggcagt 4980
ggcagcatca tgggggcacc ttcacctccg agctcatgcc tagcgccctc cctccctccg 5040
gagcaggatt ccccagtgaa caaactgctc tacgcccggg agatcccacg ctacaagcag 5100
atggtggaga ggtactatgc ggacattcgc cagagctctc cggcgagcta ccaggagatg 5160
aactctgctt tggctgagct ctccgggaac tacactttctg ctccccactg tctggaggct 5220
ctgcaagaac tctacaacca catccacagg tactatgatc agattatcag tgccctggag 5280
gaggaccctg tgggcccagaa gctgcagctg gcctgccggc tgcagcaggt cgccgccttg 5340
gtggaaaaca aagtgactga cctgtga

```

<210> 4
 <211> 1788
 <212> PRT
 <213> HOMO SAPIEN

```

<400> 4
Met Ala Arg Trp Pro Phe Gly Leu Cys Leu Leu Leu Leu Leu Leu
1      5      10      15
Ser Pro Pro Pro Leu Pro Leu Thr Gly Ala His Arg Phe Ser Ala Pro
20      25      30
Asn Thr Thr Leu Asn His Leu Ala Leu Ala Pro Gly Arg Gly Thr Leu
35      40      45
Tyr Val Gly Ala Val Asn Arg Leu Phe Gln Leu Ser Pro Glu Leu Gln
50      55      60
Leu Glu Ala Val Ala Val Thr Gly Pro Val Ile Asp Ser Pro Asp Cys
65      70      75      80
Val Pro Phe Arg Asp Pro Ala Glu Cys Pro Gln Ala Gln Leu Thr Asp
85      90      95
Asn Ala Asn Gln Leu Leu Leu Val Ser Ser Arg Ala Gln Glu Leu Val
100     105     110
Ala Cys Gly Gln Val Arg Gln Gly Val Cys Glu Thr Arg Arg Leu Gly
115     120     125
Asp Val Ala Glu Val Leu Tyr Gln Ala Glu Asp Pro Gly Asp Gly Gln
130     135     140
Phe Val Ala Ala Asn Thr Pro Gly Val Ala Thr Val Gly Leu Val Val

```

145	Pro	Leu	Pro	Gly	Arg	Asp	Leu	Leu	Leu	Val	Ala	Arg	Gly	Leu	Ala	Gly
					165					170						175
Lys	Leu	Ser	Ala	Gly	Val	Pro	Pro	Leu	Ala	Ile	Arg	Gln	Leu	Ala	Gly	
			180					185					190			
Ser	Gln	Pro	Phe	Ser	Ser	Glu	Gly	Leu	Gly	Arg	Leu	Val	Val	Gly	Asp	
		195					200					205				
Phe	Ser	Asp	Tyr	Asn	Asn	Ser	Tyr	Val	Gly	Ala	Phe	Ala	Asp	Ala	Arg	
	210					215					220					
Ser	Ala	Tyr	Phe	Val	Phe	Arg	Arg	Arg	Gly	Ala	Arg	Ala	Gln	Ala	Glu	
225					230					235					240	
Tyr	Arg	Ser	Tyr	Val	Ala	Arg	Val	Cys	Leu	Gly	Asp	Thr	Asn	Leu	Tyr	
				245					250				255			
Ser	Tyr	Val	Glu	Val	Pro	Leu	Ala	Cys	Gln	Gly	Gln	Gly	Leu	Ile	Gln	
		260						265					270			
Ala	Ala	Phe	Leu	Ala	Pro	Gly	Thr	Leu	Leu	Gly	Val	Phe	Ala	Ala	Gly	
		275					280					285				
Pro	Arg	Gly	Thr	Gln	Ala	Ala	Leu	Cys	Ala	Phe	Pro	Met	Val	Glu	Leu	
	290					295					300					
Gly	Ala	Ser	Met	Glu	Gln	Ala	Arg	Arg	Leu	Cys	Tyr	Thr	Ala	Gly	Gly	
305					310					315					320	
Arg	Gly	Pro	Ser	Gly	Ala	Glu	Glu	Ala	Thr	Val	Glu	Tyr	Gly	Val	Thr	
				325					330					335		
Ser	Arg	Cys	Val	Thr	Leu	Pro	Leu	Asp	Ser	Pro	Glu	Ser	Tyr	Pro	Cys	
		340						345					350			
Gly	Asp	Glu	His	Thr	Pro	Ser	Pro	Ile	Ala	Gly	Arg	Gln	Pro	Leu	Glu	
		355					360					365				
Val	Gln	Pro	Leu	Leu	Lys	Leu	Gly	Gln	Pro	Val	Ser	Ala	Val	Ala	Ala	
	370					375					380					
Leu	Gln	Ala	Asp	Gly	His	Met	Ile	Ala	Phe	Leu	Gly	Asp	Thr	Gln	Gly	
385					390					395					400	
Gln	Leu	Tyr	Lys	Val	Phe	Leu	His	Gly	Ser	Gln	Gly	Gln	Val	Tyr	His	
			405					410						415		
Ser	Gln	Gln	Val	Gly	Pro	Pro	Gly	Ser	Ala	Ile	Ser	Pro	Asp	Leu	Leu	
			420					425					430			
Leu	Asp	Ser	Ser	Gly	Ser	His	Leu	Tyr	Val	Leu	Thr	Ala	His	Gln	Val	
	435						440					445				
Asp	Arg	Ile	Pro	Val	Ala	Ala	Cys	Pro	Gln	Phe	Pro	Asp	Cys	Ala	Ser	
	450					455					460					
Cys	Leu	Gln	Ala	Gln	Asp	Pro	Leu	Cys	Gly	Trp	Cys	Val	Leu	Gln	Gly	
465					470				475						480	
Arg	Cys	Thr	Arg	Lys	Gly	Gln	Cys	Gly	Arg	Ala	Gly	Gln	Leu	Asn	Gln	
				485					490					495		
Trp	Leu	Trp	Ser	Tyr	Glu	Glu	Asp	Ser	His	Cys	Leu	His	Ile	Gln	Ser	
		500						505					510			
Leu	Leu	Pro	Gly	His	His	Pro	Arg	Gln	Glu	Gln	Gly	Gln	Val	Thr	Leu	
		515					520					525				
Ser	Val	Pro	Arg	Leu	Pro	Ile	Leu	Asp	Ala	Asp	Glu	Tyr	Phe	His	Cys	
	530					535					540					
Ala	Phe	Gly	Asp	Tyr	Asp	Ser	Leu	Ala	His	Val	Glu	Gly	Pro	His	Val	
545					550					555					560	
Ala	Cys	Val	Thr	Pro	Pro	Gln	Asp	Gln	Val	Pro	Leu	Asn	Pro	Pro	Gly	
				565					570					575		
Thr	Asp	His	Val	Thr	Val	Pro	Leu	Ala	Leu	Met	Phe	Glu	Asp	Val	Thr	
			580					585					590			

Val	Ala	Ala	Thr	Asn	Phe	Ser	Phe	Tyr	Asp	Cys	Ser	Ala	Val	Gln	Ala
		595					600					605			
Leu	Glu	Ala	Ala	Ala	Pro	Val	Leu	Pro	Gln	Gly	Leu	Pro	Ala	Ser	Phe
	610					615					620				
His	Cys	Trp	Leu	Glu	Leu	Pro	Gly	Glu	Leu	Arg	Gly	Leu	Pro	Ala	Thr
625					630					635					640
Leu	Glu	Glu	Thr	Ala	Gly	Asp	Ser	Gly	Leu	Ile	His	Cys	Gln	Ala	His
				645					650						655
Gln	Arg	Glu	Leu	Pro	Val	Pro	Ile	Tyr	Val	Thr	Gln	Gly	Glu	Ala	Gln
			660					665					670		
Arg	Leu	Asp	Asn	Thr	His	Ala	Leu	Tyr	Gly	Glu	Pro	Glu	Gly	Ser	Gln
		675					680					685			
Ala	Gly	Gly	Ala	Gly	Trp	Val	Ala	Asp	Arg	Arg	Arg	Ser	Ala	His	Cys
	690					695					700				
Leu	Thr	Leu	Pro	Ser	Asp	Pro	Val	Arg	Leu	Arg	His	Gly	Pro	Pro	Gly
705					710					715					720
Leu	Gln	Pro	Leu	Pro	Ser	Gly	Gln	Gln	Glu	Pro	Gly	Leu	Pro	Val	Thr
				725					730						735
Ser	Pro	Ala	Pro	Gly	Pro	Gln	Thr	Pro	Ala	Ala	Arg	Pro	Gly	Trp	Ala
			740					745					750		
Gly	Trp	Leu	Ala	Gly	His	Pro	Ala	Leu	Gln	Ser	Gly	Ala	Trp	Val	Arg
		755					760					765			
Gly	Thr	Pro	Ser	Ala	Ile	Ile	Cys	Leu	Leu	Gln	Val	Glu	Pro	Leu	Thr
	770					775					780				
Gly	Pro	Pro	Glu	Gly	Gly	Leu	Ala	Leu	Thr	Ile	Leu	Gly	Ser	Asn	Leu
785					790					795					800
Gly	Arg	Ala	Phe	Ala	Asp	Val	Gln	Tyr	Ala	Asp	Pro	Val	Leu	Leu	Ser
			805						810					815	
Leu	Ser	Pro	Arg	Trp	Gly	Pro	Gln	Ala	Gly	Gly	Thr	Gln	Leu	Thr	Ile
			820					825					830		
Arg	Gly	Gln	His	Leu	Gln	Thr	Gly	Gly	Asn	Thr	Ser	Ala	Phe	Val	Gly
		835					840					845			
Gly	Gln	Pro	Cys	Pro	Met	Gly	Gly	Arg	Leu	Ile	Arg	Val	Arg	Gly	Thr
	850					855					860				
Gly	Leu	Asp	Val	Val	Gln	Arg	Pro	Leu	Leu	Ser	Val	Trp	Leu	Glu	Ala
865					870					875					880
Asp	Ala	Glu	Val	Gln	Ala	Ser	Arg	Ala	Gln	Pro	Gln	Asp	Pro	Gln	Pro
				885					890					895	
Arg	Arg	Ser	Cys	Gly	Ala	Pro	Ala	Ala	Asp	Pro	Gln	Ala	Cys	Ile	Gln
			900					905					910		
Leu	Gly	Gly	Gly	Leu	Leu	Gln	Arg	Thr	Ala	Glu	Pro	Ser	Ser	Leu	His
		915					920					925			
Leu	Trp	Ser	Ala	Leu	Asn	Ala	Pro	Gln	Cys	Ser	Thr	Val	Cys	Ser	Val
	930					935					940				
Asn	Ser	Ser	Ser	Leu	Leu	Leu	Cys	Arg	Ser	Pro	Ala	Val	Pro	Asp	Arg
945					950					955					960
Ala	His	Pro	Gln	Arg	Val	Phe	Phe	Thr	Leu	Asp	Asn	Val	Gln	Val	Asp
				965					970					975	
Phe	Ala	Ser	Ala	Ser	Gly	Gly	Gln	Gly	Phe	Leu	Tyr	Gln	Pro	Asn	Pro
			980					985					990		
Arg	Leu	Ala	Pro	Leu	Ser	Arg	Glu	Gly	Pro	Ala	Arg	Pro	Tyr	Arg	Leu
		995					1000					1005			
Lys	Pro	Gly	His	Val	Leu	Asp	Val	Glu	Gly	Glu	Gly	Leu	Asn	Leu	Gly
	1010					1015					1020				
Ile	Ser	Lys	Glu	Glu	Val	Arg	Val	His	Ile	Gly	Arg	Gly	Glu	Cys	Leu

1025					1030					1035						1040
Val	Lys	Thr	Leu	Thr	Arg	Thr	His	Leu	Tyr	Cys	Glu	Pro	Pro	Ala	His	
				1045					1050						1055	
Ala	Pro	Gln	Pro	Ala	Asn	Gly	Ser	Gly	Leu	Pro	Gln	Phe	Val	Val	Gln	
			1060					1065					1070			
Met	Gly	Asn	Val	Gln	Leu	Ala	Leu	Gly	Pro	Val	Gln	Tyr	Glu	Ala	Glu	
	1075						1080				1085					
Pro	Pro	Leu	Ser	Ala	Phe	Pro	Val	Glu	Ala	Gln	Ala	Gly	Val	Gly	Met	
	1090					1095					1100					
Gly	Ala	Ala	Val	Leu	Ile	Ala	Ala	Val	Leu	Leu	Leu	Thr	Leu	Met	Tyr	
1105				1110					1115						1120	
Arg	His	Lys	Ser	Lys	Gln	Ala	Leu	Arg	Asp	Tyr	Gln	Lys	Val	Leu	Val	
			1125					1130						1135		
Gln	Leu	Glu	Ser	Leu	Glu	Thr	Gly	Val	Gly	Asp	Gln	Cys	Arg	Lys	Glu	
		1140					1145					1150				
Phe	Thr	Asp	Leu	Met	Thr	Glu	Met	Thr	Asp	Leu	Ser	Ser	Asp	Leu	Glu	
	1155					1160					1165					
Gly	Ser	Gly	Ile	Pro	Phe	Leu	Asp	Tyr	Arg	Thr	Tyr	Ala	Glu	Arg	Ala	
	1170				1175				1180							
Phe	Phe	Pro	Gly	His	Gly	Gly	Cys	Pro	Leu	Gln	Pro	Lys	Pro	Glu	Gly	
1185				1190				1195							1200	
Pro	Gly	Glu	Asp	Gly	His	Cys	Ala	Thr	Val	Arg	Gln	Gly	Leu	Thr	Gln	
			1205					1210						1215		
Leu	Ser	Asn	Leu	Leu	Asn	Ser	Lys	Leu	Phe	Leu	Leu	Thr	Val	Arg	Ala	
		1220					1225						1230			
Val	Trp	Arg	Glu	Cys	Pro	Val	Gly	Lys	Glu	Val	Gly	Leu	Gly	Asn	Tyr	
	1235					1240					1245					
Trp	Pro	Glu	Thr	Lys	Val	Gly	Glu	Glu	Thr	Glu	Thr	Met	Val	Glu	Lys	
	1250					1255					1260					
Leu	Leu	Thr	Asn	Trp	Leu	Ser	Ile	Cys	Leu	Tyr	Ala	Phe	Leu	Arg	Glu	
1265				1270				1275							1280	
Val	Ala	Gly	Glu	Pro	Leu	Tyr	Met	Leu	Phe	Arg	Ala	Ile	Gln	Tyr	Gln	
			1285					1290						1295		
Val	Asp	Lys	Gly	Pro	Val	Asp	Ala	Val	Thr	Gly	Lys	Ala	Lys	Arg	Thr	
	1300						1305					1310				
Leu	Asn	Asp	Ser	Arg	Leu	Leu	Arg	Glu	Asp	Val	Glu	Phe	Gln	Pro	Leu	
	1315					1320					1325					
Thr	Leu	Met	Val	Leu	Val	Gly	Pro	Gly	Ala	Gly	Gly	Ala	Ala	Gly	Ser	
	1330					1335					1340					
Ser	Glu	Met	Gln	Arg	Val	Pro	Ala	Arg	Val	Leu	Asp	Thr	Asp	Thr	Ile	
1345				1350				1355						1360		
Thr	Gln	Val	Lys	Glu	Lys	Val	Leu	Asp	Gln	Val	Tyr	Lys	Gly	Thr	Pro	
			1365					1370						1375		
Phe	Ser	Gln	Arg	Pro	Ser	Val	His	Ala	Leu	Asp	Leu	Gly	Glu	Arg	Ala	
	1380						1385					1390				
Ser	Pro	Ala	His	Pro	Pro	Gln	Gly	Pro	Phe	Pro	Thr	Pro	Pro	Ala	Pro	
	1395					1400					1405					
Gly	Ala	Pro	Gln	Leu	Cys	Leu	Thr	Met	Asn	Ile	Pro	Thr	Leu	Glu	Asp	
	1410					1415					1420					
Gly	Glu	Glu	Gly	Gly	Val	Cys	Leu	Trp	His	Leu	Val	Lys	Ala	Thr	Glu	
1425				1430				1435						1440		
Glu	Pro	Glu	Gly	Ala	Lys	Val	Arg	Cys	Ser	Ser	Leu	Arg	Glu	Arg	Glu	
			1445					1450					1455			
Pro	Ala	Arg	Ala	Lys	Ala	Ile	Pro	Glu	Ile	Tyr	Leu	Thr	Arg	Leu	Leu	
	1460						1465					1470				

Ser Met Lys Val Gly Ala Ala Trp Val Ala Gly Pro Glu Arg Arg Leu
 1475 1480 1485
 Ser Gln Gly Pro Arg Pro Ser Gln Gly Val Gly Gly Ala Gly Ala Ala
 1490 1495 1500
 Ser Ala Val Asp Gly Pro His Thr Leu Pro Ser Thr Gln Pro Leu Ser
 1505 1510 1515 1520
 Pro Ala Ser Gln Gly Thr Leu Gln Lys Phe Val Asp Asp Thr Phe Gln
 1525 1530 1535
 Ala Ile Leu Ser Val Asn Arg Pro Ile Pro Ile Ala Val Lys Tyr Leu
 1540 1545 1550
 Phe Asp Leu Leu Asp Glu Leu Ala Glu Lys His Gly Ile Glu Asp Pro
 1555 1560 1565
 Gly Thr Leu His Ile Trp Lys Thr Asn Ser Leu Leu Arg Phe Trp
 1570 1575 1580
 Val Asn Ala Leu Lys Asn Pro Gln Leu Ile Phe Asp Val Arg Val Ser
 1585 1590 1595 1600
 Asp Asn Val Asp Ala Ile Leu Ala Val Ile Ala Gln Thr Phe Ile Asp
 1605 1610 1615
 Ser Cys Thr Thr Ser Glu His Lys Val Gly Arg Val Arg Ala Val Pro
 1620 1625 1630
 Ala Ala Ala Ala Gly Arg Gly Leu Arg Arg Lys Gly Leu Trp Gly Lys
 1635 1640 1645
 Pro Arg Gly Leu Cys Thr Glu Leu Trp Val Gly Ser Gly Ser Ile Met
 1650 1655 1660
 Gly Ala Pro Ser Pro Pro Ser Ser Cys Leu Ala Pro Pro Leu Pro Pro
 1665 1670 1675 1680
 Glu Gln Asp Ser Pro Val Asn Lys Leu Leu Tyr Ala Arg Glu Ile Pro
 1685 1690 1695
 Arg Tyr Lys Gln Met Val Glu Arg Tyr Tyr Ala Asp Ile Arg Gln Ser
 1700 1705 1710
 Ser Pro Ala Ser Tyr Gln Glu Met Asn Ser Ala Leu Ala Glu Leu Ser
 1715 1720 1725
 Gly Asn Tyr Thr Ser Ala Pro His Cys Leu Glu Ala Leu Gln Glu Leu
 1730 1735 1740
 Tyr Asn His Ile His Arg Tyr Tyr Asp Gln Ile Ile Ser Ala Leu Glu
 1745 1750 1755 1760
 Glu Asp Pro Val Gly Gln Lys Leu Gln Leu Ala Cys Arg Leu Gln Gln
 1765 1770 1775
 Val Ala Ala Leu Val Glu Asn Lys Val Thr Asp Leu
 1780 1785

<210> 5
 <211> 5892
 <212> DNA
 <213> HOMO SAPIEN

<400> 5							
gcgcacgccc	ggatggctct	tcgcgccgcg	ggcggcgcac	ccttttagcgg	cccggccgcc		60
gctgccagcc	ccccgccgtt	ccagacgccg	ccgcgggtgcc	cggtgccgct	gctgttgctg		120
ctgctcctgg	gggcggcgcg	ggccggcgcc	ctggagatcc	agcgtcgggt	cccctcgccc		180
acgcccacca	acaacttcgc	cctggacggc	gcggcgggga	ccgtgtacct	ggcggccgtc		240
aaccgcctct	atcagctgtc	gggcgccaac	ctgagcctgg	aggccgaggg	ggccgtgggc		300
ccggtgcccc	acagcccgtc	gtgtcacgct	ccgcagctgc	cgcaggcctc	gtgcgagcac		360
ccgcggcgcc	tcacggacaa	ctacaacaag	atcctgcagc	tggaccccg	ccagggcctg		420
gtagtcgtgt	gcgggtccat	ctaccagggc	ttctgccagc	tgcggcgccg	gggtaacatc		480

tcggccgtgg	ccgtgcgctt	cccgcccgcc	gcgcgcggcg	ccgagcccg	cacgggtgttc	540
cccagcatgc	tgaacgtggc	ggccaaccac	ccgaacgcgt	ccaccgtggg	gctagtctctg	600
cctcccgccg	cgggcgcggg	gggcagccgc	ctgctcgtgg	gcgccacgta	caccgggttac	660
ggcagctcct	tcttcccgcg	caaccgcagc	ctggaggacc	accgcttcga	gaacacgccc	720
gagatcgcca	tccgtccctt	ggacacgcgc	ggcgacctgg	ccaagctctt	caccttcgac	780
ctcaaccctt	ccgacgacaa	catcctcaag	atcaagcagg	gcgccaagga	gcagcacaag	840
ctgggcttctg	tgagcgccct	cctgcacccg	tccgaccgcg	cgccgggtgc	acagtccctac	900
gcgtacctgg	cgctcaacag	cgaggcgcg	gcgggcgaca	aggagagcca	ggcgcgaggc	960
ctgctggcgc	gcattctgcct	gccccacggc	gccggcgggc	acgccaagaa	gctcaccgag	1020
tcttacatcc	agttgggctt	gcagtgcgcg	ggcgggcgcg	gccgcggcga	cctctacagc	1080
cgccctgggt	cggtcttccc	agcccgggag	gggtctcttg	ctgtcttcga	gcggccccag	1140
gggtcccccg	cgccccgcgc	tgtcccgccc	gcactctgcg	ccttccgctt	cgccgacgtg	1200
cgagcccgcca	tccgagctgc	gcgcaccggc	tgcttcgtgg	aaccggcgcc	cgacgtgggtg	1260
gcgggtgctcg	acagcggtgg	gcagggcacg	ggaccggcct	gcgagcgcaa	gctcaacatc	1320
cagctccagc	cagagcagct	ggactgtgga	gctgtctacc	tgacgacccc	gctgtccatc	1380
ctgcagcccc	tgaaggccac	gcccgtgttc	cgcgcccccg	gcctcacctc	cgtggccgtg	1440
gccagcgta	acaactacac	agcggctctt	ctgggcacgg	tcaacgggag	gcttctcaag	1500
atcaacctga	acgagagcat	gcaggtgggt	agcaggcggg	tggtgactgt	ggcctatggg	1560
gagcccggtc	accatgtcat	gcagtttgac	ccagcagact	ccggttacct	ttacctgatg	1620
acgtcccacc	agatggccag	ggtgaaggtc	gccgcttgca	acgtgcactc	cacctgtggg	1680
gactacatcc	gtgcggcgga	cgccctactgc	ggctggtgtg	ccctggagac	gcggtgcacc	1740
ttgcagcagg	actgcaccaa	ttccagccag	cagcatttct	ggaccagtgc	cagcgagggc	1800
cccagccgct	gtcctgccat	gaccgtcctg	ccttccgaga	tcgatgtgcg	ccaggagtac	1860
ccaggcatga	tcctgcagat	ctcgggcagc	ctgcccagcc	tcagtggcat	ggagatggcc	1920
tgtgactatg	ggaacaacat	ccgcactgtg	gctcgggtcc	caggccctgc	ctttgggtcac	1980
caagtgtcct	actgcacact	cctgccgagg	gaccagtctt	cgcccttccc	ccccaacccag	2040
gaccacgtga	ctgttgagat	gtctgtgagg	gtcaatgggc	ggaacatcgt	caaggccaat	2100
ttcaccatct	acgactgcag	ccgcactgca	caagtgtacc	cccacacagc	ctgtaccagc	2160
tgccctgtcg	cacagtggcc	ctgtttctgg	tgacgccagc	agcactcctg	tgtttccaac	2220
cagtctcggt	gcgaggccct	accaaaccct	acgagccctc	aggactgccc	ccggaccctg	2280
ctctcacccc	tggtcacccg	gcctaccggt	ggctcccaga	acatcctggt	gcctctggcc	2340
aacactgcct	ttttccaggg	tgacgccctg	gagtgtagtt	ttgggctgga	ggagatcttc	2400
gaggctgtgt	gggtgaatga	gtctgttgta	cgtgttgacc	aggtggtgct	gcacacgacc	2460
cggaagagcc	aggtgttccc	gctcagcctc	caactaaagg	ggcgggccagc	ccgattcctg	2520
gacagccctg	agcccatgac	agtcattggt	tataactgtg	ccatgggagc	ccccgactgt	2580
tcccagtggc	tgggcccgcga	agacctgggt	cacctgtgcg	tgtggagtga	tggctgcccg	2640
ctgcgggggc	ctctgcagcc	catggctggc	acctgccccg	cccccgagat	ccgcgcgatt	2700
gagcccttga	gtggcccgtt	ggacgggtggg	accctgctga	ccatccgagg	aaggaaacctg	2760
ggccggcggc	tcagtgcagt	ggcccacggc	gtgtggattg	gtggtgtggc	ctgtgagcca	2820
ctgcctgaca	gatacacggt	gtcggaggag	atcgtgtgtg	tcacagggcc	agccccagga	2880
ccgtctctcag	gtgtggtgac	cgtgaacgcc	tctaaggagg	gcaagtcccc	ggaccgcttc	2940
tcctacgtgc	tgccccctgt	ccactccctg	gagcctacca	tgggccccaa	ggccgggggc	3000
accaggatca	ccatccatgg	gaatgacctc	catgtaggct	ccgagctcca	ggtcctgggtg	3060
aacgacacag	acccctgcac	ggagctgatg	cgcacagata	ccagcatcgc	ctgcaccatg	3120
cccgaggggg	ccctgccggc	tccggtgcct	gtgtgtgtgc	gcttcgagcg	tcggggctgc	3180
gtgcacggga	acctcacctt	ctggtacatg	cagaaccggg	tcatacaggc	catcagtccc	3240
cgccgcagcc	ctgtcagtgg	cggcaggacc	atcacagtgg	ctggtgagcg	tttccacatg	3300
gtgcagaatg	tgtccatggc	cgtccaccac	attggccggg	agcccacgct	ctgcaagggtt	3360
ctcaactcca	ccctcatcac	ctgcccgtcc	cccggggccc	tgagcaacgc	atcagcgcca	3420
gtgcacttct	tcataaatgg	gcgggcctac	gcagacgagg	tggctgtggc	tgaggagcta	3480
ctggaccccc	aggaggcaca	gcggggcagc	aggttccgcg	tggactacct	ccccaaaccca	3540
cagttctcta	cggccaagag	ggagaagtgg	atcaagcacc	accccgggga	gcctctcacc	3600
ctcgttatcc	acaaggagca	ggacagcctg	gggtccaga	gtcacgagta	ccgggtcaag	3660
ataggccaag	taagctgcga	catccagatt	gtctctgaca	gaatcatcca	ctgctcggtc	3720
aacgagtccc	tgggcgcggc	cgtggggcag	ctgcccacac	caatccaggt	agggaacttc	3780

aaccagacca	tcgccacact	gcagctgggg	ggcagcgaga	cggccatcat	cgtgtccatc	3840
gtcatctgca	gcgtcctgct	gctgctctcc	gtgggtggccc	tgttcgtctt	ctgtaccaag	3900
agccgacgtg	ctgagcgtta	ctggcagaag	acgctgctgc	agatggagga	gatggaatct	3960
cagatccgag	aggaaatccg	caaaggcttc	gctgagctgc	agacagacat	gacagatctg	4020
accaaggagc	tgaaccgcag	ccaggggcatc	cccttcctgg	agtataagca	cttcgtgacc	4080
cgcaccttct	tccccaagtg	ttcctccctt	tatgaagagc	gttacgtgct	gccctcccag	4140
accctcaact	cccagggcag	ctcccaggca	caggaaaccc	acccactgct	gggagagtgg	4200
aagattcctg	agagctgccg	gcccacatg	gaagagggaa	ttagcgtgtt	ctcctcacta	4260
ctcaacaaca	agcacttcct	catcgtcttt	gtccacgcgc	tggagcagca	gaaggacttt	4320
gcggtgcgcg	acaggtgcag	cctggcctcg	ctgctgacca	tcgcgctgca	cggcaagctg	4380
gagtactaca	ccagcatcat	gaaggagctg	ctgggtggacc	tcattgacgc	ctcggccgcc	4440
aagaacccca	agtcctatgt	gcggcgca	gagtcgtggt	tggagaagat	gctcaccaac	4500
tggatgtcca	tctgcatgta	cagctgtctg	cgggagacgg	tgggggagcc	attcttcctg	4560
ctgctgtgtg	ccatcaagca	gcaaataaac	aagggtctcca	tcgacgccat	cacaggcaag	4620
gcccgcctaca	cactcaatga	ggagtggctg	ctgcggggaga	acatcgaggc	caagcccccg	4680
aacctgaacg	tgctcttcca	gggctgtggc	atggactcgc	tgagcgtgcg	ggccatggac	4740
accgacacgc	tgacacaggt	caaggagaag	atcctggagg	ccttctgcaa	gaatgtgccc	4800
tactcccagt	ggcgcgctgc	agaggacgtc	gaccttgagt	ggttcgcctc	cagcacacag	4860
agctacatcc	ttcgggacct	ggacgacacc	tcagtgggtg	aagacggccg	caagaagctt	4920
aacacgctgg	cccattacaa	gatccctgaa	ggtgcctccc	tggccatgag	tctcatagac	4980
aagaaggaca	acacactggg	ccgagtga	gacttggaca	cagagaagta	tttccatttg	5040
gtgctgccta	cggacgagct	ggcggagccc	aagaagtctc	accggcagag	ccatcgcaag	5100
aaggtgctcc	cggaaatcta	cctgaccgcg	ctgctctcca	ccaagggcac	gttgacaga	5160
tttctggatg	acctgttcaa	ggccattctg	agtatccgtg	aagacaagcc	cccactggct	5220
gtcaagtact	ttttcgactt	cctggaggag	caggctgaga	agaggggaat	ctccgacccc	5280
gacaccctac	acatctggaa	gaccaacagc	cttctctccc	ggttctgggt	gaacatcctg	5340
aagaacccccc	agtttgtctt	tgacatcgac	aagacagacc	acatcgacgc	ctgcctttca	5400
gtcatcgcg	aggccttcct	cgacgcctgc	tccatctctg	acctgcagct	gggcaaggat	5460
tcgccaacca	acaagctcct	ctacgccaag	gagattcctg	agtaccggaa	gatcgtgcag	5520
cgctactaca	agcagatcca	ggacatgacg	ccgctcagcg	agcaagagat	gaatgcccat	5580
ctggccgagg	agtcgaggaa	ataccagaat	gagttcaaca	ccaatgtggc	catggcagag	5640
atttttaggt	cgcccaagag	gtatcgcccg	cagatcatgg	ccgcgctgga	ggccaacccc	5700
acggcccggga	ggacacaact	gcagcacaag	tttgagcagg	tgggtggctt	gatggaggac	5760
aacatctacg	agtgctacag	tgaggcctga	gacacatgga	gagttggtca	ggctgctgct	5820
gggagaaatg	gacgcccact	gggcctcaac	ttgatcttct	accccgctgc	tgtgactcag	5880
actgggaaat	ac					5892

<210> 6

<211> 1925

<212> PRT

<213> HOMO SAPIEN

<400> 6

Met	Ala	Leu	Arg	Ala	Gly	Gly	Ala	Pro	Phe	Ser	Gly	Pro	Ala	Ala
1			5				10					15		
Ala	Ala	Ser	Pro	Pro	Phe	Gln	Thr	Pro	Pro	Arg	Cys	Pro	Val	Pro
		20				25					30			
Leu	Leu	Leu	Leu	Leu	Leu	Gly	Ala	Ala	Arg	Ala	Gly	Ala	Leu	Glu
		35				40					45			
Ile	Gln	Arg	Arg	Phe	Pro	Ser	Pro	Thr	Pro	Thr	Asn	Asn	Phe	Ala
	50					55					60			
Asp	Gly	Ala	Ala	Gly	Thr	Val	Tyr	Leu	Ala	Ala	Val	Asn	Arg	Leu
65					70					75				80

Gln	Leu	Ser	Gly	Ala	Asn	Leu	Ser	Leu	Glu	Ala	Glu	Ala	Ala	Val	Gly
				85					90					95	
Pro	Val	Pro	Asp	Ser	Pro	Leu	Cys	His	Ala	Pro	Gln	Leu	Pro	Gln	Ala
			100					105					110		
Ser	Cys	Glu	His	Pro	Arg	Arg	Leu	Thr	Asp	Asn	Tyr	Asn	Lys	Ile	Leu
		115					120					125			
Gln	Leu	Asp	Pro	Gly	Gln	Gly	Leu	Val	Val	Val	Cys	Gly	Ser	Ile	Tyr
	130					135					140				
Gln	Gly	Phe	Cys	Gln	Leu	Arg	Arg	Arg	Gly	Asn	Ile	Ser	Ala	Val	Ala
	145				150					155					160
Val	Arg	Phe	Pro	Pro	Ala	Ala	Pro	Pro	Ala	Glu	Pro	Val	Thr	Val	Phe
				165					170					175	
Pro	Ser	Met	Leu	Asn	Val	Ala	Ala	Asn	His	Pro	Asn	Ala	Ser	Thr	Val
			180					185					190		
Gly	Leu	Val	Leu	Pro	Pro	Ala	Ala	Gly	Ala	Gly	Gly	Ser	Arg	Leu	Leu
	195						200					205			
Val	Gly	Ala	Thr	Tyr	Thr	Gly	Tyr	Gly	Ser	Ser	Phe	Phe	Pro	Arg	Asn
	210					215					220				
Arg	Ser	Leu	Glu	Asp	His	Arg	Phe	Glu	Asn	Thr	Pro	Glu	Ile	Ala	Ile
	225				230					235					240
Arg	Ser	Leu	Asp	Thr	Arg	Gly	Asp	Leu	Ala	Lys	Leu	Phe	Thr	Phe	Asp
			245					250						255	
Leu	Asn	Pro	Ser	Asp	Asp	Asn	Ile	Leu	Lys	Ile	Lys	Gln	Gly	Ala	Lys
			260					265					270		
Glu	Gln	His	Lys	Leu	Gly	Phe	Val	Ser	Ala	Phe	Leu	His	Pro	Ser	Asp
		275					280					285			
Pro	Pro	Pro	Gly	Ala	Gln	Ser	Tyr	Ala	Tyr	Leu	Ala	Leu	Asn	Ser	Glu
	290				295						300				
Ala	Arg	Ala	Gly	Asp	Lys	Glu	Ser	Gln	Ala	Arg	Ser	Leu	Leu	Ala	Arg
	305				310					315					320
Ile	Cys	Leu	Pro	His	Gly	Ala	Gly	Gly	Asp	Ala	Lys	Lys	Leu	Thr	Glu
				325					330					335	
Ser	Tyr	Ile	Gln	Leu	Gly	Leu	Gln	Cys	Ala	Gly	Gly	Ala	Gly	Arg	Gly
			340				345						350		
Asp	Leu	Tyr	Ser	Arg	Leu	Val	Ser	Val	Phe	Pro	Ala	Arg	Glu	Arg	Leu
		355					360					365			
Phe	Ala	Val	Phe	Glu	Arg	Pro	Gln	Gly	Ser	Pro	Ala	Ala	Arg	Ala	Ala
	370					375					380				
Pro	Ala	Ala	Leu	Cys	Ala	Phe	Arg	Phe	Ala	Asp	Val	Arg	Ala	Ala	Ile
	385				390					395					400
Arg	Ala	Ala	Arg	Thr	Ala	Cys	Phe	Val	Glu	Pro	Ala	Pro	Asp	Val	Val
				405					410					415	
Ala	Val	Leu	Asp	Ser	Val	Val	Gln	Gly	Thr	Gly	Pro	Ala	Cys	Glu	Arg
			420					425					430		
Lys	Leu	Asn	Ile	Gln	Leu	Gln	Pro	Glu	Gln	Leu	Asp	Cys	Gly	Ala	Ala
		435					440					445			
His	Leu	Gln	His	Pro	Leu	Ser	Ile	Leu	Gln	Pro	Leu	Lys	Ala	Thr	Pro
	450					455					460				
Val	Phe	Arg	Ala	Pro	Gly	Leu	Thr	Ser	Val	Ala	Val	Ala	Ser	Val	Asn
	465				470					475					480
Asn	Tyr	Thr	Ala	Val	Phe	Leu	Gly	Thr	Val	Asn	Gly	Arg	Leu	Leu	Lys
			485						490					495	
Ile	Asn	Leu	Asn	Glu	Ser	Met	Gln	Val	Val	Ser	Arg	Arg	Val	Val	Thr
			500				505						510		
Val	Ala	Tyr	Gly	Glu	Pro	Val	His	His	Val	Met	Gln	Phe	Asp	Pro	Ala

- 17 -

Val	Val	Thr	Val	Asn	Ala	Ser	Lys	Glu	Gly	Lys	Ser	Arg	Asp	Arg	Phe	
				965					970					975		
Ser	Tyr	Val	Leu	Pro	Leu	Val	His	Ser	Leu	Glu	Pro	Thr	Met	Gly	Pro	
			980					985					990			
Lys	Ala	Gly	Gly	Thr	Arg	Ile	Thr	Ile	His	Gly	Asn	Asp	Leu	His	Val	
		995				1000						1005				
Gly	Ser	Glu	Leu	Gln	Val	Leu	Val	Asn	Asp	Thr	Asp	Pro	Cys	Thr	Glu	
	1010			1015						1020						
Leu	Met	Arg	Thr	Asp	Thr	Ser	Ile	Ala	Cys	Thr	Met	Pro	Glu	Gly	Ala	
1025				1030					1035						1040	
Leu	Pro	Ala	Pro	Val	Pro	Val	Cys	Val	Arg	Phe	Glu	Arg	Arg	Gly	Cys	
			1045					1050						1055		
Val	His	Gly	Asn	Leu	Thr	Phe	Trp	Tyr	Met	Gln	Asn	Pro	Val	Ile	Thr	
		1060						1065					1070			
Ala	Ile	Ser	Pro	Arg	Arg	Ser	Pro	Val	Ser	Gly	Gly	Arg	Thr	Ile	Thr	
	1075					1080						1085				
Val	Ala	Gly	Glu	Arg	Phe	His	Met	Val	Gln	Asn	Val	Ser	Met	Ala	Val	
	1090				1095						1100					
His	His	Ile	Gly	Arg	Glu	Pro	Thr	Leu	Cys	Lys	Val	Leu	Asn	Ser	Thr	
1105				1110						1115					1120	
Leu	Ile	Thr	Cys	Pro	Ser	Pro	Gly	Ala	Leu	Ser	Asn	Ala	Ser	Ala	Pro	
			1125					1130						1135		
Val	Asp	Phe	Phe	Ile	Asn	Gly	Arg	Ala	Tyr	Ala	Asp	Glu	Val	Ala	Val	
		1140				1145						1150				
Ala	Glu	Glu	Leu	Leu	Asp	Pro	Glu	Glu	Ala	Gln	Arg	Gly	Ser	Arg	Phe	
	1155					1160						1165				
Arg	Leu	Asp	Tyr	Leu	Pro	Asn	Pro	Gln	Phe	Ser	Thr	Ala	Lys	Arg	Glu	
	1170					1175					1180					
Lys	Trp	Ile	Lys	His	His	Pro	Gly	Glu	Pro	Leu	Thr	Leu	Val	Ile	His	
1185				1190						1195					1200	
Lys	Glu	Gln	Asp	Ser	Leu	Gly	Leu	Gln	Ser	His	Glu	Tyr	Arg	Val	Lys	
			1205					1210						1215		
Ile	Gly	Gln	Val	Ser	Cys	Asp	Ile	Gln	Ile	Val	Ser	Asp	Arg	Ile	Ile	
		1220						1225					1230			
His	Cys	Ser	Val	Asn	Glu	Ser	Leu	Gly	Ala	Ala	Val	Gly	Gln	Leu	Pro	
	1235					1240						1245				
Ile	Thr	Ile	Gln	Val	Gly	Asn	Phe	Asn	Gln	Thr	Ile	Ala	Thr	Leu	Gln	
	1250				1255						1260					
Leu	Gly	Gly	Ser	Glu	Thr	Ala	Ile	Ile	Val	Ser	Ile	Val	Ile	Cys	Ser	
1265				1270						1275				1280		
Val	Leu	Leu	Leu	Leu	Ser	Val	Val	Ala	Leu	Phe	Val	Phe	Cys	Thr	Lys	
			1285						1290					1295		
Ser	Arg	Arg	Ala	Glu	Arg	Tyr	Trp	Gln	Lys	Thr	Leu	Leu	Gln	Met	Glu	
			1300					1305					1310			
Glu	Met	Glu	Ser	Gln	Ile	Arg	Glu	Glu	Ile	Arg	Lys	Gly	Phe	Ala	Glu	
	1315					1320						1325				
Leu	Gln	Thr	Asp	Met	Thr	Asp	Leu	Thr	Lys	Glu	Leu	Asn	Arg	Ser	Gln	
	1330					1335					1340					
Gly	Ile	Pro	Phe	Leu	Glu	Tyr	Lys	His	Phe	Val	Thr	Arg	Thr	Phe	Phe	
1345				1350					1355					1360		
Pro	Lys	Cys	Ser	Ser	Leu	Tyr	Glu	Glu	Arg	Tyr	Val	Leu	Pro	Ser	Gln	
			1365					1370						1375		
Thr	Leu	Asn	Ser	Gln	Gly	Ser	Ser	Gln	Ala	Gln	Glu	Thr	His	Pro	Leu	
	1380							1385					1390			
Leu	Gly	Glu	Trp	Lys	Ile	Pro	Glu	Ser	Cys	Arg	Pro	Asn	Met	Glu	Glu	

- 19 -

Gln Ile Gln Asp Met Thr Pro Leu Ser Glu Gln Glu Met Asn Ala His
1845 1850 1855
Leu Ala Glu Glu Ser Arg Lys Tyr Gln Asn Glu Phe Asn Thr Asn Val
1860 1865 1870
Ala Met Ala Glu Ile Phe Arg Ser Pro Lys Arg Tyr Arg Pro Gln Ile
1875 1880 1885
Met Ala Ala Leu Glu Ala Asn Pro Thr Ala Arg Arg Thr Gln Leu Gln
1890 1895 1900
His Lys Phe Glu Gln Val Val Ala Leu Met Glu Asp Asn Ile Tyr Glu
1905 1910 1915 1920
Cys Tyr Ser Glu Ala
1925

<210> 7
<211> 601
<212> DNA
<213> HOMO SAPIEN

<400> 7
caccagagtc cctgtggagt cctgtggtca gtatcagagc tgcggcgagt gccttggtctc 60
aggcgacccc cactgtggct ggtgtgtgct gcacaacact tgcacccgga aggagcgggtg 120
tgagcgggtcc aaggagcccc gcaggtttgc ctcgagagatg aagcagtgtg tccggctgac 180
ggtccatccc aacaatatct ccgtctctca gtacaacgcg ctgctgggtcc tggagacgta 240
caatgtcccc gagctgtcag ctggcgctcaa ctgcaccttt gaggacctgt cagagatgga 300
tggtgtggtc gtgggcaatc agatccagtg ctactcccct gcagccaagg aggtgccccg 360
gatcatcaca gagaatgggg accaccatgt cgtacagctt cagctcaaat caaaggagac 420
cggcatgacc ttcgccagca ccagctttgt cttctacaat tgcagcgtcc acaattcgtg 480
cctgtcctgc gtggagagtc cataccgctg ccactgggtg aaataccggc atgtctgcac 540
ccatgacccc aagacctgct ccttcacgga aggccgagtg aagctgcccc aggtaggtcc 600
c 601

<210> 8
<211> 199
<212> PRT
<213> HOMO SAPIEN

<400> 8
Thr Arg Val Pro Val Glu Ser Cys Gly Gln Tyr Gln Ser Cys Gly Glu
1 5 10 15
Cys Leu Gly Ser Gly Asp Pro His Cys Gly Trp Cys Val Leu His Asn
20 25 30
Thr Cys Thr Arg Lys Glu Arg Cys Glu Arg Ser Lys Glu Pro Arg Arg
35 40 45
Phe Ala Ser Glu Met Lys Gln Cys Val Arg Leu Thr Val His Pro Asn
50 55 60
Asn Ile Ser Val Ser Gln Tyr Asn Ala Leu Leu Val Leu Glu Thr Tyr
65 70 75 80
Asn Val Pro Glu Leu Ser Ala Gly Val Asn Cys Thr Phe Glu Asp Leu
85 90 95
Ser Glu Met Asp Gly Leu Val Val Gly Asn Gln Ile Gln Cys Tyr Ser
100 105 110
Pro Ala Ala Lys Glu Val Pro Arg Ile Ile Thr Glu Asn Gly Asp His
115 120 125
His Val Val Gln Leu Gln Leu Lys Ser Lys Glu Thr Gly Met Thr Phe
130 135 140

Ala Ser Thr Ser Phe Val Phe Tyr Asn Cys Ser Val His Asn Ser Cys
 145 150 155 160
 Leu Ser Cys Val Glu Ser Pro Tyr Arg Cys His Trp Cys Lys Tyr Arg
 165 170 175
 His Val Cys Thr Asp Pro Lys Thr Cys Ser Phe Gln Glu Gly Arg Val
 180 185 190
 Lys Leu Pro Glu Val Gly Pro
 195

<210> 9
 <211> 6408
 <212> DNA
 <213> HOMO SAPIEN

<400> 9
 atgcctgctc tgggcccagc tcttctccag gctctctggg ccgggtgggt cctcaccctc 60
 cagccccttc caccactgc attcactccc aatggcacgt atctgcagca cctggcaagg 120
 gacccacact caggcacctt ctacctgggg gctaccaact tcctgttcca gctgagccct 180
 gggctgcagc tggaggccac agtgtccacc ggccctgtgc tagacagcag ggactgcctg 240
 ccactgtga tgcctgatga gtgccccag gccacagcta ccaacaaccc gaatcagctg 300
 ctctgtgtga gcccaggggc cctgggtgga tgcgggagcg tgcaccaggg ggtctgtgaa 360
 cagcggcgcc tggggcagct cgagcagctg ctgctgcggc cagagcggcc tggggacaca 420
 caatatgtgg ctgccaatga tctgcggtc agcacgggtg ggctggtagc ccagggcttg 480
 gcaggggagc cctctctgtt tgtggggcga ggatacacca gcaggggtgt ggggggtggc 540
 attccaccca tcacaacccg ggccctgtgg ccgcccagacc cccaagctgc cttctcctat 600
 gaggagacag ccaagctggc agtggggcgc ctctccgagt acagccacca cttcgtgagt 660
 gcctttgcac gtggggccag cgcctacttc ctgttccctg gcggggacct gcaggctcag 720
 tctagagctt ttogtgccta tgtatctcga gtgtgtctcc gggaccagca ctactactcc 780
 tatgtggagt tgcctctggc ctgcgaaggt ggccgctacg ggctgatcca ggctgcagct 840
 gtggccacgt ccaggagggt ggcgcatggg gaggtgctct ttgcagcttt ctctctggct 900
 gcacccccca ctgtggggcg gcccctatcg gggctgtctg gggcatctgg agcctctgcc 960
 ctctgtgcct tccccctgga tgaggtggac cggcttgcta atcgcacgag agatgcctgc 1020
 tacacccggg agggctcgtg tgaggatggg accgaggtgg cctacatcga gtatgatgtc 1080
 aattctgact gtgcacagct gccagtggac accctggatg cttatccctg tggctcagac 1140
 cacacgcca gccccatggc cagccgggtc ccgctggaag ccacaccaat tctggagtgg 1200
 ccagggatcc agctaacagc tgtggcagtc accatggaag atggacacac catcgcttcc 1260
 ctgggtgata gtcaagggca gctgcacagg gtctacttgg gccagggag cgatggccac 1320
 ccatactcca cacagagcat ccagcagggg tctgcagtga gcagagacct cacccttgat 1380
 gggacctttg agcacctgta tgtcatgacc cagagcacac ttctgaaggt tcctgtggct 1440
 tcctgtgctc agcacctgga ctgtgcatct tgccttgctc acagggacct atactgtggg 1500
 tgggtgcgtgc tccttggcag gtgcagtcgc cgttctgagt gctcgagggg ccaggggcca 1560
 gagcagtggc tatggagctt ccagcctgag ctgggctgtc tgcaagtggc agccatgagt 1620
 cctgcccaaca tcagccgaga ggagacgagg gaggttttcc tatcagtgcc agacctgcca 1680
 cccctgtggc cagggggagt atattcctgc cactttgggg aacatcagag tcctgccctg 1740
 ctgactggtt ctggtgtgat gtgccccctc ccagacccta gtgaggcccc agtgctgccg 1800
 agaggagccg actacgtatc cgtgagcgtg gagctcagat ttggcgctgt tgtgatcgcc 1860
 aaaacttccc tctctttcta tgactgtgtg gcggtcactg aactccgccc atctgcgcag 1920
 tgccaggcct gtgtgagcag ccgctggggg tgtaactggt gtgtctggca gcacctgtgc 1980
 acccacaagg cctcgtgtga tgcctggccc atggttgcaa gccatcagag cccgcttgct 2040
 tccccagacc ctctgcaag aggtggaccc agcccctccc caccacagc ccccaaagcc 2100
 ctggccaccc ctgctcctga cacccttccc gtggagcctg gggctccctc cacagccaca 2160
 gcttcggaca tctcacctgg ggctagtcct tccctgtcta gcccctgggg gccatgggca 2220
 ggttctggct ccatacttc ccctggctcc acagggctgc ctctccatga ggagccctcc 2280
 cctcccagcc cccaaaatgg acctggaacc gctgtccctg cccccactga cttcagaccc 2340
 tcagccacac ctgaggacct cttggcctcc ccgctgtcac cgtcagaggt agcagcagtg 2400

ccccctgcag	accctggccc	cgaggtctctt	catcccacag	tgccccctgga	cctgccccct	2460
gccactgttc	ctgccaccac	tttcccagg	gccatgggct	ccgtgaagcc	cgccctggac	2520
tggtctacga	gagaaggcgg	cgagctgccc	gaggcggacg	agtggacggg	gggtgacgca	2580
cccgccttct	ccacttccac	cctcctctca	ggtgatggag	actcagcaga	gcttgagggc	2640
cctccccccc	ccctcatect	cccgtccagc	ctcgactacc	agtatgacac	ccccgggctc	2700
tgggagctgg	aagaggcgag	cttgggggca	agctcctgcc	cctgtgtgga	gagcgttcag	2760
ggctccacgt	tgggacatgg	ccatgtggag	cgggaaatcc	ggctgttagg	caggaacctg	2820
caccttttcc	aggatggccc	aggagacaat	gagtgtgtga	tggagctgga	gggcctcgag	2880
gtggtggttg	aggcccgggt	cgagtgtgag	ccacctccag	ataccagtg	ccatgtcacc	2940
tgccagcagc	accagctcag	ctatgaggct	ctgcagccgg	agctccgtgt	ggggctgttt	3000
ctgcgtcggg	ccggccgtct	gcgtgtggag	agtgtgagg	ggctgcatgt	ggtactgtat	3060
gactgttccc	tgggacatgg	agactgcagc	cgctgccaaa	ctgccatgcc	ccagtatggc	3120
tgtgtgtggt	gtgaggggga	gcgtccacgt	tgtgtgaccc	gggaggcctg	tggtagggct	3180
gaggctgtgg	ccaccacgtg	cccagcgccc	ctcatccact	cggtggagcc	actgactggg	3240
ccgtgtagacg	gaggcacccg	tgtcaccatc	aggggctcca	acctgggcca	gcattgtgcag	3300
gatgtgctgg	gcattggtcac	ggtggctgga	gtgccctgtg	ctgtggatgc	ccaggagtag	3360
gaggtctcca	cgagcctcgt	gtgcatcacc	ggggccagtg	gggaggagg	ggccggcgcc	3420
acagcgggtg	aggtgcccgg	aagaggacgt	ggtgtctcag	aacacgactt	tgccctaccag	3480
gatccgaagg	tccattccat	cttcccggcc	cgcggcccca	gagctggggg	cacccgtctc	3540
accctgaatg	gctccaagct	cctgactggg	cggctggagg	acatccgagt	ggtggttggg	3600
gaccagcctt	gtcacttgct	gccggagcag	cagtcagaac	aactgcgggtg	tgagaccagc	3660
ccacgcccc	cgcctgccac	gctccctgtg	gctgtgtggt	ttggggccac	ggagcggagg	3720
cttcaacgcg	gcagattcaa	gtataccttg	gaccccaaca	tcacctctgc	tggccccacc	3780
aagagcttcc	tcagtggagg	acgtgagata	tgcgtccgtg	gccagaatct	ggacgtggta	3840
cagacgcca	gaatccgggt	gaccgtgggtc	tcgagaatgc	tgcagcccaa	ccaggggctt	3900
ggacggaggc	gtcgcgtggt	cccggagacg	gcattgtccc	ttggaccctc	ctgcagttagc	3960
cagcaatttg	aggagccgtg	ccatgtcaac	tcctcccagc	tcattcacgtg	ccgcacacct	4020
gccctcccag	gcctgcctga	ggacccctgg	gtccgggtgg	aatttatcct	tgacaacctg	4080
gtctttgact	ttgcaacact	gaaccccaca	cctttctcct	atgaggccga	ccccaccctg	4140
cagccactca	accctgagga	ccccaccatg	ccattccggc	acaagcctgg	gagtgtgttc	4200
tcctgtggagg	gggagaacct	ggaccttgca	atgtccaagg	aggagggtgg	ggctatgata	4260
ggggatggcc	cctgtgtggt	gaagacgctg	acgcgccacc	acctgtactg	cgagcccccc	4320
gtggagcagc	ccctgccacg	gcaccatgcc	ctccgagagg	cacctgactc	tttgcctgag	4380
ttcacgggtc	agatggggaa	cttgcgttcc	tccttgggtc	acgtgcagta	tgacggcgag	4440
agccctgggg	cttttctctg	ggcagcccag	gtgggcttgg	gggtgggcac	ctctcttctg	4500
gctctgggtg	tcattcatcat	tgtcctcatg	tacaggagga	agagcaagca	ggccctgagg	4560
gactataaga	aggttcagat	ccagctggag	aatctggaga	gcagtgtgctg	ggaccgtgtc	4620
aagaaggaat	tcacagacct	catgactgag	atgaccgatc	tcaccagtga	cctcctgggc	4680
agcggcatcc	ccttctctga	ctacaagggtg	tatgcggaga	ggatcttctt	ccctgggcac	4740
cgcgagtccg	ccttgcaccg	ggacctgggt	gtgcctgaga	gcagacggcc	cactgtagag	4800
caagggtctg	ggcagctctc	taacctgtct	aacagcaagc	tcttctctcac	caagttcatc	4860
cacacgctgg	agacccagcg	caccttttca	gctcgggacc	gtgcctacgt	ggcatctctg	4920
ctcaccgtgg	cactgcatgg	gaagcttgag	tatttctactg	acatcctccg	cactctgtct	4980
agtacctgg	ttgcccagta	tgtggccaag	aacccaagc	tgatgtctcg	caggacagag	5040
actgtggtgg	agaagctgct	caccaactgg	atgtccatct	gtctgtatac	cttcgtgagg	5100
gactccgtag	gggagcctct	gtacatgtct	tttcgaggga	ttaagcacca	agtggataag	5160
gggccagtgg	acagtgtgac	aggcaaggcc	aaatacacct	tgaacgacaa	ccgcctgtct	5220
agagaggatg	tggagtaccg	tcccctgacc	ttgaatgcac	tattggctgt	ggggcctggg	5280
gcaggagagg	cccaggcggt	gcccgtgaag	gtcctagact	gtgacacccat	ctcccaggca	5340
aaggagaaga	tgctggacca	gctttataaa	ggagtgcctc	tcaccagcg	gccagaccct	5400
cgcacccttg	atgttgagtg	gcggctctgg	gtggccgggc	acctcattct	ttctgacgag	5460
gatgtcactt	ctgaggtcca	gggtctgtgg	aggcgctga	acacactgca	gcattacaag	5520
gtcccagatg	gagcaactgt	ggccctcgct	ccctgctca	ccaagcatgt	gctccgggaa	5580
aaccaggatt	atgtccctgg	agagcggacc	ccaatgctgg	aggatgtaga	tgaggggggc	5640
atccggccct	ggcacctggt	gaagccaagt	gatgagccgg	agccgcccag	gcctcggagg	5700

ggcagccttc	ggggcgggga	gcgtgagcgc	gccaaaggcca	tccctgagat	ctacctgacc	5760
cgctctgtgt	ccatgaaggg	caccctgcag	aagttcgtgg	atgacctgtt	ccaggtgatt	5820
ctcagcacca	gccgccccgt	gccgctcgct	gtgaagtact	tctttgacct	gctggatgag	5880
caggccccagc	agcatggcat	ctccgaccag	gacaccatcc	acatctggaa	gaccaacagc	5940
ttgcctctga	ggttctggat	caatataata	aaaaaccgc	agtttgtgtt	cgacgtgcaa	6000
acatctgata	acatggatgc	gggtgtcctt	gtcattgcac	agaccttcat	ggacgcctgc	6060
accctggccg	accacaagct	gggcccgggac	tccccgatca	acaaacttct	gtatgcacgg	6120
gacattcccc	ggtacaagcg	gatgggtggaa	aggtactatg	cagacatcag	acagactgtc	6180
ccagccagcg	accaagagat	gaactctgtc	ctggctgaac	tgctctggaa	ctactccgga	6240
gacctcgggg	cgcgagtggc	cctgcataaa	ctctacaagt	acatcaacaa	gtactatgac	6300
cagatcatca	ctgccctgga	ggaggatggc	acggcccaga	agatgcagct	gggctatcgg	6360
ctccagcaga	ttgcagctgc	tgtggaaaac	aaggtcacag	atctatag		6408

<210> 10
 <211> 2135
 <212> PRT
 <213> HOMO SAPIEN

<400> 10

Met	Pro	Ala	Leu	Gly	Pro	Ala	Leu	Leu	Gln	Ala	Leu	Trp	Ala	Gly	Trp
1				5					10					15	
Val	Leu	Thr	Leu	Gln	Pro	Leu	Pro	Pro	Thr	Ala	Phe	Thr	Pro	Asn	Gly
			20					25					30		
Thr	Tyr	Leu	Gln	His	Leu	Ala	Arg	Asp	Pro	Thr	Ser	Gly	Thr	Leu	Tyr
		35					40					45			
Leu	Gly	Ala	Thr	Asn	Phe	Leu	Phe	Gln	Leu	Ser	Pro	Gly	Leu	Gln	Leu
	50					55					60				
Glu	Ala	Thr	Val	Ser	Thr	Gly	Pro	Val	Leu	Asp	Ser	Arg	Asp	Cys	Leu
65					70					75				80	
Pro	Pro	Val	Met	Pro	Asp	Glu	Cys	Pro	Gln	Ala	Gln	Pro	Thr	Asn	Asn
				85					90					95	
Pro	Asn	Gln	Leu	Leu	Leu	Val	Ser	Pro	Gly	Ala	Leu	Val	Val	Cys	Gly
			100					105					110		
Ser	Val	His	Gln	Gly	Val	Cys	Glu	Gln	Arg	Arg	Leu	Gly	Gln	Leu	Glu
		115					120					125			
Gln	Leu	Leu	Leu	Arg	Pro	Glu	Arg	Pro	Gly	Asp	Thr	Gln	Tyr	Val	Ala
	130					135					140				
Ala	Asn	Asp	Pro	Ala	Val	Ser	Thr	Val	Gly	Leu	Val	Ala	Gln	Gly	Leu
145					150				155					160	
Ala	Gly	Glu	Pro	Leu	Leu	Phe	Val	Gly	Arg	Gly	Tyr	Thr	Ser	Arg	Gly
				165					170					175	
Val	Gly	Gly	Gly	Ile	Pro	Pro	Ile	Thr	Thr	Arg	Ala	Leu	Trp	Pro	Pro
			180					185					190		
Asp	Pro	Gln	Ala	Ala	Phe	Ser	Tyr	Glu	Glu	Thr	Ala	Lys	Leu	Ala	Val
		195					200					205			
Gly	Arg	Leu	Ser	Glu	Tyr	Ser	His	His	Phe	Val	Ser	Ala	Phe	Ala	Arg
	210					215					220				
Gly	Ala	Ser	Ala	Tyr	Phe	Leu	Phe	Leu	Arg	Arg	Asp	Leu	Gln	Ala	Gln
225					230					235				240	
Ser	Arg	Ala	Phe	Arg	Ala	Tyr	Val	Ser	Arg	Val	Cys	Leu	Arg	Asp	Gln
			245						250				255		
His	Tyr	Tyr	Ser	Tyr	Val	Glu	Leu	Pro	Leu	Ala	Cys	Glu	Gly	Gly	Arg
			260					265					270		

- 24 -

705	Ala	Ser	Asp	Ile	Ser	Pro	Gly	Ala	Ser	Pro	Ser	Leu	Leu	Ser	Pro	Trp	720
					725					730							735
Gly	Pro	Trp	Ala	Gly	Ser	Gly	Ser	Ile	Ser	Ser	Pro	Gly	Ser	Thr	Gly		
			740					745						750			
Ser	Pro	Leu	His	Glu	Glu	Pro	Ser	Pro	Pro	Ser	Pro	Gln	Asn	Gly	Pro		
		755					760					765					
Gly	Thr	Ala	Val	Pro	Ala	Pro	Thr	Asp	Phe	Arg	Pro	Ser	Ala	Thr	Pro		
	770					775					780						
Glu	Asp	Leu	Leu	Ala	Ser	Pro	Leu	Ser	Pro	Ser	Glu	Val	Ala	Ala	Val		
785					790					795					800		
Pro	Pro	Ala	Asp	Pro	Gly	Pro	Glu	Ala	Leu	His	Pro	Thr	Val	Pro	Leu		
				805					810						815		
Asp	Leu	Pro	Pro	Ala	Thr	Val	Pro	Ala	Thr	Thr	Phe	Pro	Gly	Ala	Met		
			820					825					830				
Gly	Ser	Val	Lys	Pro	Ala	Leu	Asp	Trp	Leu	Thr	Arg	Glu	Gly	Gly	Glu		
		835					840					845					
Leu	Pro	Glu	Ala	Asp	Glu	Trp	Thr	Gly	Gly	Asp	Ala	Pro	Ala	Phe	Ser		
	850					855					860						
Thr	Ser	Thr	Leu	Leu	Ser	Gly	Asp	Gly	Asp	Ser	Ala	Glu	Leu	Glu	Gly		
865					870					875					880		
Pro	Pro	Ala	Pro	Leu	Ile	Leu	Pro	Ser	Ser	Leu	Asp	Tyr	Gln	Tyr	Asp		
				885					890					895			
Thr	Pro	Gly	Leu	Trp	Glu	Leu	Glu	Glu	Ala	Thr	Leu	Gly	Ala	Ser	Ser		
			900					905					910				
Cys	Pro	Cys	Val	Glu	Ser	Val	Gln	Gly	Ser	Thr	Leu	Met	Pro	Val	His		
		915					920						925				
Val	Glu	Arg	Glu	Ile	Arg	Leu	Leu	Gly	Arg	Asn	Leu	His	Leu	Phe	Gln		
	930					935					940						
Asp	Gly	Pro	Gly	Asp	Asn	Glu	Cys	Val	Met	Glu	Leu	Glu	Gly	Leu	Glu		
945					950					955					960		
Val	Val	Val	Glu	Ala	Arg	Val	Glu	Cys	Glu	Pro	Pro	Pro	Asp	Thr	Gln		
				965					970					975			
Cys	His	Val	Thr	Cys	Gln	Gln	His	Gln	Leu	Ser	Tyr	Glu	Ala	Leu	Gln		
		980						985					990				
Pro	Glu	Leu	Arg	Val	Gly	Leu	Phe	Leu	Arg	Arg	Ala	Gly	Arg	Leu	Arg		
		995					1000					1005					
Val	Asp	Ser	Ala	Glu	Gly	Leu	His	Val	Val	Leu	Tyr	Asp	Cys	Ser	Val		
	1010					1015					1020						
Gly	His	Gly	Asp	Cys	Ser	Arg	Cys	Gln	Thr	Ala	Met	Pro	Gln	Tyr	Gly		
1025					1030					1035					1040		
Cys	Val	Trp	Cys	Glu	Gly	Glu	Arg	Pro	Arg	Cys	Val	Thr	Arg	Glu	Ala		
				1045					1050					1055			
Cys	Gly	Glu	Ala	Glu	Ala	Val	Ala	Thr	Gln	Cys	Pro	Ala	Pro	Leu	Ile		
			1060					1065					1070				
His	Ser	Val	Glu	Pro	Leu	Thr	Gly	Pro	Val	Asp	Gly	Gly	Thr	Arg	Val		
		1075					1080						1085				
Thr	Ile	Arg	Gly	Ser	Asn	Leu	Gly	Gln	His	Val	Gln	Asp	Val	Leu	Gly		
	1090					1095					1100						
Met	Val	Thr	Val	Ala	Gly	Val	Pro	Cys	Ala	Val	Asp	Ala	Gln	Glu	Tyr		
1105						1110				1115					1120		
Glu	Val	Ser	Ser	Ser	Leu	Val	Cys	Ile	Thr	Gly	Ala	Ser	Gly	Glu	Glu		
				1125					1130					1135			
Val	Ala	Gly	Ala	Thr	Ala	Val	Glu	Val	Pro	Gly	Arg	Gly	Arg	Gly	Val		
			1140					1145					1150				

Ser Glu His Asp Phe Ala Tyr Gln Asp Pro Lys Val His Ser Ile Phe
 1155 1160 1165
 Pro Ala Arg Gly Pro Arg Ala Gly Gly Thr Arg Leu Thr Leu Asn Gly
 1170 1175 1180
 Ser Lys Leu Leu Thr Gly Arg Leu Glu Asp Ile Arg Val Val Val Gly
 1185 1190 1195 1200
 Asp Gln Pro Cys His Leu Leu Pro Glu Gln Gln Ser Glu Gln Leu Arg
 1205 1210 1215
 Cys Glu Thr Ser Pro Arg Pro Thr Pro Ala Thr Leu Pro Val Ala Val
 1220 1225 1230
 Trp Phe Gly Ala Thr Glu Arg Arg Leu Gln Arg Gly Gln Phe Lys Tyr
 1235 1240 1245
 Thr Leu Asp Pro Asn Ile Thr Ser Ala Gly Pro Thr Lys Ser Phe Leu
 1250 1255 1260
 Ser Gly Gly Arg Glu Ile Cys Val Arg Gly Gln Asn Leu Asp Val Val
 1265 1270 1275 1280
 Gln Thr Pro Arg Ile Arg Val Thr Val Val Ser Arg Met Leu Gln Pro
 1285 1290 1295
 Ser Gln Gly Leu Gly Arg Arg Arg Arg Val Val Pro Glu Thr Ala Cys
 1300 1305 1310
 Ser Leu Gly Pro Ser Cys Ser Ser Gln Gln Phe Glu Glu Pro Cys His
 1315 1320 1325
 Val Asn Ser Ser Gln Leu Ile Thr Cys Arg Thr Pro Ala Leu Pro Gly
 1330 1335 1340
 Leu Pro Glu Asp Pro Trp Val Arg Val Glu Phe Ile Leu Asp Asn Leu
 1345 1350 1355 1360
 Val Phe Asp Phe Ala Thr Leu Asn Pro Thr Pro Phe Ser Tyr Glu Ala
 1365 1370 1375
 Asp Pro Thr Leu Gln Pro Leu Asn Pro Glu Asp Pro Thr Met Pro Phe
 1380 1385 1390
 Arg His Lys Pro Gly Ser Val Phe Ser Val Glu Gly Glu Asn Leu Asp
 1395 1400 1405
 Leu Ala Met Ser Lys Glu Glu Val Val Ala Met Ile Gly Asp Gly Pro
 1410 1415 1420
 Cys Val Val Lys Thr Leu Thr Arg His His Leu Tyr Cys Glu Pro Pro
 1425 1430 1435 1440
 Val Glu Gln Pro Leu Pro Arg His His Ala Leu Arg Glu Ala Pro Asp
 1445 1450 1455
 Ser Leu Pro Glu Phe Thr Val Gln Met Gly Asn Leu Arg Phe Ser Leu
 1460 1465 1470

 Gly His Val Gln Tyr Asp Gly Glu Ser Pro Gly Ala Phe Pro Val Ala
 1475 1480 1485
 Ala Gln Val Gly Leu Gly Val Gly Thr Ser Leu Leu Ala Leu Gly Val
 1490 1495 1500
 Ile Ile Ile Val Leu Met Tyr Arg Arg Lys Ser Lys Gln Ala Leu Arg
 1505 1510 1515 1520
 Asp Tyr Lys Lys Val Gln Ile Gln Leu Glu Asn Leu Glu Ser Ser Val
 1525 1530 1535
 Arg Asp Arg Cys Lys Lys Glu Phe Thr Asp Leu Met Thr Glu Met Thr
 1540 1545 1550
 Asp Leu Thr Ser Asp Leu Leu Gly Ser Gly Ile Pro Phe Leu Asp Tyr
 1555 1560 1565
 Lys Val Tyr Ala Glu Arg Ile Phe Phe Pro Gly His Arg Glu Ser Pro
 1570 1575 1580
 Leu His Arg Asp Leu Gly Val Pro Glu Ser Arg Arg Pro Thr Val Glu

1585	1590	1595	1600
Gln Gly Leu Gly Gln Leu Ser Asn Leu Leu Asn Ser Lys Leu Phe Leu			
1605	1610	1615	
Thr Lys Phe Ile His Thr Leu Glu Ser Gln Arg Thr Phe Ser Ala Arg			
1620	1625	1630	
Asp Arg Ala Tyr Val Ala Ser Leu Leu Thr Val Ala Leu His Gly Lys			
1635	1640	1645	
Leu Glu Tyr Phe Thr Asp Ile Leu Arg Thr Leu Leu Ser Asp Leu Val			
1650	1655	1660	
Ala Gln Tyr Val Ala Lys Asn Pro Lys Leu Met Leu Arg Arg Thr Glu			
1665	1670	1675	1680
Thr Val Val Glu Lys Leu Leu Thr Asn Trp Met Ser Ile Cys Leu Tyr			
1685	1690	1695	
Thr Phe Val Arg Asp Ser Val Gly Glu Pro Leu Tyr Met Leu Phe Arg			
1700	1705	1710	
Gly Ile Lys His Gln Val Asp Lys Gly Pro Val Asp Ser Val Thr Gly			
1715	1720	1725	
Lys Ala Lys Tyr Thr Leu Asn Asp Asn Arg Leu Leu Arg Glu Asp Val			
1730	1735	1740	
Glu Tyr Arg Pro Leu Thr Leu Asn Ala Leu Leu Ala Val Gly Pro Gly			
1745	1750	1755	1760
Ala Gly Glu Ala Gln Gly Val Pro Val Lys Val Leu Asp Cys Asp Thr			
1765	1770	1775	
Ile Ser Gln Ala Lys Glu Lys Met Leu Asp Gln Leu Tyr Lys Gly Val			
1780	1785	1790	
Pro Leu Thr Gln Arg Pro Asp Pro Arg Thr Leu Asp Val Glu Trp Arg			
1795	1800	1805	
Ser Gly Val Ala Gly His Leu Ile Leu Ser Asp Glu Asp Val Thr Ser			
1810	1815	1820	
Glu Val Gln Gly Leu Trp Arg Arg Leu Asn Thr Leu Gln His Tyr Lys			
1825	1830	1835	1840
Val Pro Asp Gly Ala Thr Val Ala Leu Val Pro Cys Leu Thr Lys His			
1845	1850	1855	
Val Leu Arg Glu Asn Gln Asp Tyr Val Pro Gly Glu Arg Thr Pro Met			
1860	1865	1870	
Leu Glu Asp Val Asp Glu Gly Gly Ile Arg Pro Trp His Leu Val Lys			
1875	1880	1885	
Pro Ser Asp Glu Pro Glu Pro Pro Arg Pro Arg Arg Gly Ser Leu Arg			
1890	1895	1900	
Gly Gly Glu Arg Glu Arg Ala Lys Ala Ile Pro Glu Ile Tyr Leu Thr			
1905	1910	1915	1920
Arg Leu Leu Ser Met Lys Gly Thr Leu Gln Lys Phe Val Asp Asp Leu			
1925	1930	1935	
Phe Gln Val Ile Leu Ser Thr Ser Arg Pro Val Pro Leu Ala Val Lys			
1940	1945	1950	
Tyr Phe Phe Asp Leu Leu Asp Glu Gln Ala Gln Gln His Gly Ile Ser			
1955	1960	1965	
Asp Gln Asp Thr Ile His Ile Trp Lys Thr Asn Ser Leu Pro Leu Arg			
1970	1975	1980	
Phe Trp Ile Asn Ile Ile Lys Asn Pro Gln Phe Val Phe Asp Val Gln			
1985	1990	1995	2000
Thr Ser Asp Asn Met Asp Ala Val Leu Leu Val Ile Ala Gln Thr Phe			
2005	2010	2015	
Met Asp Ala Cys Thr Leu Ala Asp His Lys Leu Gly Arg Asp Ser Pro			
2020	2025	2030	

Ile Asn Lys Leu Leu Tyr Ala Arg Asp Ile Pro Arg Tyr Lys Arg Met
 2035 2040 2045
 Val Glu Arg Tyr Tyr Ala Asp Ile Arg Gln Thr Val Pro Ala Ser Asp
 2050 2055 2060
 Gln Glu Met Asn Ser Val Leu Ala Glu Leu Ser Trp Asn Tyr Ser Gly
 2065 2070 2075 2080
 Asp Leu Gly Ala Arg Val Ala Leu His Glu Leu Tyr Lys Tyr Ile Asn
 2085 2090 2095
 Lys Tyr Tyr Asp Gln Ile Ile Thr Ala Leu Glu Glu Asp Gly Thr Ala
 2100 2105 2110
 Gln Lys Met Gln Leu Gly Tyr Arg Leu Gln Gln Ile Ala Ala Val
 2115 2120 2125
 Glu Asn Lys Val Thr Asp Leu
 2130 2135

<210> 11
 <211> 2190
 <212> DNA
 <213> HOMO SAPIEN

<400> 11
 atgcctgctc tgggcccagc tcttctccag gctctctggg ccgggtgggt cctcaccctc 60
 cagccccttc caccaactgc attcactccc aatggcacgt atctgcagca cctggcaagg 120
 gacccacact caggcaccct ctacctgggg gctaccaact tcctgttcca gctgagccct 180
 gggctgcagc tggaggccac agtgccacc ggccctgtgc tagacagcag ggactgcctg 240
 ccacctgtga tgcctgatga gtgccccag gccagccta ccaacaacc gaatcagctg 300
 ctcttggtga gccaggggc cctgggtgta tgcgggagcg tgcaccaggg ggtctgtgaa 360
 cagcggcgcc tggggcagct cgagcagctg ctgctgcggc cagagcggcc tggggacaca 420
 caatatgtgg ctgccaatga tcctgcggtc agcacggtgg ggctggtagc ccagggtctg 480
 gcaggggagc ccctcctgtt tgtggggcga ggatacacca gcaggggtgt ggggggtggc 540
 attccaccca tcacaaccg gccctgtgg ccgcccagcc ccaagctgc ctctcctat 600
 gaggagacag ccaagctggc agtggccgc ctctccagt acagccacca cttcgtgagt 660
 gcctttgcac gtggggccag cgctacttc ctgttctgc ggcgggacct gcaggctcag 720
 tctagagctt ttcgtgcta tgtatctcga gtgtgtctcc gggaccagca ctactactcc 780
 tatgtggagt tgctctggc ctgcgaaggt ggccgctacg ggctgatcca ggctgcagct 840
 gtggccacgt ccaggaggt ggcgcagctg gaggtgctct ttgcagcttt ctctcggct 900
 gcacccccca ctgtgggccc gccccatcg gcggtgtctg gggcatctgg agcctctgcc 960
 ctctgtgect tccccctgga tgagggtggac cggttgcga atcgacgcg agatgcctgc 1020
 tacacccggg agggctcgtc tgaggatggg accgaggtgg cctacatcga gtatgatgtc 1080
 aattctgact gtgcacagct gccagtggac accctggatg cttatccctg tggctcagac 1140
 cacacgecca gccccatggc cagccgggtc ccgctggaag ccacaccaat tctggagtgg 1200
 ccagggattc agctaacagc tgtggcagtc accatggaag atggacacac catcgctttc 1260
 ctgggtgata gtcaagggca gctgcacagg gtctacttgg gccagggag ccatggccac 1320
 ccatactcca cacagagcat ccagcagggg tctgcagtga gcagagacct cacctttgat 1380
 gggacctttg agcacctgta tgtcatgacc cagagcacac ttctgaagg tctgtggct 1440
 tcctgtgctc agcacctgga ctgtgcatct tgccttgcct acagggacct atactgtggg 1500
 tgggtgcgtgc tccttggcag gtgcagtcgc cgttctgagt gctcgagggg ccagggccca 1560
 gagcagtggc tatggagctt ccagcctgag ctgggctgtc tgcaagtggc agccatgagt 1620
 cctgccaaca tcagccgaga ggagacgagg gaggttttc tatcagtgcc agacctgcca 1680
 cccctgtggc caggggagtc atattcctgc cactttgggg aacatcagag tcctgccctg 1740
 ctgactgggt ctggtgtgat gtgcccctcc ccagacccta gtgaggcccc agtgctgccg 1800
 agaggagccg actacgtatc cgtgagcgtg gagctcagat ttggcgctgt tgtgatcgcc 1860
 aaaacttccc tctctttcta tgaactgtgt gcggtcactg aactccgccc atctgcgcag 1920
 tgccaggcct gtgtgagcag ccgtggggg tgtaactggt gtgtctggca gcacctgtgc 1980
 acccacaagg cctcgtgtga tgctggggcc atggttgcaa gccatcaggt gatggagact 2040

cagcagagct tgagggccct cccgcccccc tcatactccc gtccagcctc gactaccagt
 atgacacccc cgggctctgg gagctggaag aggcgacctt gggggcaagc tctgccccct
 gtgtggagag cgttcagggc tccacgttga

2100
 2160
 2190

<210> 12
 <211> 729
 <212> PRT
 <213> HOMO SAPIEN

<400> 12
 Met Pro Ala Leu Gly Pro Ala Leu Leu Gln Ala Leu Trp Ala Gly Trp
 1 5 10 15
 Val Leu Thr Leu Gln Pro Leu Pro Pro Thr Ala Phe Thr Pro Asn Gly
 20 25 30
 Thr Tyr Leu Gln His Leu Ala Arg Asp Pro Thr Ser Gly Thr Leu Tyr
 35 40 45
 Leu Gly Ala Thr Asn Phe Leu Phe Gln Leu Ser Pro Gly Leu Gln Leu
 50 55 60
 Glu Ala Thr Val Ser Thr Gly Pro Val Leu Asp Ser Arg Asp Cys Leu
 65 70 75 80
 Pro Pro Val Met Pro Asp Glu Cys Pro Gln Ala Gln Pro Thr Asn Asn
 85 90 95
 Pro Asn Gln Leu Leu Leu Val Ser Pro Gly Ala Leu Val Val Cys Gly
 100 105 110
 Ser Val His Gln Gly Val Cys Glu Gln Arg Arg Leu Gly Gln Leu Glu
 115 120 125
 Gln Leu Leu Leu Arg Pro Glu Arg Pro Gly Asp Thr Gln Tyr Val Ala
 130 135 140
 Ala Asn Asp Pro Ala Val Ser Thr Val Gly Leu Val Ala Gln Gly Leu
 145 150 155 160
 Ala Gly Glu Pro Leu Leu Phe Val Gly Arg Gly Tyr Thr Ser Arg Gly
 165 170 175
 Val Gly Gly Gly Ile Pro Pro Ile Thr Thr Arg Ala Leu Trp Pro Pro
 180 185 190
 Asp Pro Gln Ala Ala Phe Ser Tyr Glu Glu Thr Ala Lys Leu Ala Val
 195 200 205
 Gly Arg Leu Ser Glu Tyr Ser His His Phe Val Ser Ala Phe Ala Arg
 210 215 220
 Gly Ala Ser Ala Tyr Phe Leu Phe Leu Arg Arg Asp Leu Gln Ala Gln
 225 230 235 240
 Ser Arg Ala Phe Arg Ala Tyr Val Ser Arg Val Cys Leu Arg Asp Gln
 245 250 255
 His Tyr Tyr Ser Tyr Val Glu Leu Pro Leu Ala Cys Glu Gly Gly Arg
 260 265 270
 Tyr Gly Leu Ile Gln Ala Ala Ala Val Ala Thr Ser Arg Glu Val Ala
 275 280 285
 His Gly Glu Val Leu Phe Ala Ala Phe Ser Ser Ala Ala Pro Pro Thr
 290 295 300
 Val Gly Arg Pro Pro Ser Ala Ala Ala Gly Ala Ser Gly Ala Ser Ala
 305 310 315 320
 Leu Cys Ala Phe Pro Leu Asp Glu Val Asp Arg Leu Ala Asn Arg Thr
 325 330 335
 Arg Asp Ala Cys Tyr Thr Arg Glu Gly Arg Ala Glu Asp Gly Thr Glu
 340 345 350
 Val Ala Tyr Ile Glu Tyr Asp Val Asn Ser Asp Cys Ala Gln Leu Pro

- 30 -

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/14420 A3

(51) International Patent Classification⁷: **C12N 15/12**,
15/62, 15/63, C07K 14/705, 16/28, C12P 21/02, A61K
38/17, 39/395, G01N 33/53

the University of California, 12th floor, 1111 Franklin
Street, Oakland, CA 94607-5200 (US). TAMAGNONE,
Luca [IT/IT]; Corso Einaudi, 43, I-10129 Torino (IT).

(21) International Application Number: PCT/US00/23365

(74) Agent: COX, Niki, D.; Biogen, Inc., 14 Cambridge Cen-
ter, Cambridge, MA 02142 (US).

(22) International Filing Date: 25 August 2000 (25.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/150,576 25 August 1999 (25.08.1999) US

(71) Applicants (for all designated States except US): UNI-
VERSITY OF TORINO [IT/IT]; Department of Biomed-
ical Sciences and Human Oncology, IRCC, SP 142, I-10060
Candiolo (IT). REGENTS OF THE UNIVERSITY OF
CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street,
Oakland, CA 94607-5200 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW). Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(72) Inventors; and

(75) Inventors/Applicants (for US only): ARTIGIANI, Ste-
fania [IT/IT]; Corso Brunelleschi, 121/B, I-10100 Torino
(IT). COMOGLIO, Paolo, M. [IT/IT]; Strada Valsalice,
183/8, I-10100 Torino (IT). GOODMAN, Corey, S.
[US/US]; Regents of the University of California, 12th
floor, 1111 Franklin Street, Oakland, CA 94607-5200
(US). TESSIER-LAVIGNE, Marc [US/US]; Regents of

(88) Date of publication of the international search report:
10 May 2002

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL MEMBERS OF THE PLEXIN FAMILY AND USES THEREOF

(57) Abstract: The invention provides methods and compositions related to novel plexins. The polypeptides may be produced re-
combinantly from transformed host cells and from the disclosed plexin encoding nucleic acids or purified from human cells. The
invention provides isolated plexin hybridization probes and primers capable of specifically hybridizing with the disclosed plexin
genes, plexin-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diag-
nosis, therapy and in biopharmaceutical industry. The invention also provides novel plexin neuropilin multimeric receptor complexes
for semaphorins and methods of use thereof, including but not limited to, the treatment and diagnosis of neurological disease and
neuroregeneration, immune modulation, and viral and oncological diseases.

WO 01/14420 A3

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/62 C12N15/63 C07K14/705 C07K16/28
C12P21/02 A61K38/17 A61K39/395 G01N33/53

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE, SCISEARCH, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL DATABASE EMHUM4:HSAB2313; ACCESSION-NO: AB002313, 1 July 1997 (1997-07-01), XP002157964	1-5
Y	the whole document & DATABASE SWALL:015031; ACCESSION-NO: 015031, 1 January 1998 (1998-01-01), the whole document & NAGASE, T. ET AL.: "Prediction of the coding sequences of unidentified human genes. VII. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro" DNA RESEARCH, vol. 4, 1997, pages 141-150, XP002102085 page 142 -page 150 'Results and Discussion' figure 3; tables 1,2 ---	6-9
	--- -/-	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

6 August 2001

Date of mailing of the international search report

3 1. 08. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Donath, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EMBL DATABASE EM_HUM:AB014520; ACCESSION-NO.:AB014520, 15 July 1998 (1998-07-15), XP002173834	1-5
Y	the whole document & ISHIKAWA, K.-I. ET AL.: "Prediction of the coding sequences of unidentified human genes. X. The complete sequences of 100 new cDNA clones from brain which can code for large proteins in vitro" DNA RESEARCH, vol. 5, 30 June 1998 (1998-06-30), pages 169-176, XP002121149 page 172 -page 176 * 'Results and Discussion' * figures 1,2; tables 1-3	6-9
X	EMBL DATABASE EMHUM4:HS5211110; ACCESSION-NO: U52111, 9 May 1996 (1996-05-09), XP002173835	1-5
Y	page 12 -page 13 * Gene="PLXB3" and product="plexin-related protein" *	6-9
X	EMBL DATABASE EMHUM6:HSOCTPROT; ACCESSION-NO: X87831, 6 February 1996 (1996-02-06), XP002173836 the whole document	1-3
X	EMBL DATABASE EM_OV:XLPLEX; ACCESSION-NO:D38175, 25 August 1995 (1995-08-25), XP002173837 the whole document & OHTA, K. ET AL.: "Plexin: a novel neuronal cell surface molecule that mediates cell adhesion via a homophilic binding mechanism in the presence of calcium ions" NEURON, vol. 14, 1995, pages 1189-1199, XP001013227	1-3
X	WO 99 04263 A (THE JOHN HOPKINS UNIVERSITY SCHOOL OF MEDICINE) 28 January 1999 (1999-01-28)	10,11
Y	page 5, line 9 -page 10, line 16 page 16, line 6 -page 22, line 3 page 23, line 22 -page 24, line 18 page 29, line 6 -page 32, line 4 --- -/--	12,13

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KAMEYAMA, T. ET AL.: "Identification of a cell surface protein plexin (the B2) in mouse, and its expression in developing nervous systems" NEUROSCIENCE RESEARCH SUPPLEMENT, vol. 18, 1993, page S115 XP000945106 the whole document	6-9
Y	COMEAU, M. ET AL.: "A poxvirus-encoded semaphorin induces cytokine production from monocytes and binds to a novel cellular semaphorin receptor, VESPR" IMMUNITY, vol. 8, April 1998 (1998-04), pages 473-482, XP000945259 cited in the application page 478 -page 480 'Discussion'	12,13
A	MAESTRINI, E. ET AL.: "A family of transmembrane proteins with homology to the MET-hepatocyte growth factor receptor" PROC.NATL.ACAD.SCI.USA, vol. 93, no. 2, 1996, pages 674-678, XP000941746 the whole document	1-9
P,X	TAMAGNONE, L. ET AL.: "Plexins are a large family of receptors for transmembrane, secreted, and GPI-anchored semaphorins in vertebrates" CELL, vol. 99, 1 October 1999 (1999-10-01), pages 71-80, XP000941702 page 72 -page 78 'Results' and 'Discussion'	1-5
P,Y	TAKAHASHI, T. ET AL.: "Plexin-Neuropilin-1 complexes form functional semaphorin-3A receptors" CELL, vol. 99, 1 October 1999 (1999-10-01), pages 59-69, XP000941701 page 60 -page 67 'Results' and 'Discussion'	6-9,12,13
P,Y	NAKAMURA, F. ET AL.: "Neuropilin-1 extracellular domains mediate semaphorin D/III-induced growth cone collapse" NEURON, vol. 21, November 1998 (1998-11), pages 1093-1100, XP002174004 cited in the application the whole document	12,13
A		10-13

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.: 10,11 (partially)
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 10-13 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 14 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 10,11 (partially)

Claims 10 and 11 concern a methods which comprise the administration of an agent capable of interfering with the association between a plexin and a neuropilin. Since in the specification this agent is exemplified only to be an antibody raised against the plexin and since it is completely unclear which kind of substances besides said antibody also will be capable of interfering with the association between a plexin and a neuropilin, the scope of said claims is totally ambiguous and undefined as far as any kind of substance other than an antibody raised against the plexin is concerned.

Therefore, the search in respect of claims 10 nad 11 has been limited to methods comprising the administration of an antibody raised against the plexin and which is capable of interfering with the association between a plexin and a neuropilin.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-9,12-14 (partially)

Claims 1-9,12-14 (partially) refer to the isolation and cloning of a member of the plexin family, plexin B-2. Antibodies specifically binding to this polypeptide, a fusion protein, and methods of diagnosing for tumors, treating a disorder involving aberrant immune regulation involving a signal pathway between plexin and a neuropilin, and suppressing aberrant cell growth, all methods by using either the polypeptide or the antibodies directed against the plexin B-2.

2. Claims: 1-9,12-14 (partially)

Claims 1-9,12-14 (partially) refer to the isolation and cloning of a member of the plexin family, plexin B-3. Antibodies specifically binding to this polypeptide, a fusion protein, and methods of diagnosing for tumors, treating a disorder involving aberrant immune regulation involving a signal pathway between plexin and a neuropilin, and suppressing aberrant cell growth, all methods by using either the polypeptide or the antibodies directed against the plexin B-3.

3. Claims: 1-9,12-14 (partially)

Claims 1-9,12-14 (partially) refer to the isolation and cloning of a member of the plexin family, plexin D-1. Antibodies specifically binding to this polypeptide, a fusion protein, and methods of diagnosing for tumors, treating a disorder involving aberrant immune regulation involving a signal pathway between plexin and a neuropilin, and suppressing aberrant cell growth, all methods by using either the polypeptide or the antibodies directed against the plexin D-1.

4. Claims: 1-9,12-14 (partially)

Claims 1-9,12-14 (partially) refer to the isolation and cloning of a member of the plexin family, plexin A-4. Antibodies specifically binding to this polypeptide, a fusion protein, and methods of diagnosing for tumors, treating a disorder involving aberrant immune regulation involving a signal pathway between plexin and a neuropilin, and suppressing aberrant cell growth, all methods by using either the polypeptide or the antibodies directed against the plexin A-4.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

5. Claims: 10,11

Claims 10 and 11 refer either to a method of suppressing or altering aberrant cell growth involving a signalling pathway between a plexin and a neuropilin in a mammal or to a method of treating, suppressing or altering a disorder involving aberrant immune regulation involving a signalling pathway between a plexin and a neuropilin in a mammal, both methods comprises the administration of an agent in general being capable of interfering with the association between the plexin and neuropilin to said mammal.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9904263 A	28-01-1999	AU 8405398 A	10-02-1999